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Neural networks are at the core of the brain’s ability to compute complex responses to
our external environment. Clinically, network dysfunction is emerging as a key compo-
nent of several psychiatric and neurodegenerative disorders such as Alzheimer’s disease or
schizophrenia. However, our ability to precisely and safely manipulate neural networks for
research and deliver network-specific therapy remains limited. To address this problem, our
lab recently developed a monosynaptically restricted Self-Inactivating Rabies virus (SiR)
which enables the targeting of neural circuits without cytotoxicity. To expand the scope
of SiR we further developed the technology in two directions: A) By incorporating the
CRISPR/CAS9 gene-editing machinery into the SiR genome to successfully edit endogenous
loci in vitro and in vivo. B) By designing an improved second generation SiR virus (SiR
2.0) which applies the same SiR technology to a challenge rabies strain (CVS-N2C). SiR
2.0 demonstrates increased neurotropism, increased trans-synaptic transfer efficiency and
markedly decreased immunogenicity compared to the SiR 1.0 vector.
These advancements expand the scope of SiR viruses to be used in the genome-editing of
circuits in vivo. A combined SiR 2.0 CAS9 virus, in physiology, allows us to investigate the
roles of genes within circuits in the brain function of live animals. For therapy, it paves the
way for the rabies virus’ potential use to edit disease-related genes in dysfunctional circuits.
Despite the circuit-basis of many neurological disorders, existing gene therapy vectors are not
circuit specific. In addition, the practical difficulties of delivering therapeutic agents at high
doses into the central nervous system exacerbates our inability to achieve high therapeutic
loads into affected circuits. In contrast, a SiR 2.0 CAS9 virus would, following injection
into peripheral organs, trans-synaptically spread into desired circuits of the central nervous
system that are affected in neurological disease (e.g. networks demonstrating pathological
protein propagation in neurodegenerative disorders) and edit disease-related genes.
Lastly, our interest in network-level pathological protein propagation also led us to investi-
gate the biology behind this observation. Due to additional evidence that a significant number
of other proteins in physiology also show interneuronal movement, we hypothesised that
perhaps this is an overlooked phenomena in neurobiology which could have key implications
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A fundamental aim of neuroscience is to understand what the brain does, and how it does
it. Its functions and workings have mystified humans across all times and cultures. One
of the oldest known descriptions of the brain comes from a 5000 year old papyrus (1700
BC) of an ancient Egyptian doctor1. Although he attributes injuries to an organ in the skull
with symptoms such as an inability to speak, walk, or track objects with one’s eyes, the first
intellectual understanding that the brain is the center of sensation, cognition, emotion and
motor control was only made 3000 years later by the Greek philosopher Alcmaeon2. Given
the highly varied and complex computations a brain can perform, defining a core function of
the brain can be difficult. A simplified yet attractive explanation is that the brain is essentially
an organ system that converts sensory input from the environment into motor outputs that
determine human behavior. Much of the drive of neuroscience research is to try dissect out
how the brain manages to carry out such a challenging task.
Anatomically, the human brain consists of approximately 100 billion neurons and each of
these neurons, on average, form 7000 synapses with other neurons. A prevalent logic in the
field is that if we can understand how these neurons connect and functionally communicate
with one another, we can come a step closer to understanding how the brain can perform
complex tasks such as make predictions, recollect memories and react to the physical and
social world around us. Experimentally, there are many approaches to studying the brain.
For example, one can take an anatomical approach and acquire connectivity diagrams of
neural circuits, thus revealing the underlying structure of the brain apparatus. This type of
information could help uncover how the brain performs complex computations. Alternatively,
one can record from or manipulate neurons or groups thereof to establish correlations or
causative relationships between the activity of brain units and perception or behavior. From a
more global perspective, one can treat the whole brain as an unknown entity and perform
psychological experiments to reveal patterns in behavior which can give rise to broader
theories of brain function. All of these approaches have been informative and it appears
that increasing cross-talk between these different fields will be crucial to furthering our
understanding of brain function.
In addition, it is interesting to consider what the pathologies of the brain reveal about the
physical substrate of mind and thought. For example, what changes occur in the brain of a
hallucinating patient who can hear real and vivid, yet hallucinatory, voices? Such patients, in
so many other aspects of brain function, are highly functional. Therefore, these symptoms
suggest an extremely specific computational deficit or hyperactivity. This further asks the
intriguing question: exactly what physical alteration in the brain gives rise to such a specific
dysfunction? There is now accumulating evidence that such deficits exist at the level of
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circuits, with many psychiatric disorders showing correlations with altered circuit architecture
and connectivity3 and neurodegenerative diseases revealing network level progression of
pathological protein aggregates4.
Despite the emerging importance of circuits in brain function, experimentally studying
the roles of neural networks in live animals has proven difficult. Nervous tissue is very
dense, heterogeneous and intricately connected making it hard to specifically target or even
label selected circuits effectively. Continuous modifications of a naturally trans-synaptic
rabies virus has been crucial to facilitate anatomical circuit visualization in mammals. In
parallel, there have been increasing improvements of calcium and voltage sensors to record
electrical activity from neurons5. For functional manipulation, chemogenetic and optogenetic
techniques have been developed6. In addition, our ability to specifically edit the genome has
been revolutionized by the development of CRISPR/CAS9 techniques7. These advancements
in isolation have been highly transformative and helped to overcome the numerous technical
obstacles experimenters face when trying to label, record from or manipulate nervous tissue
in live animals. However, we now need an integration of such tools - enabling manipulation
not of single neurons, but of neural circuits in live animals as they perform complex brain
computations. Neuroscience, like much of science, is a technology-dependent field, where
new tools enable the revelation of novel biological principles. More sophisticated methods
of recording from and manipulating structural circuits in vivo are necessary to help fill the
challenging gaps that exist between circuit theories of brain function, and the biological
validation of those theories.
In this thesis, I argue the importance of neural circuits in brain function and focus on the
development of novel tools to target and probe circuit biology. In my first two experimental
chapters I discuss the development of a second generation self-inactivating rabies virus that
can be used to perform circuit specific genome editing in vivo. Our motivation for this
tool development is twofold. First to enable, for the first time, a fusion of the experimental
methods available to specifically target circuits, precisely edit the genome of cells, and
observe behavioral paradigms. Second, to initiate the development of circuit specific gene
therapy vectors for the treatment of neurological and psychiatric disorders. In the final
experimental chapter, I work to engineer novel protein tools that enable exploration into
the mechanisms behind interneuronal protein transfer, a phenomenon observed both in
physiology and neurodegenerative disease. We hope that such tools can enable further
understanding of this process, which may have broad and deep implications for the underlying
biology of circuit communication and brain function.
4 General Introduction
1.1 Neural network theory of brain function
For the past century, neuroscience has been dominated by the "neuron doctrine" which
theorises that neurons are the fundamental structural and functional unit of the brain. This
doctrine was initially heralded by Cajal8 and Sherrington9 and this underlying dogma has
laid the foundation of modern neuroscience. This idea has prevailed predominantly due
to the single cell techniques used to make landmark discoveries. A notable example is
the Golgi stain that enabled for the first time the clear visualisation of all the dendritic
arborisations and axon processes of a small percentage (around 1%) of neurons in the brain10.
The anatomical revelations from this novel staining method led Ramon y Cajal to propose
that the nervous system was composed of individual cells rather than a reticular network
and enabled experimenters to hypothesize about neuronal function (e.g. spatial summation,
connective complexity and recurrence). Other notable examples include the development of
single-cell recording techniques such as the coupling of a triode thermionic valve amplifier to
a capillary electrometer11 which enabled the sensitive quantitative measurement of electrical
activity from single sensory nerve fibres. This technique revealed some key properties of
cell-level sensory transduction such as frequency encoding and specificity to particular types
of stimuli11,12. The introduction of the tungsten microelectrode13 was then used for single
neuron recordings in the visual cortex of unrestrained cats14. This enabled the mapping of
increasingly complex receptive fields in the visual system and revealed key information about
sensory information processing. Such single cell recording techniques have revealed that the
electrical activity of sensory neurons correlates to and encodes specific information about
sensory stimuli, giving rise to the notion of "receptive fields". Although originally derived
from more peripheral sensory fibres, this concept that single cell activity reflects neuronal
function and computation has been extended over to higher order neurons which respond
selectively to more and more abstract sensory stimuli15.
Although these studies at the neuron level have been extremely informative, the neuron
doctrine is limited in the sense that we are unable to explain all the complex aspects of brain
function by only studying neurons as individual entities. The more recently investigated
“network theory” leads us to move away from the neuron level analysis and to look at
network level functions. At the heart of our motivation to study the nervous system at the
level of networks rather than neurons is the principle that the collective concerted activity
of individual units can create new emergent properties within the network that cannot be
explained by its individual components. In the first subsection, I discuss how developments
in the field of artificial intelligence have shown that networks can generate novel emergent
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computational properties and perform complex perceptual tasks such as image or voice
recognition with unprecedented accuracy. In the second subsection I discuss the biological
experimental evidence for the role of network or population level electrical activity in normal
brain computations. In the third subsection, I present the final large body of evidence for
network theory, which is that network-level dysfunctions can drive specific pathological
human behaviours in psychiatric and neurodegenerative disease.
1.1.1 Artificial neural networks as models of the biological brain
Over 2000 years ago, before much was known about the underlying anatomy or hardware
of the brain, or even which body organ was the seat of human intelligence, philosophical
thinkers such as Aristotle and Plato proposed an associationism theory to explain how
humans were able to perform such complex cognitive functions16. Associationism was the
idea that our ability to learn, perceive, solve problems, imagine and create was explainable
by one essential mental process: the ability to form associations between temporally linked
phenomena. This theory was expanded and modified through time with a continuous flow of
advocates from the Associationist School such as John Locke, David Hume, David Hartley,
James Mill, Alexander Bain and Ivan Pavlov. In the late 1800s, the increasing anatomical
knowledge that the brain, the organ and hardware of human intelligence, consisted of a mass
of densely interconnected cells gave rise to connectionism: an updated associationist theory
where the associations enabling all complex brain functions are stored in the connections of
simpler units that form interconnected networks17. Artificial neural networks(ANNs) are the
computational realisation of connectionism.
In recent years, interest in ANNs has increased with the aim of creating connectionist
models to solve problems that have proved difficult using conventional computing systems
but seemed to be learned with relative ease in biological organisms (e.g. facial recognition).
These artificial networks often attempt to mimic biological neural systems and consist of a
dense interconnection of simple processing units that mimic neurons. In an ANN, neuronal
cell bodies and dendrites are represented as nodes, and the edges connecting the nodes
represent axonic projections. The weight of the edges represent the strength of the synaptic
connection and the network learns by changing the weights of its connections. The state
of each node is characterised by a neuron activation function that can mimic the functional
behaviour of neurons. Although there is a huge variety of ANN models, they can in summary
be described by:
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• the network topology (e.g. number of neurons, number of layers, connections between
the layers etc.)
• the neuron activation function used to convert inputs into outputs (e.g. linear vs.
non-linear, saturating vs. non-saturating)
• and the learning rules.
The earliest computational model of a biological neuron was proposed by McCulloch and
Pitts in 194318. The McCulloch-Pitts (M-P) neuron has a set of binary inputs I1, I2, I3, ..., In
and one output y. Each input has weight values W1,W2,W3, ...,Wn normalised in the range







y = f (Sum) = 1 if Sum   T
y = f (Sum) = 0 if Sum < T
In essence, the M-P neuron is a linear threshold gate which sums a set of inputs and
classifies them into two different classes (an ON or OFF state) by setting a threshold T
such that the node fires only if the inputs exceed a threshold value. This design was seen
to mimic biological properties such as the summation of pre-synaptic inputs and the all or
nothing nature of action potential propagation initiation. Although simple, the M-P neuron
can compute many boolean functions (e.g. AND, OR, NOT, NOR etc.) and was shown to
have significant computing potential when incorporated into networks. This was a crucial
first step for the field of artificial intelligence.
However, a major limitation of the M-P neuron was that its weight and threshold val-
ues were fixed. The subsequent development of the M-P neuron, Rosenblatt’s perceptron
proposed in 195819, introduced variable weight values between units and therefore enabled
networks of these units to be trained. The convergent learning algorithm incorporated into
this computation model again mimicked the biologically driven Hebbian learning rule that
"neurons that fire together, wire together."20. This development was crucial for artificial net-
works which needed to be trained to function correctly over time as opposed to conventional
computing systems which have fixed instructions to perform specific computations.
Although at the time the computing potentials of the perceptron were criticised, it was
recognised that multi-layered perceptrons (rather than individual perceptrons) could have
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considerable computing capacity and power21. The introduction of backpropagation learning
rules facilitated the training of these multiple-layered networks and has yielded increasingly
powerful results22. In addition, over time there have also been many more activation functions
designed for artificial neurons which can be binary or continuous in nature. Artificial neurons
with continuous characteristics aim to mimic "pattern" or “frequency" coding of biological
neurons and their additional characteristics (e.g. the gradient of a sigmoid activation function)
can contribute to the learning of neural networks.
Currently, ANNs are being used to perform many complex cognitive tasks with an
unprecedented level of efficiency and accuracy. The study of such ANNs is starting to
bridge the fields of biology and psychology, offering insight into the link between the brain
and the mind. Whilst neuroscience offers a wealth of knowledge about the biology and
molecular chemistry of neurons, it has not yet revealed general theories of brain function.
In contrast, psychology and philosophy have generated many theories of brain function
but they are yet unable to be tested experimentally. Although ANNs do not embody all
the known properties of neurons in the human brain, neural network theory aims not to
mimic all the intimate details of a neuron, but rather to simplify neurons as input-output
devices which can be connected into various different network arrangements, some of which
can perform brain-like tasks. They are essentially network models that mimic important
biological connectionist principles and can thus act as a "potential guide to the mind"23.
For example, ANNs demonstrate the highly complex emergent properties of connectionist
systems (e.g. visual recognition and speech recognition) and also reveal how networks can
perform such complex tasks, something which is yet difficult to study purely biologically.
In other words, ANNs help us generate computational theories of brain function from our
present knowledge of biological network architectures, neuronal connectivity and activity
tuning through a process of reverse engineering.
1.1.1.1 Artificial neural networks can store distributed memories
Biologically inspired artificial neural network models have clearly demonstrated that net-
works can generate emergent computational functions that are not present in single units.
A seminal example is the Hopfield network which clearly demonstrates that networks can
store distributed memories at a population level that can be retrieved in a content-addressable
manner24. A Hopfield network consists of a dynamic network of N neurons (V1, ...,Vi, ...,VN)
where:
• each neuron can have one of two states (-1, 1)
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• each neuron is symmetrically connected to every other, so wi j = w ji (where the weight
from the j’th to the i’th neuron is given by wi j)






In this model, as the network is updated the total energy of the system decreases with each
state flip of a single neuron. As a result, the network can store and retrieve patterns embedded
within the entire network as energy minima or "attractors". Although the design and results
of this model are not fully biologically accurate (e.g. in large networks of size N, the number
of random patterns that can be stored is approximately 0.14 N and around 1/2 of all neurons
are active for each stored state), it is a powerful recurrent neural network realisation of
associative memory and a clear demonstration that memories can be distributed as patterns
of activation states in a population of neurons rather than the code of a single neuron per
se. The drosophila mushroom body, which is the learning and memory centre of the insect
brain, also shows a highly recurrent network architecture25,26 which has inspired the design
of RNNs for memory generation27.
1.1.1.2 Deep neural networks can perform increasingly complex cognitive tasks
Rapid developments in the field of artificial intelligence has led to the development of
deep neural networks that can learn increasingly complex cognitive tasks28. Convolutional
neural networks (CNNs) have produced breakthroughs in the processing of visual imagery,
whilst recurrent neural networks (RNNs) have shown high performance for tasks involving
sequential inputs such as machine language translation29–31. These ANNs support biological
network theory in two ways: first by demonstrating the impressive emergent computational
power of connectionist systems, and second by giving mechanistic insight into how the same
cognitive processes are computed by biological neural networks.
In the field of visual recognition, deep neural networks (DNNs) have been increasingly
used to classify images with unprecedented accuracy. Notable examples include the best-
performing model of the ImageNet Large Scale Visual Recognition Challenge in 2012,
which was a deep convolutional network consisting of 650,000 neurons and 8 deep layers (5
convolutional and 3 fully-connected) and achieved a top-5 test error rate of 16%32. This was a
breakthrough for computer vision at the time, and triggered the increased use of convolutional
networks for recognition and detection tasks. Subsequently developed models have improved
error rates which have even superseded human performance in image classification, with a
5% top-5 test error rate33. This high performance level has led to investigations into whether
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the algorithmic representations of DNNs resemble human vision. In order to learn more
about exactly how such trained DNNs work, visualisation techniques (both computational
and empirical) have been developed to reveal what single neurons at any layer of the network
represent34–36. Such studies show that DNN architectures learn hierarchical representations
which are similar to the hierarchy of low- to high- level visual areas in the human visual
pathway37,38. Neurons in the DNN represent increasingly complex features at higher levels,
with increasingly more intuitively desirable properties such as invariance, class discrimination
and compositionality. In addition, a comparison of the neural population representation of
the macaque inferotemporal (IT) cortex for object recognition with that of convolutional
DNNs has shown that both IT cortex and DNNs create similar representational spaces and
that the top-level features of DNN models can predict IT responses, supporting the idea that
high-performance DNNs may provide insight into primate visual processing39.
DNNs have also shown impressive results in the field of language processing and transla-
tion. For example, NETtalk, a three layered network of around 300 neurons can learn how to
convert english text to speech over the period of half a day40. The network model, although
very simple, shows many similarities with human learning and memory. For example, spaced
learning is more effective for long-term retention than massed practice. The model also
learns different phonological rules at different speeds that correlates with sounds that children
find difficult to learn to read, such as the soft "c" sound. In addition, the ANN showed
a robustness to damage that is typical of biological networks. Its performance degrades
gradually with increasing damage to connections within the network, demonstrating that the
rules of text pronunciation are learned and distributed into the network, rather than stored in
particular units or links. As such, the model illustrates many aspects of human learning and
can be used to develop mechanistic theories of complex learning phenomena. The Drosophila
mushroom body, which is the learning and memory centre of the insect brain, also shows a
highly recurrent network architecture25,26 which has inspired the design of RNNs for memory
generation27.
1.1.2 Neural networks in physiology
In this section I present the biological experimental evidence for neural network theory of
brain function. Although the content is by no means comprehensive, here I aim to highlight
some pertinent examples of biological evidence supporting the importance of network level
activity, not individual neurons, in complex brain function. These examples include our
knowledge of neuroanatomy and network structure, the role of population coding in sensory
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perception, the ability of neuronal population dynamics to predict behaviours in live animals,
and the multifunctionality of single brain units or networks showing the significance of fluid
network activity for brain function.
Just as single cell techniques such as the Golgi stain enabled the visualisation of single
neurons in the brain and thus paved the beginning of the "neuron doctrine", our understanding
of network function has been enabled by novel techniques that allow us to study the brain
at a network-wide level. Much of the following evidence for network function in biology
has been enabled by the development of novel methods to trans-synaptically trace networks,
record or visualise the activity of many individual neurons together at high spatio-temporal
resolution in experimental animals (e.g. in vivo 2 photon imaging), to manipulate neuronal
populations and the increasingly sophisticated methods of functional and anatomical 3D
imaging in humans.
1.1.2.1 Structural evidence for distributed networks in brain function
Biological neural circuits, especially in mammals, show dense connectivity41. For example, in
the mouse cortex, an average pyramidal neuron receives inputs and projects to approximately
an order of 104 other neurons42,43. In the mouse cerebellum, each Purkinje cell receives
inputs to the order of 10644. In addition to dense connectivity, dual whole cell recordings
of local inter-pyramidal connections in the cortex show that the majority of these excitatory
connections are small in amplitude (0.2–1.0 mV)45,46. This pattern of extremely dense but
weak excitatory connectivity suggests that each neuron integrates a high number of sub-
threshold inputs and projects to many others. In addition, most cortical inhibitory GABAergic
neurons (except VIP-expressing interneurons) show an even denser local connectivity that
approaches 100% of local targets and appear to connect with as many excitatory neighbouring
neurons as possible47,48. This dense and unspecific innervating pattern has been described as
a "blanket of inhibition" and is hypothesised to play a role in network-level regulation, such as
in the oscillatory activity and synchronisation of cortical networks49. Such an architecture of
extremely dense, sub-threshold and broad connectivity suggests that each individual neuron
is highly embedded into a larger network and thus singly contributes to but cannot explain
overall circuit function. This sort of architecture consisting of many interconnected individual
elements is characteristic of physical systems that generate emergent properties. Such
emergent properties are akin to moving images on a TV screen, and cannot be understood by
studying each individual element or pixel in isolation50.
Graph theoretical analysis of connectomic data has revealed that biological neural net-
works, both human and non-human, have a "small-world architecture"51. Small-world
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networks are named after the social “small-world phenomenon” of meeting a stranger far
away from home, only to then discover that you share a mutual acquaintance52 and are used
to describe networks which show a combination of both clustered and distributed topology.
Clustered topology is a characteristic of ordered networks and are measured by parameters
such as the clustering coefficient which quantifies the fraction of connections that exist be-
tween the nearest neighbours of a node out of the maximum number of possible connections.
High clustering is associated with high local information transfer and robustness. On the
other hand, distributed topology is characteristic of random networks and can be quantified by
measures such as the global efficiency (the inverse of the mean path length between all pairs
of nodes of a network). Distributed random networks show a high global efficiency of parallel
information transfer. The decreased energetic economy of biological small-world architecture
suggests that there is a functional evolutionary purpose to such network organisation53. For
example, small-world architecture results in a brain consisting of segregated clustered hubs
that can perform specialised processes (e.g. motor speech generation or auditory language
comprehension) that are then integrated through high efficiency path architectures to perform
executive functions that require efficient communication between these hubs (e.g. the ability
to understand and generate words to have a normal conversation)54. In addition, alterations
in the balances between "randomness" and "orderedness" of networks are found to correlate
to aberrant cognition in pathology as will be discussed further in chapter 1.2.
1.1.2.2 Population coding in the inferotemporal lobe for visual perception
As highly visual animals, visual processing and recognition forms a large proportion of
human sensory cognition and brain function. The inferotemporal (IT) cortex of monkeys
and humans is crucial for visual object recognition. The IT cortex is the last purely visual
cortical processing area in the ventral visual pathway which begins from V1 and projects
through V2, V4 and area TEO of the temporal cortex. Experimental lesions of this area in
monkeys results in an inability to learn how to recognise new visual stimuli as well as an
inability to remember how to recognise visual stimuli they have seen before55. In humans,
damage to the IT cortex can also result in general visual agnosia. More rarely, IT damage can
also lead to specific agnosias resulting in an inability to recognise particular visual features
or concepts such as colours (achromatopsia) or faces (prosopagnosia). In addition to lesion
studies, functional imaging with fMRI in humans shows that visual objects activate the IT
cortex and that specific regions of the IT cortex are selective to specific classes of visual
stimuli, for example the fusiform gyrus for faces and body parts, and the dorsal and anterior
regions for recognising eye position.
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Single cell recordings of neurons in the IT cortex have enabled interesting insights into
how visual pattern recognition is computed. In most of these studies, one finds that the
majority of neurons in the IT are not narrowly tuned for a specific visual stimulus or concept
but rather respond broadly to most experimentally presented visual stimuli. However, for a
lesser proportion of cells, one finds that neurons can show preferential tuning to a particular
visual stimulus. In an exemplary study in the macaque IT cortex, it was found that 27% of IT
neurons were unresponsive to all presented stimuli, 22% responded equally to all presented
stimuli and most of the remaining stimulus-selective cells showed at least a small response
to almost every stimulus tested56. As a general rule, as you approach the anterior tip of the
IT cortex, neurons show preferential responses to increasingly complex visual stimuli, the
most complex of which have been identified are faces. For example, studies in the IT cortex
of macaques have shown cells firing preferentially to hands57 or faces56,58 in the superior
temporal sulcus. In humans, single cell recording experiments in the mediotemporal lobe
(MTL), a common foci for eplieptic patients, has also revealed that cells in this region can
show preferential tuning to very complex visual stimuli and concepts such as the Sydney
Opera House or to famous actresses (e.g. the "Jennifer Aniston cell")59. These cells fired
preferentially not only to photos of an actress’ face, but also from the visualisation of the
letters of her name.
The identification of such specific selectivity to complex trigger features has led to
many theories to explain how the IT cortex computes visual pattern processing. On one
extreme, such studies have often been interpreted to support the hypothesis that complex
perceptual concepts can be represented by single cells. These perception embodying single
neurons have been proposed independently by many and given numerous names: pontifical
cells by James60, gnostic cells by Konorski61 and grandmother cells or cardinal cells by
Barlow62. The idea is that there are single cells, such as a "grandmother cell", that only fire
selectively to highly specific visual percepts such as one’s "grandmother". As the perception
of "grandmother" is represented singly by that cell, if it is lost the conceptual perception
of "grandmother" is also lost. However, these single cell recording studies cannot truly
support a single cell code for visual percepts as they cannot prove that the identified neuron
is solely responsible for the recognition of a particular face or concept. In addition, if there
truly was a single cell code to represent such complex concepts, statistically the chances of
recording from a single neuron and matching it to the specific concept it encodes would be
extremely low. In addition, these neurons show preferential tuning, not complete selectivity,
to a complex percept. For example in the Quiroga et al. study where a large collection of
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pictures of famous individuals and landmarks were used, each unit showed strong responses
to about 3% of the stimuli59.
More convincingly, these single cell recordings support a population code of visual
percepts. Most IT neurons are not narrowly tuned for a specific stimulus, and the few that
do show preferential tuning still show responses to other non-specific visual stimuli. These
findings suggest that visual images will probably activate many cells in the IT cortex and
as such, visual concepts in the IT cortex will be represented in the activity of a population
of neurons. In addition, further investigation into the properties of "face cells" in macaque
monkeys has shown that, rather than encoding a specific person, face neurons show "axis
coding"63. When images of faces are formatted into a high-dimensional linear space, face
cells are found to fire proportionally to the projection of a visualised face onto linear axes
within this space which represent specific facial features. This results in a face cell ensemble
of around 200 cells that can identify any face within the space. The finding of face preferential
cells in humans supports a sparse population code for abstract representations64 and informs
us that, within human visual recognition networks, there are nodes that are selective to
complex trigger features65. These individual neurons participate in many different population
assemblies to form a sparse population code which is distributed in the activity of many
neurons. Such distributed storage codes theoretically allow for greater coding capacity
due to combinatorial multiplication, easier retrieval, greater capacity for generalisation and
resistance to noise. As elegantly described by Sherrington, "Where it is a question of ’mind’
the nervous system does not integrate itself by centralisation upon one pontifical cell. Rather
it elaborates a million-fold democracy whose each unit is a cell"66.
1.1.2.3 Neural population dynamics can code and predict behavioural outcomes
Decision making is another important aspect of human cognition. In essence, all movements
that are made are a consequence of decisions computed by our nervous systems, whether
consciously or unconsciously. The biological study of how decisions are made across
many different species for various experimental decision making tasks have revealed that
behavioural outcomes and reaction times correlate with population-level spatiotemporal
sequences of neuronal activation. Such findings have relied on a) improving techniques for
simultaneous recording from neural populations and b) improving analytical techniques to
extract neural population states and relate them to behaviour. The ability to correlate and
even predict behavioural parameters from neural population feature extraction, but not single
neuron activity, shows that the processes of decision making and movement generation are
population encoded67.
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In the midbody segmental ganglion of the leech central nervous system, simultaneous
recording of 143 neurons during swim vs. crawl decision making followed by principal
component analysis (PCA) to identify dimensions that separate the two behaviours showed
that neural population dynamics could discriminate behavioural outcome earlier in time than
single neurons, highlighting the emergent circuit level coding of decision making68. In the
more complex mouse posterior parietal cortex (PPC), simultaneous two-photon calcium
imaging of layer 2/3 neurons during a virtual maze navigation task revealed that whilst indi-
vidual neurons could not be used to decode the behaviour, distinct spatiotemporal sequences
of activity across the population could discern and predict different behavioural outcomes69.
The recent development of new methods to analyse neuronal population activity of single
trials, as opposed to data averaged across many trials, have enabled a deeper illumination of
the relationship between neural population activity and behaviour70,71. The need for single-
trial analyses of population activity is particularly pressing for tasks that require internal
processing (e.g. decision making, perception and motor planning). For example, in the mouse
parietal cortex, the use of a new clustering algorithm revealed high trial-to-trial variability
in a virtual maze navigation task which could be explained by past events such as previous
evidence cues, behavioural choices and reward outcomes72. This showed that dynamic
population properties could represent short-term memory. In addition, single-trial analysis of
population dynamics in the monkey premotor cortex have shown that single-trial deviations of
neural state space trajectories from the mean neural trajectory for a behavioural outcome can
predict behavioural parameters such as hand velocity and reaction time variability between
trials for complex reach tasks in monkeys70,71,73. Such studies show the subtleties and hence
significance of population dynamics for decision making and motor planning.
1.1.2.4 Single neurons and networks can participate in multiple different computa-
tions
The lack of strict selectivity of neurons or neuronal populations to specific percepts (as
demonstrated by "face cells") or specific behavioural outcomes (as demonstrated by dynamic
decision making networks) highlight another principle of brain function which is that of
multifunctionality. Just as the same "face cell" can contribute to the perception of different
visual objects59, the same neurons, networks or brain regions can participate flexibly in many
different functional groups to code different sensory or behavioural outcomes. This strongly
alters the concept of "receptive fields" and demonstrates that neurons may in fact have a
much higher dimension than we are currently aware. There is now rapidly accumulating
evidence that the previously determined low dimension of "face cells", "command neurons",
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"swim interneurons" or "primary sensory cortices" may in fact be a consequence of the
simple sensory or behavioural paradigms used in experiments.
In the study of decision making, the discovery of single neurons that are able to trigger
complex behaviours on experimental stimulation have historically been defined as being
"dedicated" to one specific behaviour. This has led to the hypothesis that there are distinct
“dedicated-command” or "decision-making" neurons for each behaviour74. However, with
time it has been shown that the activity of decision neurons are not behaviour specific and
that the stimulation of the same neuron can trigger more than one behaviour. For example,
interneurons in the leech nervous system that have previously been labelled as "swim gating"
or "swim trigger" interneurons were also excited during whole-body shortening. This finding
was generalisable to most neurons in the leech, including high-level decision neurons. In
addition, it was also observed that the electrical stimulation of a single neuron (R3b1) in
an isolated nerve cord could elicit both swimming and crawling motor patterns showing
that decision neurons are not only active during more then one behaviour, they can singly
initiate two different behaviours75. This multi-functionality of decision neurons suggests that
decisions are not conducted by a single cell identity but by a network-level combinatorial
code, where the behavioural outcome depends on the combination of decision neurons that
are active at a given time.
In the motor system, the same neuron network can elicit multiple different motor be-
haviours. For example, swim central pattern generator (swim-CPG) interneurons in the
leech are active in an oscillatory mode during swimming, but also tonically active during
withdrawal75,76. The swim-CPG network of the marine mollusk has also been suggested to
be multifunctional for both swimming and withdrawal behaviour77. More surprisingly, the
same swim-CPG network is also able to generate crawling behaviour which requires a starkly
different motor output to swimming. Swimming is a rhythmic, muscle-driven brief behaviour
whilst crawling is a tonic, cilia-mediated prolonged behaviour which requires connections to
different effector neurons78. Rodent medullary networks also demonstrate multifunctionality,
with the same networks generating different breathing patterns79 or different responses to
food80. Thus, across many species, the same motor networks can generate markedly different
motor behaviours, highlighting the importance of network dynamics rather than single cell or
network identity in behavioural movement generation.
In a more extreme example of multifunctionality, it was recently observed that primary
sensory cortical areas in the mouse that are predominantly thought of as visual processing
areas are also tuned to mouse facial movements. In this study, two-photon calcium imaging
was used to record the activity of 10, 000 neurons in the visual cortex with simultaneous facial
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movement monitoring. Analyses revealed that visual cortex activity is highly dimensional,
with a third of neural activity being predictable by a multidimensional model of the mouse’s
facial behaviour. The same neurons were found to represent both sensory stimuli and
behavioural variables, showing that neuronal multifunctionality can traverse motor and
sensory systems. In addition, subsequent neuropixel probe recording of neurons across 8
other brain regions showed that the encoding of behavioural facial movement was brain-
wide81. This is supported by anatomical findings of whole-brain connectivity and supports
the existence of brain-wide encoding of behavioural variables through widely distributed
networks.
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1.2 Neural networks in disease
In addition to the computational and physiological evidence presented in the previous sections,
another large body of evidence to support the network basis of brain function comes from
the study of pathological conditions of the human nervous system.
Psychiatric and neurodegenerative diseases manifest as pathological changes in human
cognition and behaviour and present a huge disease burden in modern society. As such
there has been intensive research into understanding the aetiology and pathogenesis of these
diseases as well as for developing therapeutic agents. However, despite huge efforts, there has
been relatively little progress82. Even for the cases of hereditary neurodegenerative disorders
where causative genes have been identified, we still do not understand the pathophysiology
and these diseases are still incurable. This relative lack of progress despite huge inputs has
suggested to many the need for new unifying theories or paradigms to approach the study and
treatment of these diseases. A paradigm shift that has already begun to take place is that the
complex behavioural and cognitive dysfunctions that are observed in these diseases emerge
due to altered temporal dynamics and functional connectivity of wide-spread large-scale
networks, rather than of micro- or macro- level dysfunctions in circumscribed regions of the
brain53,83.
In fact, this debate on whether higher human cognitive functions are localised to specific
brain regions, or distributed widely throughout the brain has been a long topic of debate over
the past few centuries. For example, the famous case of Phineas Gage, a railroad worker who
survived the impalement of a rod through his left frontal lobe, initiated many discussions in
the 19th century regarding the cerebral localisation of brain function. Although the accounts
of the symptoms of his almost total left frontal lobe lesion vary significantly, it is most often
reported as was described by Harlow, Gage’s practising surgeon. Harlow reported that the
lesion had almost no effect on Gage’s sensory, motor or cognitive function but led to a gross
and vulgar personality change84. As such, this case is commonly highlighted as a classic
example of the localisation of cerebral brain function. In this instance, the left orbitofrontal
lobe is described as a specialised region for "personality" or "social behaviour". However,
other surgeons at the time such as Bigelow reporting on Gage’s condition did not note any
significant changes in Gage’s mental functions. Rather he stated " . . . as portions of the brain
to which are allotted different functions, passions, etc, were entirely destroyed, phrenology
would teach that these functions would be entirely annihilated. This, however, was not the
case, for ‘the man was still able to walk off, and talked with composure and equanimity
of the hole in his head,’ and has never been . . . other than a rational man.85". Around
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the same time, other debates of a similar vein also include Broca’s phrenology-inspired
accounts of localised aphasia versus Wernicke’s associationist or “disconnection theory”
of speech pathologies54. As such, the idea that higher cognitive functions such as verbal
communication are dependent on network architecture and connectivity has been around
since the late 1800s.
Although lesion studies to assess theorised functional localisation have been experimen-
tally commonplace in neuroscience, experimental investigation into connectionist theories
of human pathologies have been difficult. Only recently with the advent of improved neu-
roimaging and electrophysiology techniques to study anatomical and functional connections
in living patients, have they been able to be experimentally investigated. Such studies are
now resurfacing under a newly defined field of "pathoconnectomics"83,86: the idea that
altered network architecture and functional connectivity leads to cognitive and behavioural
dysfunction. Undoubtedly, the recent technological developments enabling these investiga-
tions have contributed to the recent paradigm shift towards connectionist theories regarding
network-dysfunction in neurodegenerative and psychiatric disorders.
In this section I first examine the evidence supporting that network-level dysfunctions
underlie these pathologies, be it in the context of altered network topology and circuit
synchronisation in neuropsychiatric disorders or network-level pathological aggregate protein
progression in neurodegenerative disease. I then move on to discuss the therapeutic challenges
faced by these pathologies. Especially, I highlight the lack of effective anatomical network
targeting in the central nervous system as a key reason why these diseases have yet been so
resistant to new therapeutic developments.
1.2.1 Network dysfunction underlies neuropsychiatric and neurodegen-
erative disorders
1.2.1.1 Psychiatric disorders
A psychiatric disorder is described as a clinically significant behavioural or mental pattern
that causes significant distress or impairment of personal functioning. Mental health disorders
such as depression, schizophrenia, post-traumatic stress disorder (PTSD), phobias and autism
are common in the worldwide population, with one in four people being affected at some
point in their lives87. Patients suffering from mental disorders exhibit an extremely diverse
array of specific cognitive or behavioural symptoms. For example, a patient with agoraphobia
feels an overwhelming sense of fear when entering confined public spaces, leading to an
inability to use public transport or even leave their own home. On the other hand, an autistic
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child will, typically but not always, have difficulties making eye contact and communicating
effectively with others but will show obsessive interests in specific objects or hobbies88. In
recent years, there has been a growing body of evidence to show that these very specific
behavioural abnormalities observed in neuropsychiatric disorders have a network basis. They
are explainable not by studying individual neurons or circumscribed anatomical regions of
the brain, but rather by looking at the dynamics and properties of large-scale distributed
networks89,90.
Developments in magnetic resonance imaging (MRI) have been pivotal in enabling studies
into the altered anatomical and functional neural connectivity observed in human psychiatric
patients. Most commonly used in these studies are diffusion tensor imaging (DTI), a form of
diffusion-weighted MRI that uses the restricted diffusion of water through myelinated nerve
fibres to map white matter tracts, and functional MRI (fMRI) which detects the increased
oxygenation of active brain areas and so can be used to detect correlated activity of distinct
brain regions over time to give a measure of functional connectivity. Such neuroimaging
studies in humans typically compare anatomical and functional network connectivity between
patients and non-disease control groups. These comparisons have revealed alterations in
network connectivity that correlate to disease states, and in often cases, also to symptom
severity.
In the case of schizophrenia, over 200 DTI studies have shown that schizophrenic
patients have reduced white matter volumes in several brain regions and altered network
organisation of cortico-cortical connections91–93. Graph theory analyses of both DTI and
fMRI derived schizophrenia pathoconnectomic data have shown longer average path lengths
and therefore reduced global network efficiency94,95, supporting the hypothesis that cognitive
deficits are a result of altered network architecture and function. Interestingly, different
subpopulations of schizophrenic patients showed spatially distinct non-overlapping changes
in white matter abnormality. For example, chronic unmedicated patients showed decreased
fractional anisotropy in the left inferior longitudinal fasciculus and left inferior frontal-
occipital fasciculus that correlated with speed of visual and verbal processing and learning96.
In contrast, first-episode non-medicated paranoid schizophrenic patients showed fractional
anisotropy decreases in tracts only on the right hemisphere97, highlighting the specificity of
network dysfunctions to different clinical behavioural phenotypes.
Neuroimaging studies for other psychiatric disorders have also shown altered connectivity
in specific circuits. Patients with autism spectrum disorders display reduced connectivity that
is pronounced in circuits specific for mirror neuron systems and social processing, and the
degree of altered connectivity correlates to symptom severity98,99. Mood disorders such as
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major depressive disorder also show decreased integrity of prefrontal intercortical circuits100
and of the corticospinal tract101.
In addition to neuroimaging techniques, electrophysiological techniques such as elec-
troencephalography (EEG) and magnetoencephalography (MEG) have also been used to
map functional networks in patients. These techniques, when compared to fMRI, have the
advantage of directly measuring neuronal activity with a higher temporal resolution (1-100
Hz) which is sufficient to detect both local oscillatory patterns (gamma-band frequencies of
25-200 Hz) and the synchronisation of slower long-range networks (theta, mu, alpha and beta
frequencies of 4-25 Hz). Such studies have revealed abnormalities in network oscillation
and synchronization in many mental disorders. In schizophrenia, there is a reduction of beta
and gamma oscillation and synchronisation during cognitive tasks and during rest102,103 and
an increase in low frequency104 activity at rest. In autism, mu waves over the motor cortex
which are usually suppressed both during the generation and observation of movement show
a lack of suppression for observation of movements in autistic patients105,106. The degree
of mu suppression also correlated to the behavioural assessment of imitation105, suggesting
a dysfunction of the mirror neuron system in this condition and supporting the anatomical
findings of neuroimaging studies.
Taken together, such findings implicate altered network architecture and temporal syn-
chronization as a key process of psychiatric pathogenesis and highlight the importance of
network activity for normal brain function. They also emphasize that the specific biological
defects observed in these complex behavioural conditions can be attributed to circuits, as such
informing future novel therapeutic strategies for these debilitating yet currently incurable
conditions.
1.2.1.2 Neurodegenerative disorders
Neurodegenerative disorders are characterised by the progressive degeneration of neurons
over time that are mirrored by increasing losses of cognitive, behavioural and/or motor
function. A large number of post-mortem histopathological studies and neuroimaging studies
have revealed that the pathological protein aggregates that characterise these diseases often
appear first in an initial seeding site, and then show a stereotyped sequential pattern of
spreading through functionally and anatomically interconnected brain regions in human
patients. Table 1.1 lists the circuits that are involved in the propagation of protein pathology
in Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS),
Huntington’s disease (HD) and Frontotemporal lobe dementia (FTLD).
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Neurodegenerative Disease Prion-like IntraneuronalProtein Aggregate Spatiotemporal Pattern of Spread
Alzheimer’s Disease Tau (neurofibrillarytangles and neuropil threads)
Locus coeruleus →Transentorhinal region
(Layer Pre alpha) → Proper entorhinal cortex
and CA1 → isocortical association areas107
Parkinson’s Disease Alpha Synuclein(Lewy bodies and neurites)
Medulla oblongata/pontine tegmentum and
anterior olfactory structures → Substantia nigra
other basal mid- and forebrain nuclei
→ Neocortex108
Amyotrophic Lateral
Sclerosis SOD1, TDP-43, FUS
Agranular motor cortex, bulbar and spinal
somatomotor neurons → Reticular formation
and precerebellar nuclei → Prefrontal neocortex,
striatum → Anteromedial temporal lobe including
hippocampus109,110
Hungtington’s Disease Huntingtin
Cortical aggregates (extensive pyramidal cell loss)111–113
→ Striatum (selective degeneration of medium spiny
neurons)114
Frontotemporal Lobe
Dementia TDP-43, FUS, Tau
In TDP43 positive behavioural variant
frontotemporal dementia: basal forebrain
→ prefrontal area → motor cortex,
bulbarsomatomotor neurons, spinal cord
anterior horn→ visual cortex115
Table 1.1 The circuit spread of pathological aggregated proteins in human clinical disease.
This pattern of progressive transneuronal degeneration rather than for example, the
diffusion of the disease proteins to spatially adjacent cells, or to brain regions connected by
blood flow, suggest that the transfer of these pathological proteins occurs through functional
synapses. And indeed, increased neuronal synaptic activity is found to drive protein spreading
both in vitro and in vivo116–118. In addition, exogenous expression of human mutant P301L
Tau in the entorhinal cortex of mice through transgenic means results in the trans-synaptic
spread of tau pathology into neurons downstream of EC circuitry including the hippocampus
and cingulate cortex119.
This observation that patients with neurodegenerative diseases produce a stereotyped
sequential progression of symptoms that correlates to the stereotyped sequential spread of
pathological protein aggregates through large-scale brain networks strongly suggests that
increasing network dysfunction is a key component of pathogenesis120. This correlation
between pathological protein spread through affected circuitry and progressive symptoms
can be well demonstrated in ALS.
Patients initially presenting with ALS commonly experience motor symptoms in a
specific segment of the neuroaxis. For example, 70% of patients present with symptoms in
an asymmetrical limb121. ALS affects both upper and lower motor neurons at the same time,
causing a mixture of upper motor neuron symptoms (spasticity, poor balance, incoordination)
and lower motor neuron symptoms (muscle atrophy and twitching)121. With time, patients
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experience progressive motor losses into contiguous areas. Typically the disease may begin
in one arm, then progress to involve the ipsilateral leg or the contralateral arm, but not the
contralateral leg. As motor symptoms progress, patients will also progressively experience
cognitive deficits in frontal executive functions and memory122–125.
This clinical phenotype is mirrored by the histopathological changes observed with
disease progression. TDP-43 accumulation first begins in spinal a motorneurons and agranu-
lar motor cortex (especially Betz pyramidal neurons projecting through corticospinal and
corticobulbar tracts). This reflects the initial presentation of patients with a combination of
upper and lower motor neuron symptoms. Interestingly, lateral portions of the spinal cord
are affected more than the medial portions, mirroring the observation that distal muscles
tend to be affected first clinically in patients. In stage 2 of protein aggregate progression the
pathology spreads to the brainstem reticular formation, red nucleus and precerebellar nuclei
which receives indirect and direct input from the agranular motor cortex. In stage 3, first
the prefrontal and then post central areas of the neocortex become affected as well as the
striatum. In stage 4, anteromedial portions of the temporal lobe including the hippocampus
are subsequently affected109,110. The sequential spreading of protein pathology to prefrontal
and hippocampal regions mirrors the eventual development of frontal executive and memory
deficits in many patients. Further studies have found that the presence of cognitive decline
in patients correlates with the density and extent of pathological aggregates observed in
frontotemporal brain regions (especially the cingulate gyrus)126.
Despite such observed correlations between pathological protein progression and clinical
symptoms, it is unclear exactly how these pathological protein aggregates cause network
dsyfunction. Although the progressive death of neurons in particular brain regions correlates
with specific functional losses, cell death alone cannot explain the complex phenotypes
observed in some neurodegenerative disorders. For example, patients with neurodegenerative
dementia can have rapid fluctuations of symptoms within a day where they can have "lucid"
moments where memories and cognitive functions temporarily return127. These rapid fluctu-
ations suggest that phenotypic deficits are not purely determined by the level of neuronal
death but by complex changes in network activity that can be influenced by external factors
such as the cognitive demands of surrounding environments128 or altered physiological or
internal states. Studies show that pathological proteins can have more subtle effects than cell
death such as reducing neuronal excitability, synaptic plasticity or density129,130. In some
neurodegenerative models, degenerating neurons appear to be a phenotypic manifestation of
the "weakest link" within dysfunctional circuits131 rather than a direct effect of protein accu-
mulation. Taken together, evidence suggests that neurodegenerative pathogenesis involves a
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progressive increase in circuit dysfunction which may ultimately lead to cell death and this
in turn can explain the long prodromal stages characteristic of neurodegenerative diseases
and the rapid fluctuations of cognitive function observed in patients120,132.
1.2.2 Network-targeted therapy for circuit dysfunctions
There is a great need for developing efficient therapies for neurodegenerative and psychiatric
disorders. Even treatments that are partially effective for these diseases can have a significant
impact on quality of life of these patients, and the global market for such therapies is
extremely large. For example, the leading antidepressants have global sales of 1-3 billion
dollars p.a. and even a partially effective Alzheimer’s drug is projected to yield 20 billion
US dollars per annum. Despite the considerable amount of resources that have gone into
developing therapeutic agents for these diseases, there has been relatively little progress in
the treatment of these debilitating conditions. This shortfall has been for a variety of reasons
including an underlying lack of understanding of the aetiology of most CNS disorders,
difficulty in accessing the CNS systemically, and difficulty in producing specific therapeutic
agents that can target the CNS selectively enough to evade side effects.
Given the increasing evidence that extensive network dysfunction is a key component of
these diseases, we argue that therapeutic agents also need to target the dysfunctional circuits
that underlie the symptomology of these conditions. We propose a shift in paradigm for the
therapy of neuropsychiatric and neurodegenerative conditions and argue that there is a need
for network-specific agents that can anatomically target the circuits implemented in these
diseases. Conversely, we also suggest that the lack of efficacy of the current pharmacological
and viral therapeutics in development may be due to their lack of circuit-specificity.
In this section I present an example of effective network-based therapy as employed by
empirically verified psychotherapeutic techniques in humans and animal models of PTSD.
I also highlight the promising potential of viral gene therapy for neurological conditions,
especially hereditary ones, and then cover the notable challenges and difficulties faced when
trying to develop effective circuit specific vectors for neurological therapy.
1.2.2.1 The network-basis of effective psychotherapy regimens
Psychotherapy is a widely used and accepted method of treatment for many mental disor-
ders133–135. The general effect of psychotherapy (estimated for all types of therapy, patient
and outcome) is 0.85 standard deviation units compared to untreated controls133. When
compared to drug therapy, many studies reveal that psychotherapy not only has compa-
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rable efficacy to drug treatments but also has longer-lasting enduring effects on patient
outcome133,136. Despite this clear empirical observation, scientific explanations for the
efficacy and endurance of psychotherapy have been lacking. With the development of more
sophisticated animal models of psychiatric conditions and the ability to perform live fMRI
imaging in human patients, there has been increasing investigation into the underlying neural
bases of psychotherapeutic efficacy in order to enhance our understanding of these conditions
and improve existing therapies.
fMRI studies in human patients examining the underlying neural basis of psychotherapy
in anxiety and mood disorders show that cognitive therapies for anxiety and mood disorders
alter cognitive-affective processing networks. For anxiety and related disorders, fMRI
studies have revealed that cognitive behavioural therapy increases prefrontal control of
subcortical structures such as the amygdala that have shown to be hyperactive in these fear
conditions137. Similarly, fMRI studies in depressive patients receiving cognitive therapy
(CT) have shown subsequently increased functional use of the dorsolateral prefrontal cortex
(DLPFC) in cognitive tasks, and decreased amygdala activity in response to emotionally
related stimuli136. These fMRI findings suggest that cognitive therapies help patients to
recruit prefrontal regulatory brain mechanisms and support the underlying aims of CT which
is to replace maladaptive thought patterns and automatic emotional reactivity with altered
or more controlled cognitive processing. They also highlight the potential advantages of
modulating cognitive emotion regulation networks in the treatment of psychiatric conditions.
Animal models of psychiatric conditions have also helped to dissect the underlying neural
bases of psychotherapy. For example, Eye Movement Desensitization and Reprocessing
(EMDR) psychotherapy is one of the most recommended therapies for post-traumatic stress
disorder138–141. Post-traumatic stress disorder (PTSD) is a debilitating anxiety disorder that
is characterised by the involuntary and vivid re-experience of previous traumatic events.
Although many effective therapies for PTSD exist for short-term treatment, PTSD patients
often experience relapse142. In EMDR, patients are asked to recall traumatic images whilst
simultaneously orienting to bilateral sensory input (e.g eye movements or finger tapping).
Although a clear mechanistic explanation for EDMR efficacy is yet lacking, it is hypothesised
to work by aiding the long-term reprocessing of traumatic memories by sensory stimulation.
The long-lasting effect of EDMR in the prevention of fear recovery has been shown in
translational mouse PTSD models, enabling further experimental investigation143. Fear
reduction in mice following alternating bilateral sensory stimulation (ABS) is associated with
enhanced superior colliculus-medial dorsal nucleus excitatory transmission, and increased
inhibition of the basolateral complex of the amygdala (BLA). In addition, optogenetic
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silencing showed that both the SC-MD and MD-BLA pathway were necessary for ABS
induced fear-attenuation. In contrast, photostimulation of the SC-MD pathway was sufficient
to prevent fear reoccurrence144. This study clearly demonstrates the circuit-level effects
of EMDR therapy and supports the hypothesis that psychiatric conditions are essentially
network-disorders which can be alleviated or cured through targeted modification of these
disease circuits.
1.2.2.2 Viral gene therapy for neurodegenerative conditions
A big challenge for effective developments of CNS therapies is the underlying lack of molec-
ular understanding of CNS disease processes, posing a problem for identifying specific
molecular targets for therapy. However, in the less common cases of monogenetic hereditary
neurodegenerative disorders, the cause of the disease has been clearly identified, offering
a clearer target for therapy. For these conditions, therapeutic strategies could include gene
replacement for loss-of-function mutations, knock-out of gain-of-function toxic genes or cor-
rection of pathogenic mutations by targeted base pair substitutions using more sophisticated
CRISPR/CAS9 genome editing techniques. However, even in such cases where the aims of
gene therapy are relatively clear, therapeutically efficient execution of these aims has proved
difficult.
The two major viral vectors that have been investigated for CNS gene therapy are
lentiviruses and recombinant adeno-associated viruses (rAAVs) as they have low immuno-
genicity, low toxicity and enable stable long-term gene expression in infected cells. They
have been used in many clinical trials with varying levels of success. Problems have included
host immunity to wild type viruses from which therapeutic vectors are engineered, host
immunity to transgenes145 and difficulties in appropriate CNS targeting146 and transgene
expression levels147.
In terms of anatomical targeting, many different possible viral delivery methods have
been attempted to access affected CNS regions in disease. Local viral targeting in the
CNS can be achieved surgically by direct intracerebral stereotaxic injections into affected
brain regions. However this method is invasive and most often shows limited efficacy due
to its limited spatial coverage. One notably successful use of this method was the direct
stereotactic injection of a rAAV type 2 vector expressing the human aromatic L-amino acid
decarboxylase (AADC) gene into the putamen of children with inherited AADC deficiency.
Here, the putamen was targeted as it is the major site of AADC activity in the brain and this
method successfully stimulated motor development in treated children148. This is a proof of
principle that in vivo gene therapy in the brain is feasible and can have notable therapeutic
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effects in humans when targeted into a therapeutically relevant brain region in an efficient
way. However, the authors of this paper also note the limitations of this topical approach
which does not enable broad coverage of the entire putamen or of CNS regions outside of the
putamen that also require dopamine and cause non-motor symptoms of ADCC deficiency
such as the hippocampus and autonomic system. Thus they also suggest the need for wider
delivery of the vector into the brain.
For these reasons, other AAV serotypes (e.g. rh.8, 9 and 10149) or engineered coat
capsids150 that show an increased ability to cross the blood brain barrier (BBB) have been
pursued extensively for non-invasive, brain-wide systemic CNS gene therapy. However
the overall efficiency of BBB penetration is still sub-optimal for safely obtaining effective
therapeutic doses in the CNS. The requirement for high systemic viral load delivery poses
problems for viral transduction of non-neural peripheral tissues which can cause significant
off-target effects as well as the induction of host immune responses. In addition, BBB
crossing serotypes can show increased tropism for glial cells as opposed to neurons which
are most often the target of gene therapy methods149.
The other notably effective method of CNS access for gene therapy is the use of trans-
duced hematopoietic progeny cells that can migrate into the CNS. Such an approach is
most commonly applied to lysosomal storage diseases, where supraphysiological levels
of expression of deficient enzymes by transduced hematopoietic progeny cells that have
migrated to CNS tissues can scavenge built up toxic materials. In one promising case, ex-vivo
lentiviral gene therapy of hematopoietic stem cells followed by infusion back into patients
showed promising efficacy in the treatment of metachromatic leukodystrophy (MLD), a
neurodegenerative lysosomal storage disease caused by the deficiency of the arylsulfatase
A (ARSA) gene. Following gene therapy, patients showed reconstituted ARSA activity in
the cerebrospinal fluid and halted disease progression151. However, to date, ex-vivo gene
therapy has largely shown limited efficacy due to difficulties in achieving stable high sup-
raphysiological levels of deficient enzymes in progeny cells. In addition, such approaches
can only replace deficient proteins in transduced hematopoietic progeny cells to modify
the environment of the CNS rather than target genes in neurons themselves, which may be
necessary for the treatment of other more common acquired and hereditary CNS diseases.
1.2.2.3 Challenges of network-targeting for therapy
Despite the accumulating evidence that network dysfunction is at the heart of many neuro-
logical disorders, our ability to safely manipulate networks for therapy is limited. None of
the existing viral vectors or therapeutic molecules currently in development for the treatment
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of neurological disease are circuit-specific. As such, targeting to affected circuits in disease
are attempted non-specifically through topical local injections or brain-wide delivery through
the blood or cerebrospinal fluid. However, such methods are yet insufficient to obtain the
high therapeutic doses into circuits that are required for effective treatment.
The first challenge that determines the success of any CNS therapy, is the ability to obtain
efficient access into the CNS tissue. However, due to the high anatomical protection the
CNS receives from the skull, spinal cord and blood brain barrier (BBB), access into the
CNS can be difficult. Compared to other peripheral tissues that are separated from the blood
by single-cell thick capillaries, the brain is perfused by a specialised three-layered BBB
consisting of endothelial cells with tight junctions, astrocyte end-feet and pericytes152. As
a result, the BBB prevents large or hydrophilic molecules from entering the brain from the
blood, making the development of minimally invasive, peripherally delivered therapies that
can access the CNS very difficult. Pharmacological compounds that can efficiently penetrate
the BBB must be lipophilic or recognised by membrane transport systems. In addition, they
also must not be substrates for multi-drug resistance transporters such as the efflux transporter
P-glycoprotein that is expressed in the BBB153,154. Due to the difficulties faced by traditional
pharmacological methods, there has now been an increasing interest in novel delivery systems
into the CNS, such as lipid based nanocarrier systems155 or genetically engineered viral
vectors that can cross the BBB156. Although non-viral vectors are promising due to their more
simple production methods and preferred safety profile, they show relatively low efficacy
and require repeated administrations as they only mediate transient effects which increases
the risks of triggering immune responses. Therefore, viral gene therapy for long-term stable
expression of disease modifying proteins is a highly pursued therapeutic strategy not only for
hereditary but also for acquired neurological conditions.
Second, even with efficient access into the CNS, the density and high connectivity of
neurons in the CNS makes specific dysfunctional circuits very hard to target selectively in
vivo. No therapeutic agents in development for pharmacological or viral gene therapy in the
CNS are yet trans-synaptic or circuit specific. Although a degree of spatial specificity can
be obtained through direct local stereotactic injections of therapeutic agents, they cannot
cover the widespread circuit dysfunctions that underlie many neurodegenerative and neu-
ropsychiatric diseases and this is often a reason for the lack of or reduced therapeutic efficacy
as discussed in the previous subsection.
In contrast, we propose that such widespread brain-wide circuits can uniquely be targeted
using single injections of trans-synaptic viral vectors such as the rabies virus which has been
used extensively for trans-synaptic circuit tracing in experimental animals. Unlike pharmaco-
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logical compounds or AAVs, the rabies virus is highly neurotropic and can propagate through
functional synapses even if they are far away from the initial site of delivery. This not only
enables long-range circuit targeting in the brain by single injection, but also enables efficient
peripheral delivery of the virus into the CNS as the rabies virus can infect neuron terminals in
peripheral injection sites. For example, given the involvement of both upper and lower motor
neurons in the pathogenesis of ALS, one would ideally want a vector to target both spinal
a motorneurons and pyramidal Betz cells in layer V of the motor cortex. A single rabies
virus injection into the muscle would enable efficient infection of peripheral motor neuron
terminals in the muscle. Subsequently the rabies virus would be transported retrogradely
into the spinal motorneuron soma and from there trans-synaptically retrogradely propagate
into upper motor neurons in the motor cortex (Fig. 1.1A). In contrast attempts to target both
upper and lower motor neurons using topical injections of non-transsynaptic vectors would
require two separate invasive injections into the spinal motor neurons and cortical upper
motor neurons (Fig. 1.1B). Alternatively, systemic delivery would not enable as efficient
delivery of therapeutic agents specifically into the motor network. As such, the rabies virus
in theory overcomes two of the major problems hindering CNS therapy development (the














Fig. 1.1 Rabies virus enables non-invasive circuit-specific targeting for therapy in vivo (A) Single
rabies virus injection into the muscle enables targeting of both lower and upper motor neurons affected
in ALS. (B) Single injection of non-transsynaptic molecules or vectors can only target lower motor
neurons following intramuscular injection.
In order to develop the rabies virus from a experimental tool into a therapeutic vector, it
needs to be engineered to have key characteristics such as lack of pathogenicity, low immuno-
genicity, high neurotropism and efficient execution of permanent gene modification. In the
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first experimental chapter of my thesis, I present the design and development of a second gen-
eration self-inactivating rabies virus (SiR 2.0) vector that demonstrates increased suitability
for therapeutic use (self-inactivation, minimal immunogenicity and increased neurotropism).
In the second experimental chapter I present the incorporation of the CRISPR/CAS9 system
into the SiR genome, leading to the first production of a circuit-specific gene-modifying viral
vector (SiR CAS9 gRNA) that could be used to knock out specific genes within specific
circuits in vivo.
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1.3 A novel mechanism of circuit communication: interneu-
ronal protein transfer
The brain computes its functions through neural circuits. By and large, the focus of neural
circuit communication has been defined by synapses and the rapid transfer of electrical
signals between one neuron to another through ligand-gated ion channel (LGIC) signalling.
LGIC signalling is optimised to transmit quick, transient and membrane-localised changes in
the responding cell and so is ideal for the fast transmission of electrical signals from one cell
to another. However, interneuronal circuit communication is not defined entirely by the fast
transmission of electrical signals from one cell to another. Throughout development and adult
life, interneuronal communication must also be able to induce longer-term modifications of
synaptic properties which involve changes in gene expression and cell protein composition.
Although LGIC signalling, with all its complexities, can induce structural changes in neurons
through secondary effects of membrane potential changes, the signalling of longer lasting
changes to neuron phenotype (such as synaptic strength, cell tropism or axon growth) are
more suited to alternative signalling molecules that can directly alter the cell’s transcriptional
and translational output. For example, steroid hormones can diffuse through a cell membrane
and bind directly to cytoplasmic receptors to form hormone-receptor complexes that directly
alter gene expression.
Not surprisingly, neurons are known to be able to communicate by many other signal
transduction mechanisms such as G-protein coupled receptor signalling157, neuromodula-
tors158 and neurotrophic factors159. Recently, there has been a growing body of evidence
suggesting that neurons can also communicate with one another through the direct transfer
of effector molecules such as RNA, lipids and proteins160,161. For example, the commonly
observed transsynaptic movement of pathological protein aggregates in neurodegenerative
disease begs the question: why do these proteins move interneuronally at all? Are these
observations revealing an underlying physiological process by which neurons communicate
with one another by methods other than those classically studied? Since the 1980s, the
trans-synaptic transfer of proteins has been used as a method of neural network tracing, show-
ing that this process is not purely pathological162–168. Recently, there have been increasing
discoveries of more physiological examples of trans-synaptic protein and mRNA transfer
such as interneuronal transcription factors (e.g. Otx2169) and retroviral gag-like proteins (e.g.
Arc170). Such interneuronal protein transfer is proposed to play a role in the development
and maintenance of neuronal populations, cellular network architecture and modulation of
synaptic properties and intercellular connectivity171.
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This form of communication is inherently different from conventional signal transduction
mechanisms and is hypothetically an extremely efficient method of controlling the concerted
change of protein composition in pre and post-synaptic terminals. The advantages over classi-
cal signal transduction through secreted messenger molecules include that the transfer of such
effector molecules would be immediately spatially specific to desired synaptic connections
and that it economically overcomes the difficulties of communicating transcriptional changes
between the nucleus of a neuron to its axon or dendritic terminal. In this section of the
introduction I will present the accumulating evidence for the transfer of protein between pre-
and post-synaptic terminals as a novel method of interneuronal communication. Finally, in
the last experimental chapter (Chapter 5), I describe work that has been conducted to develop
novel molecular tools and experimental systems that would enable further exploration of the
mechanisms behind this observed phenomenon of interneuronal protein transfer.
1.3.1 Pathological protein movement in neurodegenerative disease shows
circuit logic
Histopathological studies reveal that many of the protein aggregates which characterise
neurodegenerative disease show a stereotypical sequential pattern of spreading that corre-
lates with synaptic connectivity (Table 1.1). Experimental evidence also suggests that the
propagation of these proteins may be trans-synaptic. For example, exogenous overexpression
of neurodegeneration-associated proteins in animal models leads to propagation of those pro-
teins to synaptically connected brain areas (e.g. pathological human tau (P301L) expression
in the enthorinal cortex leads to propagation to the hippocampal formation and cingulate cor-
tex119,172). In in vitro systems, activity dependent release of tau117 has been observed whilst
addition of botulinum toxin, which inactivates synaptic vesicle fusion, blocks transneuronal
spreading of mutant huntingtin protein in mixed organotypic brain slice co-cultures118.
We propose that the visualisation of the trans-synaptic movement of these disease-causing
protein aggregates may be revealing a more general and universal process of interneuronal
protein transfer. As the protein aggregates that form in disease are easier to visualise and
trace experimentally, much of the research on the movement of these proteins focuses on
observing the spread of mutant or aggregated forms. However, we suggest that this ability
for transneuronal protein transfer is most probably not limited to pathological processes. For
example, wild type tau is released from neurons in an activity dependent manner117 and wild
type tau pathology has been shown to spread faster to more distant brain areas then its mutant
counterpart173.
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1.3.2 Traditional protein based circuit tracing methods demonstrate
trans-synaptic protein movement
Proteins have historically been used to trace neural circuits. The use of proteins as circuit
tracers implies that some proteins are specifically transported through synaptically connected
circuits.
For example, plant lectins162 and wheat germ agglutinin163,164 were used as traditional
circuit tracers in olfactory165, vestibular, auditory166 and peripheral sympathetic circuits167
in a variety of different living organisms. To demonstrate an example, unilateral intranasal
irrigation with lectin-HRP leads to positive labelling unilaterally in the olfactory nerve, the
olfactory bulb and the terminal forebrain regions of mitral and tufted cells165. Bacterial
toxins such as cholera toxin and tetanus toxin have also been shown to have trans-neuronal
tracing properties in certain experimental conditions in vivo167,168. Interestingly, the patterns
of labelling intensities of primary and second order neurons suggest that different proteins
have different mechanisms of trans-synaptic labelling. For example, tetanus toxin shows
relatively low levels of labelling in both primary and secondary neurons, suggesting a high
efficiency of trans-synaptic transfer. In contrast, WGA results in extremely high labelling
intensities of primary neurons but weak labelling of secondary neurons167. This suggests that
the trans-synaptic transfer efficiency of WGA is low and that its use for trans-synaptic tracing
is dependent on the high levels of receptor-mediated endocytic uptake into the primary neuron
by binding to sialic acid and N-acetyl glucosaminyl residues on the plasma membrane.
Labelling of proteins by injection of radioactively labelled amino acids have also shown
similar results174,175. For example, intraocular injection of tritiated amino acids results in the
visualisation of radioactive proteins in optic axons, lateral geniculate body and contralateral
visual cortex suggesting that these amino acids are assimilated into proteins which are
transferred through known visual pathways174.
1.3.3 Physiological examples of functional interneuronal protein move-
ment in development and adult physiology
Neuronal transcription factors such as homeoproteins encode positional information along
various axes of neural structures throughout development176. Homeoproteins can also be
involved in the regulation of adult physiology (e.g. Engrailed is expressed in adult aminergic
nuclei177). Interestingly, these homeoproteins, which play such pivotal roles in the transfer
of positional information, can also be transferred between cells by atypical secretion and
internalisation methods169. Their DNA binding homeodomains contain highly conserved
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and distinct internalisation and secretion signals which have been confirmed through deletion
studies and gain of function studies using synthetic peptides178,179. Thus, homeoproteins
can spread transneuronally, bind directly to DNA/RNA to control transcription/translation180
and thus regulate neuronal functions such as neurotrophism179, neural morphogenesis181,
axonal arborisation and target choice182. For example, the trans-synaptic transfer of Otx2 is
physiologically implicated in vivo to activate postnatal plasticity in visual pathways169.
Another more recent discovery of a physiological neuronal protein showing a clear
ability for trans-synaptic transfer was that of Mammalian Activity-Regulated Cytoskeleton-
Associated protein (Arc). Arc is an activity-regulated immediate early gene (IEG) which
mediates many aspects of synaptic maturation and plasticity, learning and memory183. For
example, immediately after a rat is exposed for 5 minutes to a novel environment, there is
a brief burst of Arc transcription in memory consolidation networks which quickly returns
to baseline levels (nuclear signals return to baseline within 16 minutes whilst cytoplasmic
and dendritic mRNA induction decreases more slowly over a time-scale of 20-60minutes)184.
Mutations in this gene have also been implicated in neurodevelopmental disorders such as
autism185 and schizophrenia186. However, despite its clear importance in many aspects of
brain function, the molecular functions and mechanisms of Arc are still unclear. Recently
it was uncovered that the Arc protein, which contains a retroviral group antigen (Gag)-
like domain, could self-assemble into virus-like capsids that can package RNAs and are
transferred trans-synaptically through extracellular vesicles and endocytosed by receiving
partners170,187. This trans-synaptic transfer is dependent on the 3’UTR of Arc mRNA, and it
was also shown that pre-synaptic Arc mRNA with an intact 3’UTR is necessary for synaptic
expansion and plasticity across the Drosophila neuromuscular junction170.
1.3.4 Remaining questions for interneuronal protein transfer as a po-
tential interneuronal communication mechanism
Despite the rapidly growing body of evidence to support transneuronal protein transfer,
we still have very little understanding of its mechanistic details, control and functional
implications. A particular area of controversy is that, despite much observational and
indirect experimental support, there is still no direct evidence that clearly shows that these
proteins travel trans-synaptically. In addition, many other fundamental questions remain
unanswered. For example, how universal is this process? How many different proteins are
being transferred transneuronally and what are their identities? When and where are these
proteins transferred in development and adulthood? Does this process play a functional role
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in normal circuit function or malfunction? Answering these questions is of fundamental
importance as they address a key molecular aspect of interneuronal communication and
functional neural circuitry. In addition, a greater understanding of protein transfer may aid in
the identification of new potential drug targets to prevent pathological protein propagation in
neurodegenerative disease or to control circuit activity in psychiatric conditions.
1.4 Aims of the thesis
In the introduction of this thesis, I have argued for the importance of neural networks in brain
function. I have highlighted that despite much progress over the past century, we still face
many technical difficulties when trying to experimentally manipulate or visualise network
structure and function in live animals. This has resulted in gaps between the cognitive
theories of brain function and the biological investigations of these theories. In the three
following experimental chapters of my thesis I present work which aims to develop novel
circuit-specific experimental tools that can help to answer some of the important remaining
questions regarding circuit function. I also highlight the potential uses of these network
specific tools for potential gene therapy in the treatment of neurological disease.
1. In the first experimental chapter, I describe the design, production and in vivo charac-
terisation of a novel SiR 2.0 circuit-targeting viral vector. The design of this vector
combines the advantageous qualities of two previously existing trans-synaptic rabies
vectors to create a new improved trans-synaptic vector that: a) self-inactivates, thus
enabling life-long investigation into labelled circuits b) is minimally immunogenic
during its short period of transcriptional activity before self-inactivation and c) shows
higher efficiency of trans-synaptic targeting of peripheral circuits.
2. In the second experimental chapter, I aim to functionally incorporate into the SiR
2.0 genome the components of the CRISPR-Cas9 genome editing technology. The
motivation is to create a circuit specific viral vector that can efficiently and perma-
nently modify endogenous genes of host cells in vivo. This would enable long-term
experiments to establish causality between the role of specific genes within circuits and
the computation and generation of behaviours in live animals. It also has the promising
potential to be developed as a gene-therapy vector that can efficiently target large-scale
diseased networks in neurodegenerative and psychiatric conditions - something which
is yet hard to achieve with the existing non-circuit specific vectors.
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3. In the third and final experimental chapter, I aim to develop novel methods to facilitate
further mechanistic investigation into the observed phenomenon of interneuronal
protein transfer. First, I investigate the efficacy and suitability of different experimental
systems which can be used to study protein transfer in neural networks in vitro and in
vivo. Second, I aim to develop an unbiased top-down proteomic approach to visualise
and identify novel proteins showing inter-neuronal movement. Third, I aim to develop a
small split-CRE based protein tag that would enable the amplification of interneuronal
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nomenclatureDESeq2Differential gene expression analysis based on the negative bino-
mial distribution, version 2
2.1 Mice
All animal procedures were conducted in accordance with the UK Animals (Scientific
procedures) Act 1986 and European Community Council Directive on Animal Care. All
mice were bred and maintained in pathogen and opportunistic agents-free conditions and
monitored quarterly in the ARES Animal Facility in the Babraham campus. A complete
list of the wild-type (WT) and transgenic lines used in this thesis, with information of
expression patterns and origins can be found in Table 2.1. All transgenic mice were isogenic
in a C57BL/6 background. Biopsies for the genotype screening were taken by the LMB
and ARES biological service groups and the genotyping reactions performed by the LMB
genotyping facility.
All experimental procedures were performed in the LMB Animal Facility. Animals were
group-housed in a 12 hours light/dark cycle (7 a.m. to 7 p.m.) with food and water ad
libitum. Experiments in adult animals were performed on mice aged between 8 and 12 weeks.
Intramuscular injections were carried out in pups aged P3-P5.
Line Name Expression Pattern Source
C57BL/6J - The Jackson Laboratories:000644










of the YFP reporter gene
The Jackson Laboratories:
006148
Table 2.1 List of mouse lines
2.2 Cell lines
HEK293T, BHK-21 and mouse Neuro2A cells were purchased from ATTC. All cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10%
fetal bovine serum (FBS, Gibco) and 100units/mL penicillin and 100µg/mL Streptomycin
unless otherwise specified. The cells were maintained in a humidified incubator with 5% CO2
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and were passaged three times a week. For MutRS or BioID2 studies, AnI (Jena Bioscience)
or biotin was added at the stated concentrations to the culture medium respectively.
2.3 Plasmid design and construction
All plasmids produced in this thesis were generated by gibson assembly or by use of classical
restriction enzymes, backbone dephosphorylation and DNA ligation (T4 DNA ligase, NEB).
The pAAV vectors used in this thesis were generated by gibson assembly to insert se-
quences between the inverted terminal repeat (ITR) sequences of a rAAV plasmid backbone
originally supplied by Dr. Silvia Arber. Expression constructs for cell mixing experi-
ments were cloned into the pCAG-Brainbow 3.0 backbone (plasmid #45176, Addgene).
Lentiviral vectors (pLenti) were derived from an empty third generation lentivirus transfer
vector plasmid supplied by Dr. Marco Brancaccio (“361 polylinker”, originally pCCL-SIN-
18PPT.Pgk.EGFP-WPRE). The backbone was opened with XbaI and KpnI followed by
gibson assembly with PCR amplified promoters (CMV or CAMKII) and different inserts
(e.g. iCRE, GFP, P2A-human wild type 0N4R Tau). Inserts were designed with 30 base pair
overlapping regions for efficient assembly.
The F2, F6 and F9 linkers were synthesised using gBlock Gene Fragments (Integrated
DNA Technologies) and inserted by Gibson Assembly.
Coding sequences for the following genes were PCR amplified from gifted plasmid
vectors:
• Otx2 was a gift from Malin Parmar (Addgene plasmid #35001)
• WGA was a gift from Kwang-Soo Kim (Addgene plasmid #80337)
• MutRS was a gift from David Tirrell (Addgene plasmid #63177)
• BioID2 was a gift from Kyle Roux (Addgene plasmid #74224)
• GFP nanobody (GBP) was a gift from Joe Watson188
2.4 Viral production
2.4.1 Lentivirus production
Human HEK 293T cells were seeded onto 10 cm plates and transfected with polyethylen-
imine (PEI) the following day with 3 µg ENV plasmid (VSV-G), 5 µg Packaging plasmid
(pMDLg/pRRE), 2.5 µg of pRSV-REV and 16-18 µg of transfer plasmid per plate using
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polyethylenimine (PEI). Five hours later, transfection medium was removed and replaced
with fresh medium. After fourteen hours, medium was removed once more and replaced
with 5mL fresh medium to begin the collection of lentivector. The cell supernatants were
collected after 24 hours and filtered with a 40 µm filter to remove cellular debris (STERIFLIP
millipore units). The supernatants were either used directly to transduce cells in vitro or
purified by ultracentrifugation at 50, 000 RCF for 2h 30min at 4°C on a sucrose cushion for
in vivo injections. The viral pellets were resuspended in PBS and stored at -80°C until further
use. Productions were functionally titered by performing in vitro infections on HEK293T
cells, with serial dilutions of viral preparations.
2.4.2 AAV production
For each viral preparation, human HEK 293T cells were seeded onto 10 dishes of 15cm
plates. At 80% confluency, cells were transfected with AAV helper plasmid (Rep/Cap),
AAV vector (with expression cassette) and pHGTI-adenol (to provide adenoviral helper
function) using PEI. 60h after transfection, cells were dislodged from the plate and collected
by centrifugation at 2000RPM for 10 minutes. The cell pellet was then washed with 15mL
PBS and resuspended in 10mL lysis buffer (150mM NaCl, 20mM tris pH 8.0, filter sterilized
and stored at 4ºC). Cells were subsequently freeze-thawed three times using dry ice/ethanol
and a 37’C water bath. Cell lysates were dounce homogenized 20 times to destroy cell
nuclei and put into a new falcon tube. MgCl2 and benzonase (Sigma) was added to a final
concentration of 1mM and 250U/mL respectively and the mixture was incubated at 37ºC for
10-15 min to dissolve genomic DNA/protein aggregates formed during freeze-thaw cycles.
Cell debris was spun down at 4000 RPM, 4ºC for 20min and the viral supernatant was
purified further using 17, 25, 40, 60% Iodixanol gradients in PBS, 1mM MgCl2, 2.5mM KCl
(Optiprep, Sigma). 0.0005% phenol red was added to alternate layers for visualisation. Viral
lysate (14-15mL) was added to the top of the gradient in a 36mL Optiseal tube (Beckman
362183) and centrifuged for 90min at 48-50,000rpm (Beckman VTi50 rotor) at 16ºC. The
40% viral fraction was harvested, diluted in PBS and centrifuged for 30min 3500rpm at 4’C
(Eppendorf 5810R) in Millipore Amicon 100K columns (UFC910008) for a total of 3 times
for removal of iodixanol and concentration of virus. 150-250µL of virus was recuperated
after the last spin, aliquoted and stored at -80ºC. The titer was determined by calculating viral
genome copies from RT-qPCR using primer pairs for the CMV promoter, and serial dilutions
of linearized vector plasmid for the standard curve. Purified AAVs were treated with DNase
to remove residual plasmid DNA from purification (15 min, 37’C, DNAseI Roche followed
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by 10min inactivation at 95’C) and then incubated with proteinase K (Sigma Aldrich, 37’C,
15 min) before quantification with RT-qPCR.
2.4.3 WT and SiR DG rabies virus production
2.4.3.1 Generation of SiR virus production cells
HEK293T cells expressing GFP, rabies G (chimeric oG or N2C), and TEV protease to
high levels needed to be selected for efficient viral productions. Lentiviruses encoding
these proteins along with a puromycin selection marker were produced to transduce the
exogenous cassette into production cell lines. For infection, HEK293T cells were split into
T75 flasks at 40% confluency with 5mL lentiviral supernatant and 5mL culture medium.
The following morning, viral supernatant was changed to fresh cell culture medium. 24
hours after medium change, successfully transduced cells were selected for with 1ug/ml
of puromycin. A negative control of uninfected cells were also incubated with 1ug/ml of
puromycin to assess puromycin toxicity. Usually, transduced cells were selected over a
period of 2-3 days. Following puromycin selection, cells were additionally sorted for high
GFP expression by FACS on a Beckman Coulter MoFlo High Speed Cell sorter.
2.4.3.2 Recovery of SiR virus from plasmids
For each viral production, 4 wells of a 6 multi-well plate were seeded with HEK-TGG (HEK
293T expressing TEV protease, B19 oG or N2C G protein, and GFP) and transfected with
PEI at around 85% confluency with:
• the pSAD or pN2C SiR genome (12µg)
• 4 plasmids expressing the viral proteins N, P, L, G for either the N2C or B19 strain (6,
6, 3, 3 µg respectively)
• pT7 polymerase (2.4µg)
The following day, supernatant was replaced with fresh medium with additional gentamicin
at 50µg/mL. After medium change, cells were left to recover from transfection and pooled
into a T75 flask when reaching 100% confluency (typically 24-48 hours after medium
change for Sir B19, 48-72 hours after medium change for SiR N2C). When the re-plated
cells approached 80% confluency, the medium was changed to 2%FBS/DMEM solution
and incubated at 35°C, 2% CO2 for 2-3 days. For viruses that could be visualised with a
fluorescent marker, typically one would observe viral spreading in >50% of production cells
around this time. Once viral infection was visible in >50% of cells, or once cells approached
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80% confluency, viral supernatant was collected from cells after incubation for 2-3 days at
35°C, 2% CO2. Two rounds of cell expansion and supernatant collection were conducted
and used for subsequent high titer viral production.
2.4.3.3 High-titer SiR production
HEK-TGG cells were plated on a T75 flask to 80-85% confluency and and transduced with
5-6mL of supernatant collected from cells transfected with plasmids. The following day, the
medium was exchanged to 2% FBS/DMEM and cells incubated at 35°C and 3% CO2. Once
confluent, cells were split 1:2 into a T175 plate. When cells approached 80% confluency
(and for visible viruses, when 80% of cells were infected with virus), the medium was
changed to 2% FBS/DMEM and incubated for 24-48 hours for the first supernatant collection.
Subsequently, fresh 2% medium was added to the cells and incubated for another 24-48 hours
for the second supernatant collection. The length of supernatant collection was determined
by the kinetics of viral production and cellular viability. After collection of viral supernatant,
cell debris was removed by centrifugation at 4000 rpm for 10 min followed by filtration with
0.45 mm filter (Millipore, SLHV033RS). The virus was concentrated by ultracentrifugation
(4°C, 25000rpm, 4h or longer, Sw32Ti rotor) on a 20% sucrose cushion189, resuspended in
50-75uL PBS and stored at -80°C.
2.4.3.4 WT DG rabies virus production
WT DG N2C or B19 viruses were produced very similarly to SiR viruses but with HEK-GG
cells (HEK 293T expressing the B19 oG or N2C G protein and GFP). Typically, incubation
times for supernatant collection were approximately halved for WT viruses compared to SiR
viruses due to increased viral replication and spreading kinetics in cell culture.
2.4.4 Rabies virus titration
2.4.4.1 Functional titration in vitro
Functional titration of rabies virus was performed through in vitro infections of HEK293T
cells with serially diluted viral preparations as described in previous reports189–191. HEK293T
cells were plated onto 6 well plates and at 70-80% confluency infected with serially diluted
virus. 48h p.i. cells positive for virally expressed fluorescent markers were quantified by
FACS. The number of infectious units per ml was calculated referring to the dilution giving
a low multiplicity of infection (1-10%) by multiplying the number of infected cells by the
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dilution factor. This method is referred to as the "traditional" method of titration in this thesis
as it is the most commonly used method used for the titration of previous experimental rabies
virus variants.
For the titration of SaCas9-gRNA expressing rabies viruses without fluorescent markers,
the same protocol was used for the infection of cells with serially diluted virus. However,
cells were then subsequently stained for 1 hour at room temperature with a Cy3 conjugated
anti-FLAG antibody and imaged on an inverted Leica SP8 confocal microscope. Virally
infected cells were then counted manually using the ImageJ image processing program.
2.4.4.2 RT-qPCR
Due to cell tropism and fluorescence intensity biases in the traditional titration method,
relative titers between different rabies virus variants (WT vs SiR and B19 vs N2C) was
quantified by RT-qPCR. Viral genomic RNA was first obtained either by direct lysis of viral
productions using a solution of IGEPAL CA-630+BSA or by RNA purification of viral
productions using commercial kits (Directzol RNA MiniPrep, ZymoResearch). Fold changes
of viral genome copies between productions was quantified by RT-qPCR using Taqman
probes for CRE sequences present in both SiR 1.0 and SiR 2.0 viruses.
2.5 In vitro experiments
2.5.1 Single particle rabies virus sequencing
RNA viral genomes were extracted using a Direct-zol RNA Miniprep kit (Zymoresearch
R2051). The purified RNA genomes were converted to cDNA using a barcoded primer that
annealed to the 3’ rabies virus leader sequence and contained a random 8-nucleotide sequence
on its 5’end192 (Superscript IV, Invitrogen). Thus, a unique random index was incorporated
onto the 5’ end of each cDNA molecule corresponding to each individual viral particle’s
RNA genome. The cDNA sequence was then amplified from the 5’ end through to the first
half of the rabies virus P gene using Q5 Hot Start High-Fidelity DNA Polymerase (NEB)
giving a PCR amplicon of approximately 2kb length. The amplicons were extracted from an
agarose gel using a QIAquick Gel Extraction Kit and inserted into a standard cloning vector
pBluescript KS (+) opened with restriction enzymes KpnI and KbaI (NEBuilder® HiFi DNA
Assembly). The plasmids were transformed into Stbl3 competent E. coli, and 48 clones
were isolated and purified for sequencing. The sequencing procedure is summarised in Fig.
3.3. For each clone, the 8-nucleotide index and 3’-end of the N gene were sequenced. The
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sequences were aligned using Snapgene 4.1.9 with the reference sequence based on plasmid
pSiR-N2C-iCRE-P2A-mCherryPEST used for viral production. The primer sequences are as
follows:
• N2C RT primer with 8nt barcode: TCAGACGATGCGTCATGCNNNNNNNNT-
CACGCTTAACAACAAAACCAGAG
• Fw PCR primer: CCACCGCGGTGGCGGCCGCTCTCAGACGATGCGTCATGC
• Rv PCR Primer: CTAAAGGGAACAAAAGCTGGGTACTGAGAGAAAGCAGACG-
TTGTCTCC
2.5.2 In vitro immune response characterisation
Mouse neuro2A cells were seeded onto polylysine coated glass cover slips in 6 well plates
and infected at 80% confluency with WT B19 oG GFP rabies virus at a titer of 5x106 to give
approximately 60% infected cells. For the positive control, 100 ng/ml of murine recombinant
TNF-a (aa 80-235) was added to the culture medium (410-MT, Bio-Techne Ltd.). For the
negative control, equal volumes of PBS were added to the culture medium. For imaging of
immune responses at specified time points post-infection, cells were then fixed for 10 minutes
with PFA 4% at room temperature and washed in PBS. Cells were incubated with anti-NF-kB
(p65) and anti-phospho p38 MAPK antibodies under the conditions specified in Table 2.4
for immunofluorescence analysis. The glass coverslips were mounted in Fluoromount-G
(ThermoFisher) with DAPI for image acquisition on an inverted Leica SP8 microscope. For
RT-qPCR analysis of immune response genes, RNA was extracted from cells at specified
time points using RNeasy Mini kits (Qiagen). RT-qPCR was conducted using the rotor-gene
SYBR Green PCR Kit (Qiagen) with the primer pairs listed for various immune response
genes in Table2.2 which were previously experimentally verified193–195. Data was acquired
on a Corbett Rotor-Gene 6000 real-time PCR machine. Fold changes between samples was
calculated using the double delta Ct analysis with GAPDH as the housekeeping gene.
2.5.3 T7 endonuclease mismatch cleavage assay
For screening of NeuN gRNA sequences mouse neuro2A cells were transfected with CMV-
SaCas9 and U6-gRNA DNA expression plasmids. For tests of rabies virus mediated CRISPR-
Cas9 targeting, mouse neuro2A cells were infected with WT DG B19 rabies viruses ex-
pressing gRNA and SaCas9. 3 days post-transfection and/or infection, genomic DNA was
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extracted from infected cells (Qiagen, DNeasy Blood Tissue Kits). The NeuN locus (exon 1)
was PCR amplified using the following primers:
• Fw PCR primer GGCAATCAGGACGCCACGG
• Rv PCR primer GCTACACTTCCTACCTCCCAGATGG
PCR amplicons were then denatured-renatured and incubated with the T7 endonuclease I
enzyme for cleavage of heteroduplexes. Fragments were then visualised by gel electrophore-
sis on a 2% agarose gel with SYBR Gold Nucleic Acid Gel Stain (Invitrogen, S11494).
Fragmentation analysis was conducted on BioRad Image Lab software. Cleavage efficiency
was calculated using % cleavage of PCR amplicons (100 x quantity of the two fragmented
bands/total quantity of unfragmented and fragmented bands).
Table 2.2 Primer sequences for mouse immune response genes used in this thesis
2.5.4 Testing of gRNAs using a double reporter cell system
HEK 293T cells were seeded onto 6 well plates and transfected with polyethylenimine (PEI)
at 80% confluency with 2.5µg of the double reporter plasmid and 2.5µg gRNA-SaCas9
expressing plasmid. Medium was changed 24 hour post-transfection and 72 hours post-
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transfection cells were trypsinised and prepared for FACS analysis on a Becton Dickinson
LSRII SORP Flow cytometer.
2.5.5 Differentiation of neuro2A cell line
For neuro2A differentiation, cells were plated at 20% confluency and the medium was
changed to DMEM + 0.1% FBS the following morning. During differentiation, the cell
medium was replaced once every two days.
2.5.6 Generation of neuro2A synthetase cell line
Wild type neuro2A cells were transfected with linearised ROSA plasmid using PEI. Positive
cells were selected with geneticin for a course of 4 weeks (0.4mg/mL selection concentra-
tion, 0.2mg/mL maintenance concentration). Subsequently, we carried out two rounds of
fluorescence-activated cell sorting (FACS) for mCHERRY positive cells using a MoFlow
sorter to obtain a stable mCHERRY positive cell line of 99% purity.
2.5.7 Cell mixing experiments
For cell mixing experiments, donor cells and acceptor cells were initially cultured in separate
6 wells or 10 cm dishes and transfected with a donor or acceptor plasmid construct respec-
tively using PEI. The following day, cells were trypsinised, pelleted down and incubated in
PBS with 2.5mM Mg2+ and DNAse1 for 15 minutes. Cells were then mixed at specificed ra-
tios (usually 1:1) and replated. For confocal imaging studies, cells were grown to confluence
on L-polylysine coated coverslips, fixed in 4% PFA for 10 minutes at room temperature and
washed twice with PBS.
2.5.8 Click reaction for analysis of azide-incorporated proteins by con-
focal imaging, western blot analysis or mass spectrometry
For confocal imaging of azide-incorporated proteins in vitro, the click reaction was performed
on neuro2A cells post-fixation using the Click-iTProtein Reaction Buffer Kit (Invitrogen).
AF488-alkyne (Sigma) was used as the click detection reagent. For quantification of azide-
incorporated proteins by western blot, cells were lysed in RIPA (Radioimmunoprecipitation
assay buffer) and purified cellular proteins run on a NuPAGE Bis-Tris Gel (Invitrogen).
Proteins were incubated with biotin-alkyne followed by HRP-streptavidin for quantification
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with enhanced chemiluminescence western blotting substrate (32106, ThermoScientific). For
identification of azide-incorporated cells by mass spectrometry, cells were lysed in UREA
buffer and azide labelled proteins enriched from total cell protein lysates using a alkyne
agarose protein enrichment kit (C10416, Invitrogen). Following on-resin trypsin digestion
samples were run on a mass spectrometer by the LMB mass spectrometry facility.
2.6 In vivo surgical procedures
2.6.1 Stereotaxic intracerebral injections
Adult mice aged between 6-12 weeks were used for stereotaxic intracerebral injections. Mice
were anaesthetised with isofluorane (induction at 3% in 2L/min of oxygen, maintenance at
1-2% in 2L/min oxygen) and mounted onto a stereotaxic frame (David Kopf Instruments).
Rimadyl (2 mg/kg body weight) was administered subcutaneously for anti-inflammatory
peri-operative care prior to viral injection. Viruses were injected at the relevant coordinates
(Table ) relative to bregma. A small 500µm diameter hole was drilled in the skull to allow
viral injection with a 35G beveled Hamilton nanofil needle. 400-800nL of virus was injected
depending on the experiment (400nL for focal injections, 800nL for more widespread
coverage). The needle was left in the brain 5-10min post injection to prevent viral backflow
following needle withdrawal. Rabies viruses and lentiviruses were injected at titers of around






CA1 -2.3 1.65 1.48
CA3 -2.06 2.65 2.45
NAc +1.3 1.3 4.75
BLA -1.65 2.9 4.7
Table 2.3 Stereotaxic coordinates for intracerebral injections Anterior/Posterior and Dor-
sal/Ventral coordinates were measured from Bregma. Medial/Lateral coordinates were measured from
the midline.
2.6.2 Intraocular injections
Adult mice aged between 6-12 weeks were used for intraocular injections. Mice were
anaesthetised with isofluorane delivered through a nose cone (induction at 3% in 2L/min of
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oxygen, maintenance at 1-2% in 2L/min oxygen). To dilate the pupil, tropicamide was applied
to the eye for 2 minutes, followed by pheylephrine hydochloride. Viscotear gel was then
applied to the eye before injection with a 65RN Hamilton syringe with a ga34/10mm/pst4
needle. The needle was positioned to enter the eye from behind the ring muscle and pointed
towards the posterior side of the eye before injection of 2µl of virus or protein solution.
Recombinant AAVs were injected at titers of 8 x 1012. Cholera toxin B subunit-AF488 was
injected at 3mg/mL (C22841, Invitrogen). Human mutant A53T alpha synuclein-Dylight594
was kindly prepared by Sophie Morgan from Goedert Lab and injected into the right eye (3µ l
at 400 µM) in aggregate form. The needle was left in the eye for 1 minute before withdrawal.
Viscotears and proxymetacaine were applied to the eye immediately post-procedure and
chloramphenicol drops added later during recovery.
2.6.3 Intramuscular injections
C57BL/6J WT or transgenic pups were fostered onto CD-1 foster mothers shortly after
birth. At P3, pups were anaesthetized with isofluorane (induction at 3% in 3L/min oxygen,
maintenance at 1-2% in 1-2L/min oxygen). A small incision was made in the skin over the
quadriceps muscle and 5µL of viral mixture was injected with a picospritzer (Parker Hannifin).
The viral mixture consisted of 2.5µL of rabies virus and 2.5µL of AAVs expressing either
oG or N2C G protein and a nuclear H2B FLAG epitope for staining. B19 strain rabies viruses
were injected at titers of 3x109 to enable efficient targeting of motor neurons (titers below
109 led to inefficient motor neuron labelling). N2C strain rabies viruses were injected at
titers of 3x108 for efficient motor neuron targeting. AAVs were injected at 3x1012.
2.6.4 In utero electroporation
CD-1 embryos were electroporated at embryonic day (E) 14.5-15.5. The noon of a day
when a vaginal plug was found was designated as E0.5. The mother was anaesthetized
with isofluorane in 1L/min oxygen (induction at 3-5%, maintenance at 1.5-2%). Buprex
( 0.1mL subcutaneous at 0.03mg/mL for 0.1ug/g of body weight) and ritrodine ( 0.1mL
intraperitoneal at 14 mg/mL for 0.05mg/g of body weight) were administered post-induction
of anaesthesia. A midline skin incision of the lower abdomen was made followed by a
paramidline incision in the muscle sheath. The uterus was then gently pulled out onto a
sterile surgical cover. Embryos were gently positioned with blunt ended round forceps and a
pulled glass capillary containing DNA (1ug/mL) diluted in fast green dye for visualization
was injected into the ventricles using a mouth pipette. The electrodes (CUY650P5, nepagene)
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were positioned with the positive electrode covering the somatosensory cortex and the DNA
electroporated with transfer pulse settings: pulse number 5, 950ms interval, 50ms pulse
length, strength 45V and polarity + (NEPAGENE Super Electroporator NEPA21 Type II
). During electroporation, tissues were kept moist with warm NaCl 0.9%. Following the
procedure, the uterus was re-inserted into the abdomen and previous surgical incisions
sutured. The surgical wound was disinfected with Videne antibiotic solution, and the mother
recovered at 37’C for 5-10 minutes. A timer was set from the beginning of anaesthesia
induction and the whole procedure limited to 40 minutes to ensure good recovery of the
mother and successful pregnancy. Glass capillaries were pulled before procedure to give
0.8-1cm tip lengths (e.g. 1B120F-4 borosilicate glass capillaries pulled on P2000 shutter
with sequence: heat 600, FIL 4, velocity 35, del 130, pull 65). The procedure was adapted
from Wang and Mei196 and with much help from Alfredo Llorca Molina.
2.6.5 In vivo BioID
Recombinant AAV expressing GFP and biotin ligase (AAV-GFP-BioID2) was injected into
the eye as described above in section 2.6.2 of methods. 3 weeks p.i., biotin was administered
once intraocularly (0.3mg) and daily intraperitoneally for a period of 7 days (1mg/day). Mice
were then perfused for immunohistochemistry analyses (section 2.7.3 of methods).
2.7 Immunohistochemistry
2.7.1 Sample preparation
For immunohistochemistry experiments, mice were terminally anaesthesized with Eu-
thatal (0.2mL) and transcardially perfused with 20mL ice cold PBS followed by 20mL
4% paraformaldehyde (PFA).
For analysis of brain samples, brains were dissected out and post-fixed overnight in
4% PFA at 4°C. Post-fixation, samples were dehydrated in 30% sucrose/PBS overnight for
cryoprotection. Subsequently, free-floating coronal sections (35 m thickness) were cut from
the brain using a freezing sledge microtome for immunofluorescence.
For spinal cord samples, spinal cords were dissected out and fixed for 4-8 hours at 4°C.
Post-fixation, samples were dehydrated in 30% sucrose/PBS overnight for cryoprotection.
Spinal cords were subsequently frozen in O.C.T. compound (VWR, Radnor, PA) and sliced
into 30 µm sections using a CM1950 cryostat (Leica, Wetzlar, Germany). Sections were
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mounted on glass slides immediately after cryosectioning using an anti-roll blade and stored
at -80°C.
2.7.2 Antibody staining
Primary and secondary antibodies used in this thesis and the concentrations and incubation
lengths are listed in the tables below (Table2.4, 2.5). All incubation steps were conducted at
4’C on a rocking platform. Antibodies were diluted in blocking solution (1% bovine serum
albumin and 0.3% Triton X-100 in PBS), unless stated otherwise. Between primary and
secondary antibody staining, sample were washed four times with PBS at room temperature.
Table 2.4 List of Primary antibodies and working dilutions
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Table 2.5 List of Secondary antibodies and working dilutions
2.7.3 Visualisation of biotinylated proteins
Biotinylated proteins were visualised either by incubation with Streptavidin-AF555 (3 hours,
room temp, 5 µg/mL in blocking solution) or streptavidin-HRP (Table2.5). After incubation
with streptavidin-HRP, the biotinylated protein signal was amplified by 10 minutes incubation
with the TSA Plus Cyanine 3 system (Perkin Elmer, NEL744001KT). Streptavidin-HRP
incubation enables higher sensitivity of biotinylated protein visualisation as the HRP en-
zyme can subsequently catalyze the the covalent deposition of fluorophores adjacent to the
immobilized enzyme resulting in signal amplification.
2.7.4 Image acquisition
For cell counting experiments, spinal cord or brain sections were automatically detected and
imaged on a robot assisted Nikon High Content Analysis microscope equipped with a 10X
air objective (0.45 NA) operated by NIS-Elements HC software (Nikon, Tokyo, Japan). For
higher resolution images of certain immune markers or candidate trans-synaptic proteins,
fluorescence was visualised using a Leica SP8 inverted confocal microscope.
2.7.5 Immunofluorescence analysis
For cell survival experiments in the brain, the whole hippocampus was sampled. For cell
survival experiments in the spinal cord, the whole region of T5-S5 was sampled. In both
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cases, every fourth 35 or 30 m thick section respectively was acquired on a Nikon High
Content Analysis microscope and RFP or YFP positive cells manually counted using Nikon
HCA software.
For quantification of immune response markers, a total of 10 sections were analyzed for
each animal. These sections covered the maximally infected hippocampal area. Positively
stained immune cells were then quantified for cell number, cell area, cell circularity, cell
elongation and average fluorescence intensity using Nikon General Analysis software.
2.8 RNAseq
2.8.1 RNA extraction and cDNA library preparation
Mice were injected in triplicates with WT B19, WT N2C or SiR N2C rabies viruses. 1
week p.i., mice were culled and the injected hippocampi dissected out for homogenization
(Tissuelyser II, QIAGEN) and total RNA extraction with direct-zol RNA Miniprep kit
(Zymoresearch R2051). The quality and quantity of purified RNA was analysed using
Agilent RNA 6000 Pico chips on a Agilent 2100 Bioanalyzer. Subsequently, cDNA libraries
were generated from total RNA using a TruSeq® Stranded Total RNA Library Prep Kit
(Illumina, San Diego, CA) using low throughput single adaptors for each individual sample.
The samples and pooled library were quantified using the KAPA Library Quantification Kit
for Illumina Platforms (KR0405) and sequenced on an Illumina HiSeq 4000 machine (paired
end, 150bp read length).
2.8.2 RNAseq data processing and analysis
RNA-seq sequence reads were trimmed using Trim Galore (version 0.4.2) with default
parameters to remove the standard Illumina adapter sequences.
For differential expression analysis of host genes, RNA-seq reads were mapped to the
GRCm38v95 mouse genome assembly using STAR version 2.5.3amodified167 and reads
with MAPQ scores <20 were discarded. Downstream quantitation was conducted using the
RNA-seq quantitation pipeline in SeqMonk software (www.bioinformatics.babraham.ac.uk/
projects/seqmonk/). Raw counts were used to conduct differential expression analysis using
the DESeq2 statistical filter. Genes were considered to be differentially expressed if p<0.05
after Benjamini and Hochberg multiple testing correction. Gene ontology (GO) enrichment
analysis was conducted using the panther classification system197 with PBS injected control
RNA-seq transcripts used as the background list against which the target list was compared.
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Hierarchy diagrams were generated using the Gene Ontology enRIchment anaLysis and
visuaLizAtion tool (GOrilla) using a single ranked list of genes198.
For viral mutation detection, RNA-seq reads were aligned to reference viral genomes
using the Burrow-Wheeler Aligner199 (BWA-0.7.17d). The reference viral genomes were
taken from the viral genome starter plasmids used for viral productions. We then used the
freeBayes software to detect polymorphisms present within the length of a short RNA-seq
read. For quantification of mapped read density, SeqMonk software was used. A running
window generator was used to create probes of 30bp length all along the viral genome.
Subsequently, read count quantitation was carried out to generate log2 RPM values for each
30bp probe.
2.9 General Analysis
Throughout the thesis, mean values are accompanied by SEM. Statistical analyses and
graphical visualisation of data were performed using Prism 8 software (Graphpad). The
significance of differences between the means of experimental conditions are depicted as
follows: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Statistical analyses used throughout the theses (unless stated otherwise) are:
• Two-tailed, unpaired Student’s T-tests in experiments containing two groups separated
by one independent variable
• One-way ANOVA where more than two groups are separated by one independent
variable. Tukey correction was performed for multiple comparisons where every group
is compared to every other group.
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The Development of Self-Inactivating
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3.1 Introduction
The computations underlying behaviour are implemented by neuronal circuits. In order to
understand how these computations are carried out, one must a) determine the anatomical
structure by which the network is connected, b) correlate the concerted activity of neurons
within these networks to behaviours or other experimentally tractable aspects of brain function
and c) establish causality between circuit activity and brain function.
Until now, much focus has been dedicated to the development of tools that allow us to
address challenge a) the anatomical dissection of complex biological network architectures.
The importance of developing such tools has been appreciated from the beginnings of
modern neuroscience. In 1979, Crick included as one of three suggestions for "invaluable"
developments in neuroscience, "a method that would make it possible to inject one neuron
with a substance that would then clearly stain all the neurons connected to it, and no others"200.
In addition, Brain Research through Advancing Innovative Neurotechnologies (BRAIN), one
of the largest neuroscience initiatives to date, has as one of its main goals "the aim of deÞning
the structural map of all neurons and synaptic connections of entire nervous systems". Serial
EM reconstruction is the gold standard of circuit mapping and enables polysynaptic mapping
in the absence of prior knowledge of network structure. A full connectomic map of the
entireC. elegansnervous system was mapped in this way in 1986201, and with increasing
improvements in volume EM imaging and reconstruction hardware and software, larger
nervous systems can be traced with this approach. Recently, a complete adultDrosophila
melanogasterbrain was imaged with EM at synaptic resolution202 and circuit mapping is
currently around 30% complete.
However, for larger mammalian brains (e.g. rodents and primates), serial EM recon-
struction is not yet a practically feasible method due to the larger volumes that need to be
covered to perform synaptic tracing. In such cases, monosynaptic tracing using! G rabies
virus is the only way of labelling the direct presynaptic neurons to a targeted neuronal group
in the absence of prior hypotheses within an experimentally tractable time frame203Ð207. In
addition, the ability to use the virus in live animalsin vivo allows not only for network
tracing post-mortem, but live network manipulation. This is crucial as anatomical network
conÞgurations in isolation cannot explain to us how neural circuits generate behaviour. In
order to understand brain function, we also need to observe live network activity and estab-
lish behavioural causality in live animals208,209. The experimental tractability and circuit
speciÞcity of the rabies virus in mammalian behavioural model organisms sets its up nicely to
be used not only as a tracing vector but also as a vector to enable circuit-speciÞc recording or
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manipulation experiments. However, an inherent challenge of using the rabies virus for such
long-term functional studies is its inherent cytotoxicity and immunogenicity190. So although
it targets circuits very well, it can have detrimental effects on the very circuits that are being
studied. Previously in our lab, a self-inactivating rabies (SiR 1.0) was developed whereby
the addition of a PEST domain to the C terminus of one of the five viral proteins generated a
trans-synaptic circuit-specific virus which could label neurons and then be degraded by the
host cell191. However, for the short time during which the SiR is active (after initial infection
but before viral shut-off) the virus still exerts cytotoxic and immunogenic effects on the host
cell. In this chapter, I discuss the development of a new SiR vector, called Self-Inactivating
Rabies 2.0 (SiR 2.0) with markedly reduced immunogenicity, higher neurotropism and trans-
synaptic transfer efficiency compared to its predecessing rabies vectors. With this, we aim to
forward the development of a non-toxic and minimally-immunogenic circuit-specific viral
vector that can be used to conduct long term network-to-behaviour experiments. In addition,
we expect continued improvements of the rabies virus in such a way could lead to its eventual
development as a promising therapeutic vector to target circuit-based neurological disorders.
3.1.1 The historical development of rabies virus as a trans-synaptic
tracing tool
The Rabies lyssavirus is a member of the Rhabdoviridae family and has a single stranded,
negative strand RNA genome of approximately 12kb encoding 5 viral proteins: N, P, L, G and
M. The viral nucleoprotein (N) encapsulates the RNA genome enabling it to act as a template
for transcription and replication by the viral polymerase complex. This polymerase complex
consists of the large protein (L) which functions as the polymerase and phosphoprotein (P)
which is a non-catalytic subunit. The RNA-N complex together with viral proteins P and
L form the ribonucleoprotein (RNP) core of virus particles and forms cytoplasmic active
RNP complexes in virus-infected cells210. The viral RNP core is bridged to an encapsulating
host-derived membrane via the matrix protein (M). Lastly, the rabies glycoprotein (G) is a
transmembrane protein that facilitates viral entry into host cells and virus release. Although
the receptor for the rabies virus to which the glycoprotein binds is still unknown, the
glycoprotein is essential for viral infectivity211 and trans-synaptic spread212.
In the wild, the rabies virus is a highly virulent pathogen that is transmitted via the saliva
of a rabid animal into a new host through existing scratches in the skin or bites. The virus
then enters neurons at peripheral sites and continues a sequence of viral replication and
retrograde trans-synaptic spread until it spreads from peripheral organs to the spinal cord and
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then to the brain121. As such, the rabies virus vector encompasses some qualities which are
highly advantageous for circuit neuroscientists: high neurotropism and efficient retrograde
trans-synaptic transfer. For widespread use as an experimental tool however, the inherent
toxicity and immunogenicity of the virus also needs to be overcome. Thus, there has been a
long history of iterative modifications to various rabies virus strains to develop the virus as a
safe trans-synaptic tracing tool190,191,211,213,214.
Initially, viruses isolated from the wild were "fixed": a term used to describe the repeated
passaging of viruses isolated from the wild in cell culture or animals resulting in a virus that
had a stabilized incubation period and virulence. In 1994, a reverse genetics technique was
established that enabled for the first time, the direct production of infectious rabies virus
from plasmid cDNA in cell culture. This not only enabled a more consistent method of
virus production for experiments, it also enabled the ability to introduce mutations, exchange
genes between vaccine and pathogenic strains, or excise certain genes altogether213. This
reverse genetics technique was first conducted on a genomic sequence of an attenuated rabies
virus vaccine strain called SAD-B19. Subsequently, the next notable development was that
of the G-deleted rabies virus (DG rabies)211,214. Here, the viral G protein was deleted from
the same SAD-B19 strain, thus modifying it into a mono-synaptically restricted DG rabies
virus. As the viral genome did not encode G, the virus on its own could no longer spread
trans-synaptically. However, if the G was expressed specifically in a starter population in
trans, the virus would be able to spread to its direct presynaptic partners but no others as no
other cells would express the glycoprotein required for further trans-synaptic transfer203,204.
This monosynaptic restriction was important as the polysynaptic rabies virus was able to
jump multiple synapses at different rates, resulting in ambiguity as to the number of synapses
crossed in the circuit. In addition, the starting population could be pre-defined to a small
subpopulation of neuronal cells by pseudotyping the rabies virus with EnvA (the envelope
protein of subgroup A avian sarcoma and leukosis virus (ASLV-A)). The EnvA coat protein
binds specifically to its cognate TVA receptor which can be exogenously expressed in starter
cells but is not expressed by normal mammalian cells214. Thus, the combination of mono-
synaptic restriction and EnvA pseudotyping enabled the unambiguous labelling of the direct
pre-synaptic inputs into a pre-defined starting population215.
However, the mono-synaptically restricted WT DG SAD-B19 rabies virus, which by
most intents and purposes was optimized for tracing experiments, still has limitations for
long-term behavioural studies as the virus is cytotoxic and can cause infected neurons to die
within a timescale of weeks191. As of date, two parallel approaches have been taken in an
attempt to reduce the inherent cytotoxicity of this trans-synaptic virus.
3.1 Introduction 59
In 2016, a DG CVS-N2C virus was published where the problem of toxicity was reduced
by applying the same monosynaptic restriction and EnvA pseudotyping method as previously
described in the SAD-B19 strain to a more virulent strain called CVS-N2C190. Increasing
virulence of rabies virus strains often results in advantageous characteristics such as increased
neurotropism, decreased immunogenicity, and delayed toxicity. A comparison of the WT DG
CVS-N2C and DG SAD-B19 virus revealed that the DG CVS-N2C virus showed noticeably
delayed toxicity. The survival of infected cells in vivo was extended to around 4 weeks for
retrogradely infected cortical projection neurons and around 2 weeks for retrogradely infected
hippocampal neurons which was longer than for the DG SAD-B19 virus190. In addition to
delayed cytotoxicity, the DG CVS-N2C virus exhibited 10- to 20 -fold higher transsynaptic
tracing efficiency than the DG SAD-B19 virus, enabling a more complete labelling of direct
pre-synaptic inputs into starter cells.
Another parallel approach taken by our lab was to abolish, rather than delay, rabies
virus-induced cell toxicity by applying a "Self-inactivating Rabies virus" (SiR) technology.
Here, a PEST degradation signal was added to the viral nucleoprotein N in the original DG
SAD-B19 strain. This PEST tag directs the nucleoprotein for degradation by the proteosome,
thus reducing its availability to bind to the viral RNA genome which is essential for viral
transcription and replication. It was found that this led to the gradual disappearance of
the virus from infected cells in vivo over approximately 3 weeks and consequently, the
once-infected cells were observed to be alive and functionally unimpaired for effectively the
whole life-span of the animal191.
3.1.2 The innate immune response to rabies virus infection
Host organisms have co-evolved with viral pathogens, resulting in a complex interplay
between viral and host cell molecular machinery. In general, the host organism needs to
quickly identify foreign antigens that are "pathogenic" and trigger appropriate immune
responses to the pathogen in question. On the other hand, pathogens have developed many
mechanisms to evade recognition by host cells or to misdirect or dampen the immune
responses initiated by host cells.
The first step of host antiviral activity is initiated by genetically encoded pattern recogni-
tion receptors (PRRs) of the innate immune system. PRRs bind repeating antigenic signatures
called pathogen associated molecular patterns (PAMPs) that are representative of different
pathogenic challenges. The rabies virus, as a cytosolic ssRNA virus, presents PAMPs such as
antigenic viral RNA intermediates that are not usually produced by the host cell as well as for-
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eign viral proteins. The PRRs that recognise rabies infection include retinoic acid–inducible
protein I (RIG-I) which binds uncapped 5’-triphosphate RNA (3pRNA) presented by viral
genomic RNA and Toll-like receptor 3 (TLR-3) which recognizes dsRNA produced during
the replication of RNA viruses. They are found to be upregulated in neurons following viral
infection in vitro216,217 and by Purkinje cells in the cerebellum in humans following rabies
infection218. Following activation, these PRRs trigger signaling cascades which lead to IRF3
activation and the transcription of interferon (IFN)-b , as well as IFN-stimulated genes (ISGs).
The activation of type-I interferon ((IFN-a/b )) responses establishes antiviral responses in
infected cells as well as directing appropriate adaptive immune responses through the release
of inflammatory cytokines (Fig. 3.1).
In response to host immune responses, the rabies virus has in turn developed many
anti-immune mechanisms (Fig. 3.1). In fact, only minimal inflammation and necrosis is
observed in the brains of deceased human rabid patients and experimental mice infected
with pathogenic street strains of the rabies virus220,221. Conversely, lab-attenuated non-
pathogenic rabies strains induce extensive inflammation, cytokine and chemokine expression
and apoptosis of infected cells in the CNS193,220,222,223. Therefore, it appears that more lethal
street strains somehow evade host immune responses to promote long-term survival of the
virus and enable their high pathogenicity. In contrast, less pathogenic strains have greatly
reduced abilities to cause rabid disease after inoculation into an animal and show a much
higher propensity to trigger host immune responses (e.g. the SAD-B19 attenuated vaccine
strain). The mechanisms by which this immune evasion is executed needs further study, but
appears to be due to a mixture of different factors. For example, street viruses whilst not
triggering apoptosis in infected neurons, do trigger apoptosis in inflammatory cells, possibly
using this as a mechanism to prevent the release of cytotoxic cytokines following cell lysis220.
In addition, attenuated strains through the induced activation of CXCL10, IFN-g and IL17,
enhance BBB permeability enabling entry of immune effectors into the main site of viral
replication in the CNS whilst pathogenic strains do not224,225.
Further studies into the differences between pathogenic and non-pathogenic strains have
revealed that pathogenic gene variants of the 5 virally encoded proteins increase immune
evasion or antagonism. For example, switching of N, P or M genes from a lethal pathogenic
strain (Ni) into the genetic background of a non-lethal strain (Ni-CE) results in lethal hybrid
strains which show increased immune evasion mechanisms226. The lethal N-hybrid strain
shows reduced RIG-I activation of the IRF-3 pathway227 which can be attributed precisely
to variations in AA273 and 394228. The lethal P-hybrid strain showed decreased sensitivity
to host type I IFN responses226. Mechanistically, the viral protein P can prevent IRF3 S386
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Fig. 3.1 Interferon activation and antagonism by the rabies virus
Rabies virus infection is detected by viral RNA sensor RIG-I which is a helicase with a N-terminal
CARD domain that recruits the adaptor Cardif/VISA/MAVS/IPS-1 which acts as a scaffold to recruit
signalling components that activate either the IRF3 pathway or NF-kB pathways involving RelAp43.
This results in the assembly of an enhanceasome complex on the IFN-b promotor thus activating the
expression of type-I IFNs and proinflammatory cytokines. Type I IFNs are released from cells and
bind to cell receptors (IFNAR) to activate JAK/STAT signalling pathways that induce the expression
of antiviral ISGs. Rabies viral proteins can antagonise this innate viral response at many steps. The N
protein can reduce RIG-I activation possibly by inhibiting PAMP-PRR recognition due to its roles in
encapsidating the RNA genome and/or forming cage-like structures around virally active Negri bodies.
The P protein inhibits the JAK/STAT pathway at multiple steps whilst the M protein inhibits NF-kB
pathway activation by inhibiting RelAp43. Host cellular molecules are indicated with white letters,
rabies viral proteins are indicated with black letters. Mechanisms directly implicated in pathogenicity
are indicated by an asterisk. Figure taken from Ito et al. 2016219
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phosphorylation229, inhibit nuclear accumulation of IFN activated STATs230,231 and inhibit
DNA binding of STAT1232. The M protein has also been found to target and inhibit RelAp43,
a member of the NF-kB pathway233. The exchange of G from lethal street viruses into a lab
attenuated strain also results in decreased chemokine expression, immune cell infiltration
and BBB permeability enhancement234. In addition more pathogenic strains show a lower
level of G expression and incorporation into virions which contributes to increased immune
evasion235,236.
3.1.3 Aims
Given the clear advantage of pathogenic viral strains for long-term circuit targeting (i.e.
increased neurotropism, reduced cytotoxicity and reduced immunogenicity), we aimed
to further improve the first-generation SiR vector by applying the same self-inactivation
technology to a more virulent CVS-N2C strain. Although the SiR 1.0 modification essentially
abolishes the toxicity of the DG SAD-B19 virus by shortening its transcriptionally active
life-span, the SAD-B19 strain from which it is derived is an attenuated vaccine strain with
high immunogenicity and very fast transcriptional kinetics194. Therefore, during the short
transcriptionally active phase of the SiR 1.0 before viral shut off, the vector is notably
immunogenic and can have short-term detrimental effects on labelled circuits. In contrast,
the recently developed WT DG CVS-N2C shows significantly delayed cytotoxicity, reduced
immunogenicity and increased neurotropism compared to the SAD-B19 strain, but still
causes cell death as it does not have a switch-off mechanism like the SiR190.
Therefore, we aimed to combine the inherent reduced immunogenicity and increased
neuroinvasiveness of the CVS-N2C strain with the SiR technology to produce a second
generation SiR virus (from now on called SiR N2C, or SiR 2.0) that self-inactivates itself
very much like the first generation SiR virus (SiR B19, or SiR 1.0) but also enables:
(A) More efficient peripheral targeting of neural circuits
(B) Increased trans-synaptic transfer efficiency
(C) Decreased immune response to SiR infection during the brief period of SiR transcrip-
tional activity after initial infection but before viral silencing.
These developments are particularly important for the long-term targeting of more sensitive
neuron types such as spinal motor neurons and with the view of developing the rabies virus
as a promising therapeutic vector for circuit-dysfunctions.
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3.2 Results
3.2.1 The design and production of SiR 2.0
The SiR 2.0 was designed by the addition of the same TEVs-PEST modification used in the
production of SiR 1.0 to the C terminus of the N protein of the DG CVS-N2C rabies virus
(Fig. 3.2). As mentioned previously, the PEST sequence is a signal peptide that directs the
viral N protein for degradation. This leads to the gradual loss of viral proteins necessary
for viral translation and replication, leading to self-inactivation of the rabies virus. The
PEST signal peptide is attached to the C terminus of the viral nucleoprotein via a linking
sequence which includes the Tobacco Etch Virus cleavage site (TEVs). This enables us to
cleave off the PEST modification from the N-TEVs-PEST protein during viral production
by expressing a highly sequence specific Tobacco Etch Virus Protease (TEVp) within the
host cell. By expressing TEVp within production cells, we release the attenuation of the viral
translation an replication to facilitate efficient viral recovery from plasmids and high titer
viral production in vitro.
As the sequence of the 5 genes of the rabies virus are all different in the CVS-N2C
strain compared to that of the SAD-B19 strain from which the SiR 1.0 is derived, the
production of SiR 2.0 required multiple adjustments. First, we needed to clone the TEVs-
PEST modification into the correct location of the CVS-N2C rabies genome plasmid to
produce a pSiR N2C plasmid. We also needed to produce 4 plasmids expressing the viral
proteins N, P, L and G of the CVS-N2C strain for co-transfection during the recovery of
SiR N2C virus from plasmids. We also needed to produce new viral production cell lines
expressing TEV protease, GFP and the G protein of the CVS-N2C strain (HEK-TGG). The
detailed protocol for SiR 2.0 production is listed in the methods section.
3.2.1.1 SiR 2.0 can be produced at high titer and volume using HEK cells
In order to enable efficient use of SiR 2.0 as an experimental or therapeutic vector, the SiR
2.0 must be able to be produced within a reasonable time frame and be scalable for high titer,
high volume productions. The WT DG CVS-N2C rabies virus is reported to take 2-3 times
longer to produce than the WT DG SAD-B19 due to its slower kinetics and production in
mouse neuro2A cells as opposed to BHK-21 cells190. The SiR B19 also takes approximately
two times longer to produce than the WT DG SAD-B19 (Table 3.1). As such, producing
the SiR N2C in neuro2A cells would in theory take over 2 months to produce from DNA
transfection.
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Fig. 3.2 Evolution of SiR 2.0 (A) WT SAD-B19 vaccine strain rabies virus which is polysynaptic
and highly immunogenic. (B) Monosynaptically restricted DG SAD-B19 rabies virus. (C) SiR 1.0.
The monosynaptically restricted SAD-B19 strain is modified further to enable viral self-inactivation,
abolishing viral toxicity in host cells. (D) Monosynaptically restricted DG CVS-N2C rabies virus.
This virus originates from a more virulent rabies virus strain and as such displays delayed cytotoxicity,
decreased immunogenicity and increased neuroinvasiveness compared to its SAD-B19 counterpart.
(E) The SiR 2.0. This virus effectively abolishes the delayed cytoxicity of the CVS-N2C strain whilst
incorporating the decreased immunogenicity and increased neuroinvasiveness of the CVS-N2C strain
for monosynaptic circuit-targeting.
Cell type used Length of viral production(weeks)
WT B19 HEK 293T / BHK-21 2-3189
WT N2C Neuro2A 6-8190
WT N2C HEK 293T 2-3
SiR B19 HEK 293T 5-6191
SiR N2C HEK 293T 5-6
Table 3.1 Comparison of production times of WT and SiR viruses of B19 and N2C strains
3.2 Results 65
The slow metabolism of neuro2A cells necessitates long viral supernatant collection
periods of up to 28 days for the WT DG N2C rabies. The rationale of using murine neuro2A
cells in the original WT DG N2C production protocol was explained to be due to the high
likelihood that the continued maintenance of the virus exclusively in murine neural cells
would be important to maintain the high neurotropism of the CVS-N2C strain. To support
this hypothesis, it has previously been shown that the passaging of the highly neurotropic
CVS-24 strain (from which the CVS-N2C is derived) through BHK-21 cells can select for
substitutions in the viral G protein that significantly reduce viral neurotropism237. However,
in the original paper, the less neurotropic CVS-24 subpopulation that is selected for in
BHK-21 cells is referred to as a conserved minor subpopulation already existent in the
CVS-24 preparation. In our case, viral productions begin from cDNA and so the starting
viral population is homogeneous. In addition, variations in the G protein are recognised as
the main driver for the selection of different subpopulations237. In our case, as the G protein
is expressed from cells and is not encoded in the rabies genome, we did not expect to see
a significant reduction in viral neurotropism by using a different cell type. We therefore
attempted to produce the SiR N2C using HEK293T cells which have a faster metabolism.
However, we needed to verify that the WT and SiR N2C viruses produced in this way still
exhibited high neurotropism. In addition, we also wanted to ensure the genetic stability of
SiR 2.0 viruses produced from HEK 293T was not compromised as it has been reported that
different host cell environments can alter RNA virus mutation rates238.
We find that we can produce both DG WT N2C virus and SiR N2C viruses at high titers
using HEK 293T cells in a much shorter time scale then previously reported using neuro2A
cells. The WT N2C viruses produced in HEK 293T cells within 2-3 weeks show titers similar
to those published previously using neuro2A cells using the same titration protocol (Fig.
3.6C). We also find that SiR 2.0 viral particles produced using this method are genetically
stable (Fig. A.2) and that their high neurotropism is also retained in vivo enabling efficient
central (Fig. 3.8) and peripheral (Fig. 3.9) targeting of neural networks.
3.2.2 Genomic stability of SiR viral particles in vitro
All RNA viruses, including rabies viruses, are known to be subject to a high rate of mu-
tations238,239. As such, we systematically investigated the genomic stability of SiR. Most
importantly, we wanted to investigate the likelihood of the virus to obtain mutations in the
crucial C-terminal TEVs-PEST modification of the SiR which could result in the loss of
66 The Development of Self-Inactivating Rabies Virus 2.0
self-inactivating behaviour. Such WT reverting mutations had been reported recently in two
SiR productions192.
3.2.2.1 The crucial C-terminal TEVs-PEST modification is not selectively mutated
during SiR production
First, we sequenced 50 individual SiR viral particles each from 10 independent productions
of SiR viruses to investigate the accumulation of mutations in SiR during viral production in
cell culture. A barcoding RT-PCR protocol was used to prepare genomic libraries for sanger
sequencing of individual viral particles as described in Matsuyama et al. 2019192 (Fig. 3.3A).
This molecular method enabled the unique indexing of each single starting genomic RNA
strand by the incorporation of a random octamer barcode in the reverse-transcriptase (RT)
primer binding to the 3’ leader sequence of the viral genome. In the total of 494 individual
viral particles sequenced, we did not observe a single SiR viral particle that had obtained
revertant mutations (Appendix A) demonstrating that the occurrence of revertant mutations
is rare.
We did observe mutations elsewhere in the rabies virus genome. This was in line with
the previous literature regarding the high mutation rates of RNA viruses and confirmed
the validity of our sequencing method. A comparison of mutation frequency in different
genome regions showed also that there was no positive selection or "hot spot" of mutation
accumulation at the attenuating TEVs-PEST coding sequence of SiR viruses (Fig. 3.3D).
Rather, we identified a polyA stretch in the intergenic region between the N and P coding
sequences which showed a statistically increased mutation rate for insertion mutations.
In summary, these results show that revertant mutations are rare and do not accumulate
when the virus is produced in appropriate conditions in cell culture as previously described191.
3.2.2.2 SiR 2.0 shows decreased mutagenicity compared to SiR 1.0 during viral pro-
duction
As SiR 1.0 and 2.0 are derived from different rabies viral strains with different replication
kinetics and toxicity190, we suspected that they may also have inherently different mutagenic
rates. As we were producing these two SiR variants in the same host cell conditions, we
deduced that a comparison of their mutation rates would reflect inherent virus-derived
differences in their propensity for mutation accumulation. Analysis revealed that the SiR
2.0 had a significantly lower inherent mutation rate (Fig. 3.3C). This lower mutagenicity
may in turn be related to the WT N2C strain’s decreased neurotoxicity and slower replication
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Fig. 3.3 SiR Viral particles do not selectively accumulate nonsense mutations at the TEVs-PEST
site
(A) Scheme of procedure to sequence individual viral particles from 10 independent SiR preparations:
ssRNA genomes from a viral production are extracted and treated with DNAse I. The RNA is
retrotranscribed and the entire N-TEVs-PEST sequence and portion of the P gene is PCR amplified.
The amplicon is then inserted into a pBluescriptKS(+) sequencing vector to create genomic libraries.
10 independent productions were prepared in this way and approximately 50 individual clones are
sequenced by the Sanger method for each production, giving a total of 500 individual clones. (B)
Example of one viral production showing no mutations in the region upstream of the PEST domain
(clones with mutations in other regions of the analysed amplicon are marked with a star). The position
of the nonsense mutations reported in Matsuyama et al. are marked with red stars above the reference
sequence. The comprehensive analysis of mutations for all batches is in Appendix A. (C) SiR N2C
productions show a lower inherent rate of mutagenic variation compared to SiR B19 productions.
Two-tailed Student’s T-tests. (D) A comparison of mutagenic events in different genomic regions
reveals that the TEVs-PEST region of SiR viruses is not a hot-spot for mutation accumulation. Rather,
a polyA stretch in the N-P intergenic region shows increased propensity for mutation accumulation
compared to other regions of the genome. One-way ANOVA with Tukey correction for multiple
comparisons.
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kinetics240,241. In the context of high volume and titer production of SiRs in cell culture, this
is an advantageous quality of SiR 2.0 as it is an inherently more stable virus and reduces the
mutagenic variation of RNA virus populations used for in vivo experiments.
3.2.3 Genomic Stability of SiR viral particles in vivo
In addition to looking at the stability of rabies virus genomes during production in vitro, we
also investigated the mutagenicity of the rabies viruses in vivo following infection of neurons
in the central nervous system. This was to investigate a number of different things.
First, to investigate the robustness of the SiR N terminal TEVs-PEST addition in vivo.
The in vivo system is very different to the non-neuronal in vitro system from which the viruses
are produced, and this is likely to impact viral replication biology. Most importantly, unlike in
cell culture, infected neurons do not express the TEV protease enzyme. The TEV protease is
required to cleave and consequently "switch off" the PEST domain induced viral attenuation
during high titer viral production in vitro. As no TEV protease is expressed in neurons in vivo,
if a mutant WT viral particle were to arise it would have a significant selective advantage
over the SiR, leading to amplification of the revertant viral population. Thus, we wanted
to directly experimentally verify the stability of the TEVs-PEST modification in SiR viral
particles in vivo both in primarily infected neurons, as well as trans-synaptically labelled
neurons.
Second, we also compared the differing mutagenicities of the WT B19 and N2C strains
in vivo to further verify our findings that the N2C strain showed decreased mutagenicity from
the barcoding Sanger sequencing method in vitro.
3.2.3.1 Next generation sequencing of SiR N2C RNA extracted from primarily in-
fected neurons in vivo shows absence of mutation accumulation in TEVs-PEST
modification
In order to investigate viral mutagenicity in vivo, we injected the CA1 of adult mice with
PBS or SiR N2C virus and sacrificed 1 week post injection (p.i.) for RNA extraction from
the hippocampus. Ribosomal RNA was extracted from the preparation and the remaining
total RNA was prepared for next generation sequencing (NGS) using a single-indexed library.
Following sequence acquisition, the sequencing reads from each injected brain were aligned
to the SiR N2C reference viral genome using Burrows-Wheeler Aligner software199 (Fig.
3.4A). Successful alignment was then confirmed by visualization of sequence alignments us-
ing the Seqmonk program (https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/).
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Visualization of read alignments from SiR N2C injected brains onto the SiR N2C viral
genome showed, as expected,very high numbers of successfully mapped reads. In contrast,
there were a very small number of chance alignments from the PBS injected samples (Fig.
3.4B).
Following successful alignment, we first investigated whether there were changes in the
aligned read density over the TEVs-PEST coding sequence compared to other regions of the
viral genome. This was to assess for possible deletions of the TEVs-PEST coding sequence
from the viral genome. Visual observation and quantification of read density did not reveal
any appreciable difference between the number of reads aligned to this part of the genome
compared to other coding regions (Fig. 3.4B, D). However, a decrease in read density was
observable in the N/P intergenic region as would be expected due to the lack of mRNA
transcription from intergenic sequences (Fig. 3.4C, D).
Subsequently, the sequencing reads that were aligned to the viral genome were screened
for small polymorphisms using a genetic variant detector called freeBayes (version 1.3.0)242.
FreeBayes uses bayesian inference to find small polymorphisms that are smaller than the
length of a short-read sequencing alignment. Specifically, it can detect: SNPs (single-
nucleotide polymorphisms), indels (insertions and deletions), MNPs (multi-nucleotide poly-
morphisms), and complex events (composite insertion and substitution events).
First, to verify this pipeline for the detection of viral mutations, we conducted mutation
analysis for virally aligned reads against a rabies reference genome sequence that had
purposefully introduced SNPs, indels, MNPs and complex mutations at known locations. As
expected, we found that BWA alignment followed by freeBayes polymorphism detection
very robustly identified these apparent "mutations" in the virally aligned sequence reads
(Table 3.2). All introduced mutations were detected in 3 out of 3 brain samples with a high
read depth of >2,000.
Having validated our method, we then screened the virally aligned reads from SiR N2C
infected hippocampal samples against the unedited, original SiR N2C genome to identify
mutations that would have accumulated during the total time from high titer viral production
in vitro to 1 week post-injection in vivo. From the 3 samples obtained from 3 injected mice,
we identified a total of 89 mutagenic events with varying read depths across the viral genome
(Fig. 3.4E). As expected, the frequency of detection of these spontaneous mutations was
much lower than that identified in the pipeline verification (3-200 vs. 2,000-40,000). The
individual positions and nature of mutations identified are detailed in table B.1 in Appendix
B. Notably, none of the 89 identified mutagenic events identified from the 3 injected samples
fell into the TEVs-PEST coding region (Fig. 3.4F). Taken together, this suggests that the
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Fig. 3.4 RNA-sequencing of SiR N2C infected hippocampi shows stability of TEVs PEST mod-
ification in vivo (A) The CA1 of mice were injected with SiR N2C virus or PBS control. 1 week p.i.
the hippocampi were dissected for total RNA-seq sample preparation. Sequenced reads were aligned
to the SiR N2C viral genome using Burrows-Wheeler Aligner199 (BWA). Aligned reads were then
quantified and screened for mutations using freebayes variant detector242. (B) Visualisation of high
density of reads from SiR N2C injected samples aligned to the SiR N2C genome using Seqmonk
software. Samples from PBS injected samples show only very few chance alignments in comparison.
(C) Zoom in to TEVs-PEST region of the genome to show high read density at N, TEVs-PEST and P
coding sequences, but reduced read density at the N/P intergenic region. (D) Quantification of read
density to viral genome regions. N, PEST and P coding regions show no significant differences in read
density (n=3, one-way ANOVA with Tukey correction for multiple comparisons). (E) Visualisation of
mutagenic events identified across SiR N2C genome. (F) Zoom in to the TEVs PEST coding region
(yellow) shows zero mutations identified in this region from a total of 3 injected samples.
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Table 3.2 Verification of mutation detection pipeline from next generation sequencing data
SiR N2C virus does not particularly accumulate mutations on the criticial TEVs-PEST
modification either during production in vitro or following 1 week of infection of neurons in
vivo.
3.2.3.2 NGS reveals reduced mutagenicity of N2C strain compared to the B19 strain
in vivo
We also applied the same mutation analysis pipeline to NGS reads obtained from hippocampal
samples infected with WT DG B19 and N2C viruses produced from HEK cells as described
in the methods section. In line with our findings from Sanger sequencing of viral particles in
vitro, we found that the B19 strain showed a higher accumulation of mutations then the N2C
strain. We identified 32 different polymorphic events in WT B19 injected brains as opposed
to only 2 in WT N2C injected brains (Table 3.3 and 3.4). In line with our findings from in
vitro Sanger sequencing of individual viral particles, there was a predilection for insertion
mutations to accumulate in polyN sequences in the viral genome (specifically polyA and
polyT sequences in both intergenic and coding regions). Again this supported the inherently
increased genome stability of the N2C strain, and thus its increased suitability for repeatable
production of more genomically homogenous populations of virus for experimental and
therapeutic use.
3.2.3.3 SiR retains the TEVs-PEST domain in vivo upon transsynaptic transfer
In addition to characterizing SiR genome stability in vitro and in vivo through RNA sequenc-
ing, we also examined the stability of the TEVs-PEST site at the protein level in vivo. We
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Table 3.3 WT DG B19 mutation accumulation post-viral production and 1 week injection in
vivo
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Table 3.4 WT DG N2C mutation accumulation post-viral production and 1 week injection in
vivo
did this by infecting neurons in vivo with the SiR virus, and then testing for TEVs-PEST
expression in infected neurons by using an antibody that binds specifically to the TEVs linker
protein.
Fig. 3.5 SiR Viral particles do not selectively accumulate nonsense mutations at the TEVs-PEST
site
(A) Intramsucular injection of p3 pups with an SiR or WT N2C rabies virus expressing CRE and an
AAV expressing G required for pre-synaptic transfer of viral particle results in trans-synaptic tracing
of premotor neurons from primarily infected motor neurons. (B) TEVs specific antibody recognizes
the expression of the TEVs domain added to the C terminus of N in SiR viruses. (C) Premotor
neurons trans-synaptically infected by SiR (top panel) but not WT G Rabies (bottom panel) show
TEVs staining.
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The use of antibody immunofluorescence also enabled us to spatially distinguish the stabil-
ity of SiR genomes in both primarily infected neurons, and spatially distinct trans-synaptically
infected secondary neurons. Using this method, we aimed to directly experimentally in-
vestigate the recent suggestion that non-revertant SiR virus particles could not propagate
trans-synaptically in vivo192. The assumption here was that the replicated viral particles in
vivo enabling trans-synaptic viral transfer must be WT revertants, as the SiR virus should
be unable to replicate in vivo in the absence of TEV protease. However, published findings
showing that SiR transcription attenuation takes a period of 2-3 weeks to fully inactivate the
virus following in vivo injection suggested to us that revertant mutant accumulation may not
necessarily be the only explanation for the ability of SiR to jump trans-synaptically in vivo.
In order to directly investigate this hypothesis, we first trans-synaptically traced premotor
neurons in the mouse spinal cord by co-infecting spinal motor neurons with SiR-CRE and
AAV-G by intramuscular injection (Fig. 3.5A). We then visualized whether trans-synaptically
propagated SiR viral particles in premotor neurons had developed nonsense mutations at
the PEST site by staining pre-synaptic neurons with an antibody that recognizes the TEVs
domain downstream to the reported nonsense mutations (Fig. 3.5B). SiR-traced premotor
neurons (but not WT-traced premotor neurons) were positively stained, indicating the absence
of premature stops and the presence of an intact TEVs-PEST tail at the C-terminal of the N
protein of trans-synaptically spread SiR viral particles (Fig. 3.5C). As such, these results show
that SiR particles with intact TEVs-PEST modifications can propagate trans-synaptically in
vivo and supports the genomic stability of SiR in vivo.
3.2.4 Development of alternative titration methods for SiR viruses
The established method of rabies virus titration is by fluorescence activated cell sorting
(FACS) of virally expressed fluorescent proteins in human HEK 293T cells infected with
serially diluted virus190,191,243. However, we found that for the case of SiR 2.0, this method
was not suitable due to its lower tropism for non-neural HEK 293T cells, low transcriptional
levels and self-inactivating nature, all of which significantly decreased the fluorescence levels
of infected HEK 293T cells. Without additional staining, we were in fact unable to visualise
SiR 2.0 driven fluorescence in HEK 293 T cells at all (3.6D). Compared to the very low
apparent titers in vitro, we observed high numbers of virally infected neurons in vivo for the
same viral productions of SiR 2.0 highlighting the need for alternative titration methods.
We proposed that these apparent differences in titer could be due to several possible
reasons. First, the N2C strain has lower transcriptional levels then the B19 strain mak-
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Fig. 3.6 Traditional viral titration by quantifying virally driven fluorescence signals Demonstra-
tion of the titration of (A) WT B19, (B) SiR B19, (C) WT N2C, (D) SiR N2C viruses by quantifying
virally driven fluorescence of infected HEK 293 T cells. Light microscopy images of highly infected
cells (first row) show that the viral expression of fluorescent proteins is lower in SiR viruses then in WT
viruses (C vs. D), and also lower in the N2C strain compared to the B19 strain (B vs. D). This results
in a reduced efficiency (C) or lack (D) of detection of virally infected cells by FACS quantification
(second row) and thus unrepresentative titer calculations (bottom row). FACS quantification dot-plots
represent each detected cell as a single dot. The axes are logarithmic and represent the level of side
scatter (SSC) on the y-axes and the level of GFP or RFP fluorescence intensity on the X-axes (using
B-525-A or YG-610-A filters respectively).
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ing infected cells harder to visualise and so leading to a decrease in apparent titers using
fluorescent markers (compare Fig. 3.6B and D). Second, the addition of the TEVs-PEST
degradation domain to the viral N protein in SiR viruses reduces transcriptional efficiency
and thus reduces fluorescent protein expression levels further (Fig. 3.6C and D). This shifts
the apparent SiR titers to lower levels than for WT viruses. Third, the CVS-N2C strain is
known to have higher neurotropism than the SAD-B19 strain. As such, the N2C may be less
effective in infecting non-neural human HEK 293T cells than the less neurotropic B19 strain,
leading to decreased cell infectivity and thus decreased apparent titers.
In order to fairly compare these different viral strains, we had to develop new methods of
viral titration that would enable us to accurately quantify and compare the amount of virus
present in preparations spanning WT vs SiR viruses, and B19 vs N2C strains. Initially we
produced a HEK 293T stable cell line expressing constitutive BFP and floxed mCHERRY
thus enabling the detection of CRE activity driven by the different viruses. We hypothesized
that this would give a more binary read out of viral quantity and that detection would not
be as dependent on transcriptional levels of the virus. This development confirmed that
there was indeed a much higher titer of SiR CRE viruses than had been measured using the
traditional method (Fig. 3.7). This confirmed that weaker fluorescent levels of SiR viruses
had previously led to under-estimations of SiR titers compared to WT viruses.
However, we were still unable to quantify SiR 2.0 viral particles using this CRE reporter
method suggesting that the increased neurotropism of the N2C virus was decreasing the
efficiency of HEK 293T cell infection in vitro. This discrepancy was also observed in a
more neurogenic neuro2A cell line (N2A). Therefore, we decided to develop a more direct
molecular method of viral quantification. Following the direct lysis of viral productions using
a solution of IGEPAL CA-630+BSA or following RNA purification of viral productions
using commercial kits, fold changes of viral RNA between productions was quantified by
RT qPCR using Taqman probes for sequences present in both SiR 1.0 and SiR 2.0 viruses.
This revealed that compared to the apparent "zero" titer of SiR 2.0 preps observed with other
methods, SiR 2.0 productions were only around 3 fold lower in titer than SiR 1.0 productions
(Fig. 3.7). In addition, the relative titers of WT N2C viruses also increased significantly.
Typically, cell based titration methods quantify WT N2C preparations as being 100 fold lower
than WT B19 preparations (Reardon et al. 2016190, Fig. 3.6). Using RT-qPCR methods, we
found that the fold difference between WT B19 and N2C viruses was much smaller and more
on the order of 2-5 (Fig. 3.7). Such information was crucial to inform our further in vivo
work.
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Fig. 3.7 Comparison of new titration methods 4 productions of WT B19, SiR B19, WT N2C and
SiR N2c viruses were titered using three methods. Results show that only the RTqPCR method was
able to detect SiR N2C viral particles for quantification (*). The use of a CRE-reporter cell line,
rather then traditionally used virally driven fluorescence, to quantify CRE-expressing SiR and WT
B19 viruses resulted in a higher proportional increase in the titers of CRE-expressing SiR B19 viruses
compared to WT B19 viruses (**)
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3.2.5 Confirmation of SiR 2.0 self-inactivation in vivo
Following high titer productions of SiR 2.0, we injected the virus both intracerebrally and
intramuscularly to confirm that the SiR 2.0 could infect neuronal populations in vivo and
exhibit the properties of viral switch-off. This would enable long-term survival of infected
neurons as would have been predicted by the effects of the C terminal TEVs-PEST design.
3.2.5.1 SiR 2.0 self-inactivation kinetics are slower then for SiR 1.0
We monitored viral self-inactivation in vivo by injecting SiR 2.0 expressing mCHERRY
fluorescent protein and CRE recombinase into a YFP CRE reporter mouse. In this way
all virally infected cells were permanently labelled with a YFP fluorescent marker, whilst
active viral transcription could be monitored by mCHERRY fluorescence. We found that
following injection of the SiR 2.0 (but not the WT N2C control virus expressing the same
transcriptional cassette) there was a gradual increase in the proportion of mCHERRY-/YFP+
neurons, representing increasing viral self-inactivation over time (Fig. 3.8B). Interestingly,
comparison of the self-inactivation kinetics of the new SiR 2.0 with SiR 1.0 revealed that viral
self-inactivation was slower in the SiR 2.0, most probably due to different viral transcription
and replication mechanisms and kinetics in the N2C strain.
3.2.5.2 SiR 2.0 shows no observable cytotoxicity in hippocampal and motor neurons
To confirm long-term survival of virally infected cells, we monitored the total number of
virally infected neurons over time in vivo. As we knew that the hippocampal and spinal
motor circuits are especially susceptible to viral cytotoxicity, we longitudinally monitored
virally infected cells in both these neuronal populations. We found no significant decrease of
YFP+ virally infected cells for up to two months in the hippocampus following intracerebral
stereotaxic injection of virus into CA1 of YFP CRE reporter mice (Fig. 3.8C). We also
monitored the number of SiR 2.0 infected neurons in the spinal motor-premotor circuit over
time and again found that there was no decrease in the total number of SiR 2.0 CRE infected
neurons following intramuscular injections into pups of a TOMATO CRE reporter line. This
was in contrast to the SiR B19 and WT N2C virus which did exhibit cytotoxicity and loss of
virally infected neurons over a period of 1-4 weeks (Fig. 3.9D). This is the first assessment
of motor and premotor neuron survival following intramuscular SiR infection in vivo and
presents the SiR 2.0 as the preferred vector of choice for long term targeting of spinal motor
circuits.
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Fig. 3.8 SiR 2.0 self-inactivation kinetics and reduced cytotoxicity in CA1 (A) WT or SiR N2C
rabies viruses expressing a fluorescent mCHERRY protein and CRE recombinase were injected into
the CA1 of YFP CRE reporter mice, followed by longitudinal monitoring of infected cell numbers
and fluorescence. (B) Proportion of mCHERRY-/YFP+ neurons at 1week, 2 weeks, 1 month and 2
months p.i. The gradual increase in the proportion of mCHERRY-/YFP+ cells over time following
injection with SiR viruses represents viral self-inactivation. No such self-inactivation is observed with
the WT N2C virus (mean ± SEM, n = 3 animals per time point). (C) Number of YFP+ neurons at
1week, 2 weeks, 1 month and 2 months p.i. normalized to 1 week time point (mean ± SEM, n = 3
animals per time point).
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3.2.5.3 Addition of CRE is not sufficient to reduce toxicity of WT virus
It was previously suggested that an alternative mechanism by which the SiR CRE viruses
exhibited decreased cytotoxicity could be due to the expression of a CRE recombinase which
could reduce viral cytotoxicity192. Here, we find that a comparison of WT N2C and SiR
N2C viruses expressing exactly the same cassette including a CRE recombinase show clear
differences in self-inactivation (Fig. 3.8B) and survival of infected neurons (Fig. 3.8C, Fig.
3.9D). This suggests that the addition of a CRE sequence is not sufficient to reduce toxicity
of the WT N2C virus. Rather, as these viruses differ only by the addition of a TEVs-PEST
addition to the C terminus of the N, the reduced cytotoxicity and self-inactivation of the SiR
virus compared to the WT virus is much more likely due to the effects of our appended N
protein modification.
3.2.6 SiR 2.0 shows enhanced neurotropism and trans-synaptic trans-
fer compared to oG coated B19 rabies virus in motor circuits
In addition to confirming SiR 2.0 viral self-inactivation and reduced cytotoxicity, we also
confirmed that the SiR 2.0 exhibited increased neuroinvasive properties as would be expected
from the newly modified N2C strain. When compared to the WT DG SAD-B19, the WT
DG CVS-N2C strain has been reported to show 10- to 20- fold better trans-synaptic tracing
efficiency in corticostriatal and spinal motor circuits190.
The trans-synaptic transfer of the WT DG SAD-B19 strain has also recently been im-
proved through the engineering of an optimized glycoprotein (oG) which is composed of
a mouse codon-optimized chimeric G consisting of the transmembrane and cytoplasmic
domain of the original B19G of the SAD-B19 strain with the extracellular domain of the
rabies Pasteur virus strain G. Use of the oG to complement the WT DG SAD-B19 strain
instead of the B19G has also been shown to improve monosynaptic tracing efficiency by
around 10- to 20- in thalamocortical circuits244.
Therefore when compared to the B19G complemented WT DG SAD-B19, both the oG
coated SAD-B19 and the CVS-N2C strain show 10- to 20- fold increased trans-synaptic
transfer in different intracerebral and spinal circuits. However, as far as we are aware, there
has been no direct comparison of the trans-synaptic labelling efficiency of the two improved
viruses in the same experimental set up. In the following experiments I directly compare
the neurotropism and trans-synaptic labelling efficiency of the oG coated SAD-B19 against
the CVS-N2C strain in motor-premotor circuits in the spinal cord following peripheral
intramuscular injection.
3.2 Results 81
3.2.6.1 SiR 2.0 shows increased peripheral neurotropism for motor neuron terminals
in muscles
Here, we conducted a comparison of the total number of primarily infected motor neurons
following injection of either the SiR N2C virus or the oG coated SiR B19 virus into the
quadriceps of P3 pups (Fig. 3.9A). Equal volumes and comparable titers of either virus
were injected. In general, we would inject around 3 fold higher titers of oG coated SiR B19
purely due to the fact that injections with titers below 5 x 108 (as set with traditional titration
methods) resulted in unsuccessful labelling of motor neurons post-procedure. Quantification
of infected motor neurons revealed that the N2C strain was significantly more efficient at
infecting peripheral motor neuron terminals, giving an average of around 10- fold higher total
number of infected motor neurons despite being injected at 3-fold lower titers (Fig. 3.9B).
3.2.6.2 SiR 2.0 shows increased trans-synaptic transfer efficiency
We also compared the trans-synaptic transfer efficiency of the SiR N2C compared to SiR
B19 by calculating the ratio of pre-synaptically labelled premotor neurons per primarily
infected motor neuron. Motor-premotor targeting was achieved by intramuscular co-injection
of SiR viruses with AAVs expressing the oG or the N2C G protein and a nuclear FLAG
tag (H2B-FLAGx3) for visualisation (Fig. 3.9A). Both the SiR B19 and SiR N2C encoded
the same mCHERRYPEST CRE cassette, and the design of the G complementing AAVs
were also identical apart from the coding sequence of the G protein. We found that SiR 2.0
shows both faster and more complete targeting of pre-synaptic inputs. At 3 days p.i. the
SiR 2.0 already exhibited a premotor-motor neuron ratio of 6, whilst the SiR 1.0 exhibited
only a ratio of 0.33 (Fig. 3.9C, representative images in Fig. 3.9E, G). This shows that
despite the lower transcriptional levels and slower replication of the N2C strain, the virus
can transport faster and more efficiently into secondary trans-synaptic neurons. At 1 week
p.i. the premotor-motor ratios increased further to an average of 110 labelled premotor
neurons/motor neuron for the SiR N2C as opposed to 40 for the SiR B19 (Fig. 3.9C,
representative images in Fig. 3.9F, H).
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Fig. 3.9 SiR 2.0 shows enhanced neurotropism and trans-synaptic transfer efficiency in motor-
premotor spinal circuits Legend on following page...
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Fig. 3.9 (A) TOMATO CRE reporter P3 pups were co-injected with a SiR CRE virus (B19 or N2C) and
AAV-H2BFLAGx3-P2A-G (oG or N2CG) in the quadriceps muscle for mono-synaptic tracing from
motor neuron terminals. (B) Quantification of total motor neurons infected post-injection, normalised
by relative titer of the two viruses as determined by RT-qPCR. (mean ± SEM, n = 3, Two-tailed,
unpaired Student’s T-test) (C) Quantification of premotor neurons trans-synaptically labelled per
infected motor neurons infected at 3d, 1w and 4w. The SiR N2C shows both faster and more complete
mono-synaptic tracing compared to the SiR B19. (D) Quantification of total virally infected cells at
3d, 1w and 4w. (E-H) Representative images of SiR N2C or B19 infected neurons (tdTOMATO, red)
and AAV infected neurons (FLAG+, green) at 3d and 1w p.i. Double positive (tdTOMATO+,FLAG+)
neurons are starter neurons from which premotor neurons are trans-synaptically traced.
3.2.7 SiR 2.0 shows markedly reduced immunogenicity compared to
other rabies tracing vectors
Having confirmed the self-inactivation and higher neuroinvasiveness of the SiR 2.0, we also
investigated the immunogenicity of the new SiR 2.0 vector compared to the other existing
rabies vectors for circuit tracing (WT DG B19, SiR B19, and WT DG N2C viruses).
3.2.7.1 Innate immune response to rabies virus infection in mouse neuroblastoma
cells in vitro
First, we began by investigating whether the secondary neuronal cell line (neuro2A) could
activate an innate immune response to rabies virus infection. Mouse neuroblastoma cells
have been shown to detect and respond to viral infections in vitro. For example, infection of
neuro2A cells with japanese encephalitis virus, a positive strand single-stranded RNA virus,
has been shown to be recognized by the pattern recognition receptor RIG-I PRR leading to
downstream activation of MAPK and NF-kB signalling245. RIG-I has also been shown to
play a significant role in the activation of innate immune responses to rabies virus infection
in bone marrow derived dendritic cells246. As such, we decided to investigate the neuronal
response to rabies virus infection by infecting mouse neuro2A cells with an oG coated
WT DG B19 GFP virus. For the positive control, we added recombinant mouse TNFa to
the culture medium. The two cognate TNFa receptors p55 (TNF-RI) and p75 (TNF-RII)
are expressed on neurons and are known to upregulate the NF-kB signaling pathway on
activation247.
24-48 hours post infection, cells were fixed and immunostained for NF-kB and p38
MAPK (Fig. 3.10A). We found that there was a clear activation of NF-kB within neuro2A
cells following infection with the virus that was maintained for up to 48 hours. The MAPK
pathway was also activated within neuro2A cells but the response was more transient and only
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Fig. 3.10 Rabies viral infection can induce innate immune responses in vitro (A) Rabies infection
of mouse neuro2A cells induces both NF-kB and p38 MAPK activation. oG coated WT B19 rabies
virus expressing GFP was used to infect mouse neuroblastoma cells in culture and fixed 24 and 48
hours post infection for immunostaining for NF-kB (upper row) or p38 MAPK (bottom row). Equal
volumes of PBS was added to cells as a negative control, and 100ng TNFa added as positive control
for induction of innate interferon responses). (B) RTqPCR fold changes of selected immune response
genes following rabies virus infection in vitro. Fold changes normalised to SiR N2C induced immune
response gene transcript levels.
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visible at the 24 hour time point but not the 48 hour timepoint. Having confirmed that mouse
neuro2A cells could activate immune responses to WT B19 rabies virus infection, we wanted
to compare the degree and extent of this immune activation by neuro2A cells following
infection by each of the WT B19, SiR B19, WT N2C and SiR N2C. We also wanted to
investigate any potential differences in the molecular responses to infection between each of
the four vectors. Therefore we performed RTqPCR analyses on infected neuro2A cells with
primers specific for various interferon stimulated genes and cytokines downstream to NF-kB
and MAPK activation. We also investigated mRNA fold changes in the potential upstream
PRR RIG-I which could potentially have triggered the observed NF-kB and MAPK response.
We found that the IL-6 response showed significant variation between the 4 viruses, with
WT B19 causing the strongest IL6 activation followed by SiR B19, WT N2C and lastly the
SiR N2C. This indicated that the degree of immune response activation following neuro2A
infection was lesser in SiR compared to WT viruses, and lesser in the N2C strain compared
to the B19 strain. However, none of the other immune responses genes investigated showed
significant differences in transcript levels between the four vectors.
This experiment indicated to us that the rabies virus did induce immune responses in
vitro, and that there was potentially a difference in the degree of immune activation caused
by the different viral vectors. This led us to further characterise the degree and molecular
nature of immune activation following infection by the four rabies virus vectors in a more
physiologically relevant setting in vivo. Although the in vitro system did reveal some
patterns, we wanted to investigate further using a more physiological setting where not only
undifferentiated neuroblastoma cells, but mature neurons, astrocytes, microglia and other
immune related components could all act in concert to react to rabies virus infection.
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3.2.7.2 SiR 2.0 downregulates the activation of innate viral sensor RIG-I in vivo
To investigate the early initiation stage of host immune responses to rabies viral infection in
vivo, we studied the induction of RIG-I expression. RIG-I is an innate pattern recognition
receptor that binds 5 triphosphate-ended RNA and activates potent type I IFNs in response to
rabies virus infection216. We investigated this RIG-I response 1 week p.i. as this is within the
short transcriptionally active time window of SiR viruses after initial infection but before viral
shut off. CRE recombinase expressing rabies vectors were injected into the CA1 of YFP CRE
reporter mice and sacrificed 1w p.i. for both studies at the transcriptional level (RT-qPCR
from total extracted hippocampal RNA, Fig. 3.11A) and protein level (immunofluorescence,
Fig. 3.11C).
RT-qPCR analysis of transcriptional levels of RIG-I and two downstream interferon
stimulated genes IFIT1 (Interferon-induced protein with tetratricopeptide repeats 1) and Mx1
(Interferon-induced GTP-binding protein Mx1) confirmed that infection with the B19 strain
led to an induction of RIG-I driven interferon responses when compared to PBS injected
controls (Fig. 3.11B). Comparison of RIG-I, IFIT1 and Mx1 transcript levels between WT
B19 and WT N2C injected hippocampi also revealed that the B19 strain induced higher
levels of RIG-I activation than WT N2C (Fig. 3.11B). The same pattern of RIG-I activation
was apparent from immunofluorescence studies. WT B19 infected hippocampal neurons
trigger a more widespread area of positive RIG-I staining with very intensely stained RIG-I+
neurons and glial cells. In contrast, WT N2C infected neurons trigger significantly lower
levels of RIG-I staining that is not visible at low zoom images (Fig. 3.11D, left inset). In
addition, we also compared the RIG-I response in WT vs SiR viruses in both strains and
found that the attenuation of the N protein in the SiR viruses resulted in further reduction of
RIG-I responses in comparison to their parent WT strains. Reduced RIG-I activation was
evident by a reduced intensity of RIG-I staining in SiR B19 transduced areas compared to the
WT B19 (Fig. 3.11D, left inset) as well as by decreased density of RIG-I stained cytoplasmic
antiviral stress granules (avSGs)248–250 surrounding SiR N2C infected cells compared to the
WT N2C (Fig. 3.11D, right inset). Taken together, we found that the attenuated SiR of the
less immunogenic N2C strain resulted in a viral vector that showed minimal RIG-I activation
compared to all other vectors.
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Fig. 3.11 SiR N2C attenuates activation of innate viral sensor RIG-I in vivo (A) Mouse CA1
was injected with PBS, WT B19 or WT N2C rabies virus. 1 week p.i. total RNA was extracted
from hippocampi for RT-qPCR. (B) mRNA fold change of immune response genes (RIG-I, IFIT1,
Mx1) normalised to WT N2C injected transcript levels. (mean±SEM, n=3, two-tailed unpaired
student’s T-tests) (C) YFP CRE reporter mice were injected in CA1 with rabies viruses expressing
CRE recombinase (WT B19, SiR B19, WT N2C or SiR N2C) for immunofluorescence studies 1 week
p.i. (D) Hippocampal slices were stained for RIG-I (magenta), YFP (green, virally infected cells) and
DAPI (blue, nuclei). (E) Higher resolution images to show the "speckle" like distribution of RIG-I
positive cytoplasmic antiviral stress granules.
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3.2.7.3 SiR 2.0 triggers significantly reduced microglial responses following in vivo
injection
Microglia are resident macrophages of the central nervous system and form a critical role
in innate immunity. In the post-natal brain, microglia exist in a "resting" ramified form
acting as sensitive surveyors of brain parenchyma. On detection of microbial infections
or brain damage, they transform into an "active" ameboid form which can rapidly migrate
into areas of brain injury to perform pro-inflammatory macrophagic functions251. They can
also themselves be infected by viruses. For example, the rabies virus can infect microglia
directly252.
Although the underlying signalling mechanisms underlying this switch from "rest" to
"active" state are not well understood, studies have shown that this microglial response
is heterogeneous, with microglia responding to different inflammatory signals in different
ways depending on anatomical location, species and age253,254. The role of microglia in
inflammation can also be varied depending on their polarisation to the typically "damaging"
pro-inflammatory phenotype (M1) characterized by TNF-a and IL-1b expression or the
"repairing" anti-inflammatory phenotype (M2) characterized by IL-10 and TGF-b expression.
We investigated the degree of activated microglial recruitment to rabies virus infected
neurons in the hippocampus (Fig. 3.12) and the spinal cord (Fig. 3.13). We found a pattern
similar to that observed for RIG-I activation in both anatomically distinct circuits. The B19
strain induced stronger microglial responses than the N2C strain, and again the SiR viruses
induced weaker microglial reponses compared to their WT counterparts (Fig. 3.12A, Fig.
3.13A-D). In combination, the attenuated SiR virus of the less immunogenic N2C strain
led to very minimal microglial activation and recruitment compared to all other vectors.
Quantification of Iba1+ cells showed that the SiR 2.0 virus recruited markedly smaller
numbers of activated microglial cells then all other vectors in the hippocampus (Fig. 3.12B)
and in the spinal cord (Fig. 3.13E). Quantification of other cellular parameters of Iba1+ cells,
such as cell area (Fig. 3.12C and Fig. 3.13F), circularity (Fig. 3.12D) and Iba1+ staining
intensity (Fig. 3.12E) showed that the few Iba1+ cells that were detected around SiR 2.0
infected cells did not show as prominent features of microglial activation as for the other
vectors.
Longitudinal studies into Iba1+ activation between WT and SiR N2C infected neurons
showed that the peak of microglial responses in the hippocampus are at 2 weeks p.i., and
that the WT N2C induces stronger microglial responses then the SiR N2C at all time points
post-infection (Fig. 3.12F). Longitudinal comparisons of microglial responses between SiR
B19 and SiR N2C infected motor and pre-motor neurons in the spinal cord also revealed
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that SiR B19 induces stronger microglial responses then the SiR N2C at all time-points
investigated (Fig. 3.13E).
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Fig. 3.12 SiR 2.0 shows minimal microglial activation in the hippocampus compared to alterna-
tive rabies virus vectors in vivo (A) YFP CRE reporter mice were injected in CA1 with rabies viruses
expressing CRE recombinase (WT B19, SiR B19, WT N2C or SiR N2C) and sacrificed 1 week p.i. for
immunofluorescence studies. Hippocampal slices were stained for microglial marker Iba1 (magenta,
microglia), YFP (green, virally infected cells) and DAPI (blue, nuclei). (B-E) Quantification of Iba1+
cell number, area, circularity and staining intensity staining (mean±SEM, n=3, one-way ANOVA with
tukey correction for multiple comparisons). (F) Longitudinal quantification of Iba1+ cell numbers in
infected hippocampi at 1, 2, 4 and 9 weeks post-injections with WT or SiR N2C viruses (mean±SEM,
n=3). WT N2C 9w time point not investigated as WT N2C infected neurons die 4w post-injection.
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Fig. 3.13 SiR 2.0 shows minimal microglial activation in the spinal cord compared to alterna-
tive rabies virus vectors TOMATO CRE reporter pups were co-injected at P3 with a rabies virus
expressing CRE recombinase (WT B19, SiR B19, WT N2C or SiR N2C) and an AAV expressing
nuclear FLAG and the rabies G of the appropriate strain (N2C G or oG). Spinal cord sections were
stained for Iba1 (cyan, microglia), TOMATO (red, virally infected cells) and FLAG (green). (A-D)
representative images of spinal cord sections 1 week p.i. SiR N2C shows markedly reduced Iba1+
staining compared to all other rabies vectors. (B’) WT N2C infected spinal cord section 2w p.i. during
period of infected cell loss shows intense Iba1+ staining. (C’ and D’) SiR B19 and SiR N2C infected
spinal cord section 4w p.i. respectively. Right side of white-dotted line shows reflected mirror image
of injected side with only Iba1+ staining. Legend continued on following page.
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Fig. 3.13 SiR 2.0 shows minimal microglial activation in the spinal cord compared to alternative
rabies virus vectors (E) Number of Iba1+ cells at 3d, 1w, 4w p.i. with SiR B19 or N2C viruses. (F)
Area of Iba1+ cells at 3d, 1w, 4w p.i. with SiR B19 or N2C viruses.
3.2.7.4 SiR 2.0 triggers significantly reduced astrocyte responses following in vivo in-
jection
Astrocytes are the most abundant glial cells in the central nervous system and play multiple
roles including regulation of the CNS micro environment, synaptic transmission, neuronal
metabolic and trophic support, maintenance of the BBB and in innate immunity. Following
immune activation, astrocytes undergo reactive astrocytosis or astrogliosis. These reactive as-
trocytes are hypertrophic, have longer and thicker cytoplasmic processes and show enhanced
expression of various proteins such as the glial fibrillary acidic protein (GFAP)255. The
mechanisms underlying astrogliosis are not well understood, but it is known that astrocytes
can be activated by many different triggers (e.g. direct infection by virus, neuronal damage
or death etc.). Microglial release of cytokines such as IL-1, IL-6, TNF-a , IFN-g is widely
accepted to play a critical role in the induction of astrogliosis in viral infection256. Many of
these pro-inflammatory molecules trigger the expression of inducible NO synthase (iNOS) ex-
pression in astrocytes, and NO has been shown to play a major role in the induction of GFAP
activation257. Once activated, astrocytes can increase BBB permability258, express proinflam-
matory cytokines259 (e.g. TNF-a, IL-1, IL-6, macrophage CSF and granulocyte-macrophage
CSF) and execute antiviral IFN responses257.
Studies into the role of astrocytes in rabies virus pathogenesis have shown that rabies virus
can directly infect astrocytes in vitro252. In addition, it has been found that non-pathogenic
rabies (e.g. the SAD-L16 vaccine strain260 or lab-attenuated CVS-B2C strain261) triggers
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Fig. 3.14 SiR 2.0 shows minimal astrocyte activation in the hippocampus compared to alterna-
tive rabies vectors in vivo (A) YFP CRE reporter mice were injected in CA1 with rabies viruses
expressing CRE recombinase (WT B19, WT N2C or SiR N2C) and sacrificed 1 week p.i. for im-
munofluorescence studies. Hippocampal slices were stained for astrocyte marker GFAP (magenta,
astrocytes), YFP (green, virally infected cells) and DAPI (blue, nuclei). (B-D) Quantification of
GFAP+ cell number, area, staining intensity staining (mean±SEM, n=3, one-way ANOVA with tukey
correction for multiple comparisons).
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Fig. 3.15 SiR 2.0 shows minimal astrocyte activation in spinal motor circuits compared to alter-
native rabies vectors in vivo TOMATO CRE reporter pups were co-injected at P3 with a rabies virus
expressing CRE recombinase (WT B19, SiR B19, WT N2C or SiR N2C) and an AAV expressing
nuclear FLAG and the rabies G of the appropriate strain (N2C G or oG). Spinal cord sections were
stained for GFAP (cyan, astrocytes), TOMATO (red, virally infected cells) and DAPI (blue, nuclei).
(A-D) representative images of spinal cord sections 1 week p.i. SiR N2C shows reduced GFAP+
staining compared to all other rabies vectors.
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RIG-I induced IFN responses in infected astrocytes which results in abortive infections. In
contrast, pathogenic street isolates of rabies virus can maintain persistent astrocyte infections
by evading immune recognition.
Here, we investigated the induction of astrocyte activation following both central and
peripheral injections of SiR 2.0 compared to other experimental rabies virus vectors (WTB19,
SiRB19, WTN2C). Again, we found a gradation of response similar to that observed for RIG-
I activation and microglial activation. Namely, the B19 strain induced significantly stronger
astrogliosis in the hippocampus compared to the WT N2C strain. Immunofluorescence
staining for GFAP revealed a more widespread and intense staining for GFAP surrounding
WT B19 injected areas then WT or SiR N2C vectors (Fig. 3.14A, representative images).
Quantification of GFAP+ cells revealed significantly reduced numbers of activated astrocytes
(Fig. 3.14B), reduced astrocyte hypertophy (Fig. 3.14C) and GFAP staining intensity (Fig.
3.14D) following WT N2C infection compared to WT B19. In addition, as for RIG-I and
microglial responses, the SiR attenuated viruses showed decreased GFAP activation than their
WT counterparts in both the hippocampus (Fig. 3.14A) and the spinal cord (Fig. 3.15 A vs C
for B19, or B vs D for N2C). Quantification of GFAP+ cells revealed a markedly reduced
number of GFAP+ activated astrocytes surrounding SiR N2C infected neurons compared to
WT N2C in the hippocampus.
3.2.8 Investigating the varied transcriptional responses to rabies virus
infections in vivo via RNA-seq
Given our findings regarding the innate immune response to rabies virus in neuroblastoma
cells in vitro and in the mouse hippocampus and spinal cord through immunohistochemistry,
we wanted to investigate with higher throughput the molecular players involved in this
immune response, and how it may be different between WT B19, WT N2C and SiR N2C
viruses. Therefore we decided to conduct whole transcriptome shotgun sequencing (more
commonly called RNA-seq) in order to identify differentially regulated transcripts following
rabies virus infection. Mice were injected with PBS, WT B19, WT N2C or SiR N2C virus in
the CA1 region of the hippocampus (n=3 animals, per virus). 1 week p.i. the hippocampi
were dissected out, RNA extracted and prepared for next generation sequencing (NGS).
As we were interested to look not only at mRNAs but also non-coding RNAs involved in
antiviral responses and also the viral genome RNA itself, we used a total RNA preparation
kit that removed only ribosomal RNA from our sample preparation.
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3.2.8.1 Large-scale functional characterisation of transcripts up or downregulated
following WT rabies virus infection in the mouse hippocampus
Using the DESeq2 differential gene expression analysis262 and intensity difference filtering,
we identified 1577 differentially regulated transcripts in WT N2C infected hippocampi when
compared to PBS injected controls (Fig. 3.16A). For WT B19 infected hippocampi, we
also identified 1139 differentially regulated transcripts compared to PBS injected controls.
Comparing the differentially regulated transcripts between WT N2C and WT B19 infected
hippocampi, we found that around 50% of identified transcripts were overlapping between
the two viruses (red, Fig. 3.16B). This suggested to us that the two different strains induce
partly different transcriptional responses following injection in vivo.
To further understand this large-scale transcriptional response, we conducted gene on-
tology (GO) enrichment analysis using the panther classification system to identify over-
represented gene groups in our list of 1577 differentially regulated genes.
In the up-regulated transcripts, over-represented GO groups revealed many defense
immune system processes enriched in WT N2C infected brains (Fig. 3.16C). This was as we
were expecting; the parental biological process GO term 0006955 for "immune response"
was enriched with a P-value of 9.89E-20. Looking further at the enriched child terms
of this GO term we identified more detailed immune system processes such as cytokine
production, interluekin signalling, MHC class II antigen presentation, CD4 and CD8+ T
cell differentiation, B cell activation, neutrophil activation and monocyte extravasation.
These findings were all in line with previous work describing immune responses to rabies
virus, including interferon signalling, increased BBB permeability, and induction of humoral
immune responses resulting in the production of virus neutralising antibodies (VNAs).
Interestingly, when looking at enriched GO terms for the regulation of immune responses,
we found that there was an overall pattern of positive regulation of innate immune responses,
but a negative regulation of adaptive immune response (Fig. 3.16C and 3.17). This may
in part be a result of viral immune evasion mechanisms, as previous research has shown
that more virulent rabies virus strains are better at evading increased BBB permeability and
neuroinflammation in the CNS post-infection.
For the down-regulated transcripts, we found over-represented GO groups relating to
synapse regulation, signalling and neurogenesis (Fig. 3.16D). This suggested to us that
WT N2C infection of neurons in the hippocampus at 1 week p.i. was impairing usual
synapse functions, as may have been expected from our knowledge that WT N2C infection
is eventually toxic and leads to death of infected neurons by 4 weeks p.i.. More specifically,
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Fig. 3.16 Transcriptional response to WT rabies virus infection (A) Scatter plot depicting dif-
ferentially regulated transcripts in WT N2C injected vs. PBS injected control mice (blue). (B)
Scatter plot depicting genes that are differentially regulated following WT N2C injection (blue) as
in subfigure (A) but also depicting genes that are commonly differentially regulated following both
WT B19 and WT N2C injection (red), and genes that differentially regulated following WT B19
injection only (orange). (C) Gene ontology (GO) terms enriched in upregulated transcripts following
WT N2C injection compared to PBS injected controls. (D) Gene ontology (GO) terms enriched in
downregulated transcripts following WT N2C injection compared to PBS injected controls. n=3 for
all experiments
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P-value Colour Scale: > 10-3 10-3  to 10-5 10-5  to 10-7 10-7  to 10-9 <10-9
Fig. 3.17 Hierarchy of GO terms of "immune system process" enriched in upregulated RNA
transcripts from rabies virus infected hippocampi
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GO terms 0098685 and 0098686 signifying gene groups related to "Schaffer collateral - CA1
synapse" and "hippocampal mossy fiber to CA3 synapse" respectively. This was notable as
these were the very neurons being targeted for viral infection by our injections. Therefore,
downregulation of these GO terms revealed a clear specific impairment of function of neurons
infected with WT N2C rabies virus in CA1. In converse, these GO terms were not identified
for the 4 identified downregulated genes following SiR N2C infection, showing that at 1 week
the SiR N2C does not impair synapse function like the WT N2C virus does (Fig. 3.18A).
The 4 transcripts downregulated by SiR N2C are listed in Fig. 3.18B.
3.2.8.2 SiR N2C induces a significantly reduced transcriptional response following
infection of hippocampal neurons
When applying the DESeq2 statistical filter to find differentially expressed transcripts in
SiR N2C infected hippocampi vs. PBS infected controls, we found that the SiR virus
upregulated only 50 genes post-infection compared to the 895 genes upregulated for the
WT N2C virus (Fig. 3.18A). The SiR N2C upregulated transcripts are listed in Appendix3
(TableC.1). In a similar line, the SiR N2C virus downregulated only 4 transcripts compared
to the 173 transcripts downregulated following WT N2C injection. The SiR N2C did not
induce downregulation of synaptic or Schaffer collateral - CA1 proteins as seen with the WT
N2C virus (Fig. 3.18A,B), strongly supporting the reduced synaptic toxicity of the SiR N2C
virus. The scatter plot in Fig. 3.18C shows all WT N2C differentially regulated genes (blue,
purple) as identified by the DESeq2 filter, and highlights in red the transcripts that are also
commonly upregulated following SiR N2C infection. Notably one can see that the immune
markers that we visualised using immunofluorescence methods (the microglial marker (Iba1),
astrocytosis marker (GFAP) and the viral RNA sensor (RIG-I)) were found to be upregulated
only following WT N2C infection but not following SiR N2C infection. This was very much
in line with the increased staining intensity for these markers observed in WT N2C infected
hippocampi compared to SiR N2C hippocampi.
3.2.8.3 Immune related transcripts reveal details of the decreased immunogenicity of
SiR N2C
Having observed enriched GO terms related to immune responses, we wanted to study the
immune response to WT N2C and SiR N2C infections in more molecular detail. In order
to do this we first identified genes upregulated following WT N2C injection that fell under
various receptor families, known signalling pathways and antiviral immune processes. The
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Fig. 3.18 SiR N2C upregulates less transcripts following injection compared to WT N2C (A)
Table showing the number of up- or downregulated transcripts following WT or SiR N2C infection as
identified by DESeq2 analysis. Identified genes falling under selected GO-terms depicts the lesser
immunogenic response and lesser perturbation of synapse biology following SiR N2C injection
compared to WT N2C injection. (B) Table listing the 4 downregulated transcripts following SiR N2C
injection. Gene summaries taken from UniProtKB/Swiss-Prot. (C) Scatter plot of genes found to be
differentially regulated following WT N2C injection vs. PBS control using the DESeq2 statistical
filter (blue, purple). WT N2C upregulated genes that are also upregulated following SiR N2C injection
are shown in red. The names of some notable examples of upregulated genes are noted on the upper,
right side of the transcript. Examples of only WT N2C upregulated transcripts include GFAP, Iba1
and RIG-I which are in line with histological immunofluorescence findings from previous section and
are circled in red.
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fold changes in expression level of these genes in WT N2C infected samples compared
to PBS injected controls was noted. We then also investigated whether these same genes
were upregulated following SiR N2C infection. We found that in most cases the SiR N2C
did not upregulate these immune response transcripts, and for the cases where there was
co-upregulation, the SiR N2C caused a lesser fold change increase.
Starting from viral detection, WT N2C upregulates pattern recognition receptors (PRRs)
of the RIG-I like receptor (RLR), toll-like receptor (TLR) and NOD-like receptor (NLR)
family (Fig. 3.19A). Pro-inflammatory signalling pathways downstream of activated PRRs
result in the activation of NF-kB and IRF transcription factors which can bind ifna and
ifnb promoters to induce the production of type I interferons (Fig. 3.19D). Indeed, we also
found many members of the NF-kB and IRF family to be upregulated following WT N2C
injection (IRF1, 2, 4, 5, 7 and NFkB1, 2). Type I interferons upregulated by NF-kB and IRF
transcription factors in initially infected cells bind IFNA receptors in other cells to activate
JAK/STAT (Janus kinase/Signal Transducers and Activators of Transcription) signalling
cascades. Activated STATs then induce the activation of interferon stimulated genes (ISGs)
that have antiviral functions (Fig. 3.19E). As expected, we identified in our list of WT N2C
upregulated transcripts, many genes involved in the antiviral interferon response. WT N2C
upregulated IFN receptors, members of the JAK/STAT signalling pathway and downstream
ISGs such as those of the 2’-5’-oligoadenylate synthase (Oas) and Oas-like family (Fig.
3.19B).
As for the SiR N2C virus, no PRRs were found to be significantly upregulated following
injection. Of the downstream IRF/NF-kB pathway members, only IRF7 was found to be
upregulated. In antiviral immune responses, IRF7 forms a positive regulatory feedback
loop with type I interferons resulting in enhanced expression of IRF7. Following initial
"priming" activation by phosphorylation downstream to activated PRRs, IRF7 binds ifna
and ifnb promoters to induce expression of type I interferons. Type I interferons bind IFNA
receptors to activate JAK/STAT signalling cascade in other cells. Activated STAT1/2 bind
to IRF9 to form IFN-stimulated gene factor 3 (ISGF3) which induces the synthesis of more
IRF7263. This newly synthesized IRF7 then induces more IFN production leading to a
positive feedback loop resulting in a high level of IRF7 and IFN expression following viral
infection. In line with this, the SiR N2C was also found to upregulate STAT2 and 4 and the
expression of some ISGs (e.g. Mx1, IFIT1,3 etc.). These findings show that the SiR N2C
induces a lower grade antiviral immune response following infection compared to the WT
N2C virus.
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We then looked at WT N2C upregulated transcripts downstream to interferon activation.
We observed that there was an upregulation of many IFN induced cytokines associated
with increased blood brain barrier permeability and leukocyte infiltration into the CNS
(CXCL10, CXCL9, CCL5). It has previously been shown that the expression of inflammatory
chemokines is closely associated with leukocyte infiltration and BBB permeability increases
following infection by apathogenic lab strains of rabies virus, whilst pathogenic strains
do not cause such an upregulation of chemokine expression and do not recruit immune
cells into the CNS for rabies virus clearance264. The chemokines CXCL10, CXCL9 and
CCL5 are three structurally and functionally related IFNg induced proteins that bind the
CXCR3+ receptor265. They are most commonly attributed to leukocyte trafficking into
the CNS, principally acting on activated CXCR3+ CD4+ Th1 cells, CD8+ T cells and NK
cells. In addition it is hypothesised that infiltrating Th1 cells following rabies infection
differentiate into IL-17 producing Th17 cells which initiates the alteration of tight junctions
and increased BBB permeability266,267. Intercellular adhesion molecules such as ICAM1
known to facilitate leukocyte endothelial transmigration were also found to be upregulated in
WT N2C infected brains.
Lastly, we also found that 3 out of the top 5 upregulated genes following WT N2C
infection were major histocompatibility complex (MHC) class I and II proteins involved in
the presentation of either cytosolic or extracellular peptide antigens onto the cell surface
respectively. MHC class I is expressed in all nucleated cells, whilst MHC II expression is
generally restricted to antigen presenting cells (APCs) such as macrophages, dendritic cells
and B cells. Both MHC class I and II expression can be upregulated by IFNg signalling. The
two NOD-like receptor (NLRs) family members (NLRC5 and CIITA) known to regulate
MHC class I and II transcription respectively268, were also found to be upregulated in WT
N2C infections. These findings show that increased antigen presentation is a component
of the antiviral immune response to rabies virus and that again, this immune response is
decreased in SiR N2C infected hippocampi.
3.2.8.4 Non-coding RNA transcriptional response to rabies infection
Given increasing studies highlighting the role of long non coding RNAs (lncRNAs) in an-
tiviral immune responses, and one recent study that identified 140 lncRNAs differentially
regulated following CVS11 rabies virus infection, we also looked at the differential expres-
sion of lncRNAs in WT N2C and SiR N2C infected brains. The field of virus-induced
lncRNA responses is still fairly young, with the first virus-induced transcript being reported






























Fig. 3.19 Key viral immune response genes upregulated following WT N2C injection but not
following SiR N2C injection Legend on following page...
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Fig. 3.19 Key viral immune response genes upregulated following WT N2C injection but not
following SiR N2C injection Fold change and P-values of WT N2C upregulated genes involved in
viral detection (A)), antiviral interferon response (B) and immune cell responses (C). Most genes
are not found to be upregulated following SiR N2C injection, and those that are show lower fold
change values. (D) Diagram showing the IRF and NF-kB transcription factor responses downstream
of PRR activation (copied from Iwanszko and Kimmel. (E) Diagram showing pro-inflammatory
receptor activation, downstream JAK/STAT pathways resulting in the expression of antiviral interferon
stimulated genes (ISGs) (copied from Aaronson et al.). (F) Diagram showing the cytokines involved
in increasing blood brain barrier permeability in neuroinflammation (copied from Lecuyer).
now many examples showing that lncRNAs can play key roles in host immune repsonses
following infection by other RNA viruses. For example, the lncRNA NRAV can inhibit HIV-1
replication and regulate the expression of antiviral genes during influenza virus infections270.
We identified many upregulated lncRNA transcripts following WT N2C infection. The
top 25 upregulated lncRNAs and their fold changes are depicted in Fig. 3.20. Many of
these upregulated lncRNAs overlap with previously identified lncRNAs involved in the host
immune response to rabies infection and show fold changes of up to 300 fold. Although the
roles of these lncRNAs in host immune responses to rabies virus are unclear, our findings are
consistent with previously observed dynamic changes in lncRNA expression following rabies
virus injection and suggest that they play significant biological roles in the host response. Of
the top 25 upregulated lncRNA genes, only 4 were also found to be significantly upregulated
following SiR N2C infection using the same DEseq2 statistical analysis (Gm1966, Gm2682,
AU020206 and 4930533I22Rik). Again suggesting that the lncRNA host immune response






























































































































































































































Fig. 3.20 Non-coding RNA transcripts upregulated following WT N2C infection, but not follow-
ing SiR N2C infection Fold change of the top 25 upregulated non-coding RNA transcripts following
viral injection (WT N2C or SiR N2C) compared to PBS injected controls. The 4 transcripts also signif-
icantly upregulated following SiR N2C injection (Gm1966, Gm2682, AU020206 and 4930533I22Rik)
are labelled with asterisks.
3.3 Summary
In this chapter, I have described the development of a novel self-inactivating rabies vector
which we call SiR 2.0. We show here that this vector design, derived from a combination
of the viral N protein attenuation technology of SiR 1.0 and the use of a less immunogenic
parent strain (CVS-N2C), can be produced in vitro successfully to high titers for in vivo use.
Given concerns regarding the genomic stability of self-inactivating rabies viruses, es-
pecially with regards to "revertant" mutation of the N-TEVs-PEST modification crucial
for viral self-inactivation, we have investigated the genomic stability of the TEVs-PEST
modification of the SiR at both the sequence and protein level both during viral production in
vitro and post-infection and trans-synaptic transfer in vivo. These results confirm that the
N-TEVs-PEST mutation is not susceptible to revertant mutation accumulation in any of the
contexts studied.
We then go on to characterize further various aspects of SiR 2.0 vector function. We
show that the CVS-N2C strain from which the SiR 2.0 is derived shows greater genome
stability then the SAD-B19 strain. This is advantageous in the context of ensuring the quality
control of high batch viral productions. In addition, the delayed transcriptional kinetics of
the CVS-N2C strain results in a slower self-inactivation of the SiR 2.0 virus compared to
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SiR 1.0. This could in theory be useful in certain experimental cases, where more prolonged
exogenous transgene expression from the viral genome may be desired. SiR 2.0 also has a
greater neuroaffinity for peripheral motor neuron terminals post muscle injection in vivo and
a greater trans-synaptic transfer efficiency in motor-premotor circuits (enabling better circuit
tracing coverage).
Further characterisation of the induction of immune responses to rabies virus infection by
the different rabies virus vector variants by immunofluorescence and NGS has shown that the
combination of a less immunogenic rabies strain with a TEVs-PEST modification resulting
in transcriptional attenuation significantly reduces the immunogenicity of the SiR 2.0 vector
compared to its predecessing rabies virus vectors. Our findings suggest that SiR 2.0 is the
least cytotoxic and therefore most preferable rabies vector for long-term peripheral targeting
of motor neurons.
Chapter 4
Genome-editing of Neural Circuits with
Rabies Virus
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4.1 Introduction
In the previous section, I have discussed the design and characterization of a novel circuit
tracing tool (SiR 2.0) that allows us to genetically modify trans-synaptically connected
neurons with increased neurotropic efficiency and reduced perturbations of normal circuit
physiology. In these previous examples, genetic modification was conducted using the virally
driven expression of CRE recombinase to activate the life-long expression of fluorescent
markers in transgenic mice. I have also mentioned in the previous section, the implications
of using life-long visualisation of once synaptically traced neurons for further research
in synaptic longevity and plasticity. However, as also mentioned previously, anatomical
visualisation of network architecture is on its own insufficient for us to decipher exactly
how the brain processes information and generates behaviour. Ideally, what neuroscientists
need is a vector that can allow us not only to label circuits specifically but also manipulate
them in order to visualize dynamic activity and establish clear causality between circuit
function and behaviour. In this instance, the rabies virus has been used as such a tool for
investigations in mammals. In the case of WT DG rabies viruses (SAD B19 or CVS-N2C),
virally driven channelrhodopsin2 (ChR2) or GCaMP6 expression has been used within the
time frame before the virus causes notable toxicity (1-4 weeks) to monitor or manipulate
neuronal activity190. For longer time scales, SiR B19 CRE infected cells were found to show
effective ChR2 and GCaMP6 activity for up to 4 months p.i.191,271.
In this chapter, we aim to combine the SiR’s unique ability to trace circuits without
prolonged toxicity or immunogenicity with another method of manipulating circuits - which
is that of genome editing, using the CRISPR/CAS9 technology.
4.1.1 The CRISPR/CAS9 revolution
Gene therapy has been termed as "the holy grail of modern medicine"272. Many diseases
are caused by defective genes, and genome editing techniques can in theory be used to
add, replace or inactivate genes for therapeutic purposes. In order to do this however, one
needs a precise method of introducing DNA strand breaks at pre-determined sites out of 3
billion possible cut sites in a patient’s genome. Until recently, targeted DNA cleavage in
order to achieve such goals relied on the design of specific DNA binding sites into nuclease
proteins (e.g.zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases
(TALENs)273). However, enzyme dependent systems are not versatile, and re-direction of
nuclease activity to different genomic sites requires time-consuming adjustments of protein-
DNA binding sites. Other gene silencing methods such as RNA interference are, in contrast,
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more easily directed to target genes by alteration of the RNA base sequence but often results
in incomplete knock down and requires repeated delivery in order to obtain long-term gene
suppression.
Recently, our ability to target specific genomic locations in eukaryotes has seen a huge
advancement with the development of CRISPR-Cas9 based systems for genome editing.
Clustered regularly interspaced short palindromic repeats (CRISPR) were first observed in
bacterial and archaeal genomes in 1993274,275. Over the course of two decades, these initially
mysterious sequences were revealed to be components of the bacterial adaptive immune
system276,277. CRISPR sequences are transcribed into RNA molecules called CRISPR RNA
(crRNA) that contain complementary sequences to incoming plasmid or phage DNA278 and
direct CRISPR associated proteins (Cas) to create double-stranded breaks 3 nucleotides
upstream of the proto-adjacent motif (PAM) in targeted DNA279. In type II CRISPR systems,
the only protein required for cleavage is the Cas9 endonuclease280. This system was shown
to transfer immune resistance between different bacteria281,be modifiable to target genomic
loci of choice by changing the crRNA sequence282, and shown to be functional in cleaving
endogenous genome sequences in eukaryotic cells7,283,284. A single guide RNA (gRNA),
which is a hybrid of the two RNAs used in natural type II systems (a crRNA and trRNA)
was also designed and shown to efficiently target Cas9 endonuclease to target genomic
loci285. The gRNA is approximately 100 bases long, has a hairpin secondary structure and
contains a 21bp sequence in its 5’ terminus which is complementary to the target genomic
site. These developments have output a versatile CRISPR-Cas9 system that enables, by
the co-expression of one CAS9 endonuclease enzyme and one gRNA, a means of targeting
endonuclease activity to predetermined specific sites of the genome.
Modifications of CRISPR-Cas9 systems for gene engineering has enabled an array
of different gene modifications in mammalian cells. For example, Cas9 nickase mutants
cause only single-stranded nicks in targeted sequences as opposed to DSBs induced by WT
enzymes282,285,286. Depending on the type of DNA damage resulting by Cas9 activity (single-
strand nicks or double strand breaks (DSBs)) and on the type of repair system used by the
host cell (homologous or non-homologous) the CRISPR-Cas9 system can be used to insert
novel sequences using pre-designed DNA donor fragments for homologous recombination,
or disrupt genes by causing indel mutations as a result of non-homologous end joining of
double strand breaks. In addition, the fusion of catalytically inactivated Cas9 to a cytidine
deaminase enzyme enables other genome modification methods such as direct targeted base
editing (C->T, or G->A on the opposite strand) without the induction of dsDNA breaks287.
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Ultimately, CRISPR-Cas9 systems enable direct permanent editing of eukaryotic genomes
after a short period of expression in a targeted cell or tissue, and can easily be designed
to target a specific genomic sequence complementary to the 20bp targeting sequence in
gRNA and adjacent to a protospacer adjacent motif (PAM). In the past two years, there have
been over 325 articles published on the modification and application of such CRISPR-Cas9
systems for basic research and potential therapeutic purposes.
4.1.2 Suitability of SiR viruses for neurological CRISPR-Cas9 gene
therapy
Successful gene therapy requires not only a efficacious molecular system to conduct the
gene editing, but also a means to deliver these gene editing tools efficiently into target cells
that are implicated in disease pathogenesis. Another main barrier to successful gene therapy
development is finding a safe and efficient vector system to transfer gene modification tools
into cells, tissues, or in our case, neural circuits, of choice.
For the treatment of neuropsychiatric and neurodegenerative conditions, the advantages
of using a circuit specific vector to conduct gene modifications includes both the ability
to increase the payload of gene therapy to the widespread circuits that are affected in
pathogenesis whilst also reducing off-target side effects resulting from transduction of
untargeted cells not involved in disease pathogenesis. As discussed in the introduction,
this is extremely difficult to achieve using non-circuit specific vectors. Non circuit-specific
vectors (e.g. AAVs or lentiviruses) can only target diseased neural circuits either by systemic
or widespread CNS delivery which increases off-target anatomical side effects, or more
anatomically specific invasive surgical techniques which do not have coverage of widespread
networks implicated in disease. In contrast, the rabies virus can, following peripheral
injection, trans-synaptically retrogradely transport itself to anatomically distant but connected
neurons in appropriate areas of the central nervous system with high efficiency.
In addition to anatomical specificity, one also needs to consider gene-editing specificity.
Despite its unprecedented specificity and versatility, CRISPR-Cas9 systems can still have
off-target effects288, and the side-effects of long term expression of endonucleases in cells are
unclear. Short-term expression of CRISPR-Cas9 can cleave targeted sites with high efficiency
whilst reducing the accumulation of off-target gene modifications. This is a consideration for
DNA vectors such as AAVs or lentiviruses which can permanently integrate into the host
genome, increasing the risk of insertional mutagenesis but also resulting in more off-target
modifications due to long-term expression of gRNAs and endonucleases. Therefore, ideally
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the CRISPR-Cas9 should be delivered to target cells for a short period long enough to achieve
efficient targeting of the desired loci, but minimal off-target effects. And in this instance, the
SiR, which expresses transgenes for a short period of 2-3 weeks before self-inactivation may
overcome the problems associated with long term Cas9 gRNA expression.
4.1.3 Aims
In this chapter of the thesis, my aim is to functionally incorporate into the rabies genome
the two components of the CRISPR/Cas9 system (the CAS9 endonuclease, and 100bp
gRNA). This combines the rabies virus’ unique ability to trans-synaptically infect neurons
with our unprecedented ability to precisely edit the genome of mammalian cells using
CRISPR-Cas9 systems. Such a tool would finally allow researchers to probe the role of
specific genes within circuits in the computation of behaviours in live animals, and pave the
way for the development of effective circuit-targeted gene therapy for neuropsychiatric and
neurodegenerative disorders.
Here, we describe the design, screening and production of rabies viruses expressing both
components of CRISPR-Cas9 system to induce targeted DSBs in mouse genomes both in
vitro and in vivo.
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4.2 Results
4.2.1 Designing gRNA to target the mouse NeuN gene
In order to test for rabies virus mediated genome editing, we decided to target the NeuN locus.
NeuN (also known as Fox-3 or Rbfox3) is a RNA binding protein which is commonly used
as a nuclear marker for neurons in vertebrates as it is expressed at a high level in almost all
neuronal populations (exceptions include purkinje cells and photoreceptors)289. We designed
3 sgRNAs against the first exon of the NeuN gene using the CRISPOR (http://crispor.org)290
and GPP sgRNA Designer webtool (https://portals.broadinstitute.org/gpp/public/analysis-
tools/sgrna-design)291. We selected for gRNA sequences with high predicted efficiency and
specificity (i.e. high on-target but low off-target activity). The target sequences of these 3
gRNAs with their adjacent PAM sequences are shown in Fig. 4.1A.
We experimentally validated the targeting of the endogenous mouse NeuN locus in vitro
by these gRNA sequences using a mismatch cleavage assay (Fig. 4.1A). In order to do this, we
transfected mouse neuro2a cells with DNA plasmids encoding the Cas9 endonuclease enzyme
under a type II CMV promoter and the single gRNA sequence using a type III U6 promoter.
3 days post-transfection, we extracted genomic DNA from infected cells for amplification
of the first exon of the NeuN gene (Fig. 4.1B). Any indel mutations introduced by NHEJ
repair of gRNA targetted DSBs would also be amplified in the PCR products. Following
PCR amplification, PCR products were denatured-renatured, resulting in the annealing of
mismatched DNA fragments which can be detected by "resolvase" enzymes, such as the T7
endonuclease enzyme which cleaves DNA heteroduplexes292. The resulting reaction mixture
was then run on an agarose gel to identify the site and degree of fragmentation. We found
that gRNA NeuN3 showed the highest cleavage activity (Fig. 4.1C) and so we used this
sequence for further expression from the rabies virus genome.
4.2.2 Preliminary design of a WT DG gRNA NeuN Cas9 rabies virus:
the molecular challenges of expressing gRNA and Cas9 endonu-
clease from the rabies genome
Having designed and experimentally validated a gRNA sequence targeting the endogenous
NeuN gene (now called gRNA NeuN), we wanted to engineer the rabies virus genome to
functionally express both the Cas9 endonuclease and the gRNA NeuN sequence. In order to























































gRNA NeuN1         5’  - CATGCCGTGCTCGGGGGGAAC AGGGGT  - 3‘
gRNA NeuN2         5’  - ATGAGTCTGTGCGGGTGTGTA  GAGGGT - 3‘






Fig. 4.1 Design and screening of gRNA to target the NeuN locus using the T7 endonuclease I
assay (A) 3 gRNAs were designed to target the mouse NeuN locus. Their target sequences (black)
and adjacent PAM motifs (red) are shown. (B) Mouse neuro2A cells were transfected with DNA
plasmids to drive CMV-Cas9 and U6-gRNA NeuN expression. 3 days post-transfection genomic DNA
was extracted from cells, the exon 1 of the NeuN locus amplified by PCR, and mutations resulting
from effective Cas9 targeting were detected using the T7 endonuclease I assay. (C) PCR primers
were designed to amplify a region of 542bp length spanning exon 1 and a portion of the subsequent
3’ intergenic region. As gRNAs were designed to target near the 3’ end of the exon, indel detection
would result in fragemntation of the PCR amplicon to give two fragments of approximately 200 and
340bp in size. Exact numbers are given for cleavage caused by gRNA NeuN3 targeting. (D) Gel
electrophoresis of NeuN PCR amplicon fragmentation by T7 endonuclease I resulting from mismatch
cleavage. One can see only gRNA NeuN3 causes siginficant targeting of Cas9 to the NeuN locus.
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Our first consideration was the limited coding capacity of viral vectors (Fig. 4.2). The
native WT SAD-B19 genome is 11.9Kb293. We have previously replaced the G locus (1.5kb)
with a CRE-GFP transgene (2kb) without affecting viral recovery from plasmids or high-titer
production. In addition, recombinant DG rabies viruses have been recovered from plasmids
that are up to 13.6kb in size (SADDG-GFP-ERT2CreERT2) which is 1.7kb larger than the
native SAD-B19 genome294. Here, we wanted to add to the viral genome sequences for
the expression of both the Cas9 endonuclease and gRNA for genome editing. The most
commonly used Cas9 endonuclease (that from Streptococcus pyogenes) alone is 4.2kb in
size resulting already in a 2.7kb payload over the WT virus. Therefore we used a 1kb shorter
variant of the Cas9 endonuclease enzyme from Staphylococcus aureus (SaCas9) which has
been previously used for efficient packaging into other viral vectors with limited coding
capacity such as AAVs. We expected this 2kb payload in genome size may potentially impair
the efficiency of viral production, but given that other transgenes of similar sizes had been
inserted successfully into the rabies virus before, that with altered cell culture conditions we
would still be able to produce high titer productions of recombinant rabies viruses with a
genome of that size.
Second, there was the structural incorporation of gRNA sequence into the viral genome.
The sgRNA is a designed hybrid of native crRNA:tracrRNA duplexes in natural type II cas9
systems with conserved secondary structures which are necessary for effective Cas9 targeting.
The bulge and nexus structures are necessary for DNA cleavage, whilst the nexus and hairpin
structure dictates Cas9 orthoganality295. Structurally, the nexus structure positions both the
Cas protein and RNA to receive target DNA duplexes for cleavage. Given the high propensity
of sgRNA for secondary structure formation, we were concerned that incorporating its
primary sequence into the single stranded RNA genome of the rabies virus may lead to
the formation of secondary structures within the viral genome which could impair viral
packaging, replication or transcription mechanisms.
Lastly, in addition to the structural consequences of gRNA incorporation into the ssRNA
genome, we needed to ensure functional expression of sgRNA. This was arguably one of our
major considerations as efficient Cas9 targeting requires high levels of gRNA expression and
precise start and stop regulation of transcription. The vast majority of literature regarding
CRISPR technology is based either on direct delivery of CAS9 mRNA together with pre-
transcribed gRNAs, preassembled ribonucleocomplexes or DNA-mediated expression of
CAS9 and gRNA in the nucleus of the cell using DNA viruses or plasmids. These DNA
vectors express the Cas9 protein under polymerase II promoters to recruit cellular RNA pol II
machinery for the production of mRNA, whilst gRNA is expressed under type III promoters
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Fig. 4.2 Molecular challenges of expressing CAS9 endonuclease and gRNA from the rabies
genome (A) The WT SAD B19 rabies virus is 11.9kb. (B) Transgene expressing DG rabies viruses
used in this thesis have shown that viral productions and infectivity are not impaired by additions
of sequences resulting in genetic payloads of 0.5kb. (C) Here we try to incorporate into the DG
rabies virus a Cas9 endonuclease and gRNA coding sequence. Commonly used S. pyogenes Cas9
endonuclease is 4.2kb, but there are smaller alternatives available such as the S. aureus Cas9. gRNA
sequences are approximately 100bp and can form complex secondary structures which may interfere
with viral genome structure and hence viral function.
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(e.g. U6) recognized by the cellular RNA polymerase III machinery which naturally produce
small RNAs. However, the rabies virus is a ssRNA virus with no DNA intermediates that
resides exclusively in the cytosol and uses its own viral transcription machinery. As such, it
is not possible to use reported methods of nuclear DNA driven Cas9 gRNA expression in
virally infected cells.
In order to express exogenous Cas9 endonuclease and gRNA from the rabies virus
genome, we had to consider existing knowledge about rabies virus transcriptional biology.
The rabies virus is a negative strand RNA virus. The ssRNA genome is encapsulated by
the viral nucleoprotein (N) to act as a template for transcription and replication by the
viral L-P polymerase complex. For transcription, the L-P polymerase complex sequentially
produces mRNAs from the 3’ to 5’ end by recognition of viral transcription start and stop
sites to initiate synthesis and polyadenylation respectively. At stop sites, the L-P complexes
dissociate from the genome but a proportion are able to re-initiate transcription at the
subsequent TSS of the viral genome. Transgenes such as CRE and GFP have been expressed
exogenously from the rabies virus before by replacing cell endogenous pol II promoters with
viral transcriptional start stop sequences. However, the expression of small RNAs using
rabies virus transcriptional start and stop sequences and the viral L-P RNA polymerase was
a novel method that was previously unreported in the literature. As such, it was unclear
whether the viral transcriptional machinery was capable of producing functional gRNAs. We
needed to ensure the virus would be able to process gRNAs functionally and express it to
high enough levels.
Taking all these things into consideration, we made a preliminary first design of a WT
DG SAD B19 rabies virus expressing the Staph aureus Cas9 (SaCas9) endonuclease and
gRNA NeuN in the G locus (Fig. 4.3A) in order to test whether a rabies virus genome
of that size, incorporating a hairpin gRNA sequence could be recovered from plasmids
and produced at titers appropriate for in vivo injections. In addition to successful viral
production, we also tested whether these viruses were functionally expressing both the Cas9
endonuclease and gRNA elements in the cytosol using the viral transcriptional machinery
via viral transcriptional start and stop sites
4.2.3 Successful production of WT DG Rabies gRNA NeuN SaCas9-
3xFLAG, design A
Our preliminary design of a WT B19 DG gRNA NeuN Cas9 virus (Design A, Fig. 4.3A)
consisted of a WT B19 DG viral vector with a Staph aureus Cas9 (SaCas9) and gRNA
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sequence inserted into the M/L locus of the WT virus with unedited standard rabies virus
transcriptional start and stop sites for viral transcription regulation. Due to the already large
size of this construct, we did not incorporate any fluorescent proteins for visualisation of
viral productions in this design. For eventual visualisation of viral proteins we did add a 3x
tandem repeat of the FLAG epitope to the C terminus of the SaCas9 coding sequence. But
as FLAG visualisation requires antibody staining, we were unable to use this marker live to
follow the production of this virus in real time. As such, productions were conducted "blind"
with absence of a fluorescent marker to monitor viral packaging, replication and spreading.
As a positive control for viral production steps, we would make in conjunction with the
"blind" rabies virus, a WT B19 DG CRE-mCHERRY with the same experimental conditions
to assess the success of plasmid transfections. We also were able to monitor "blind" viral
production by observing "rounding" of production cells which are indicative of successful
rabies virus replication in cells in vitro. Once we obtained potentially infective supernatant
from blind production cells, we infected mouse neuro2A cells with the supernatant to test
first, whether the WT B19 DG gRNA NeuN Cas9 virus could be produced, and second,
whether this virus retained its ability to infect cells in vitro. 3 days post infection, we stained
the mouse neuro2A cells with an anti-FLAG primary antibody which we had conjugated
to a Cy3 antibody for quick visualization of viral Cas9 expression. We found that addition
of 250µl of viral supernatant to a 6 well of neuro2A cells resulted in FLAG+ staining of
70% of cells. This was a high level of infectivity comparable to the titer of our positive
control (WT B19 DG CRE-mCHERRY). As such, this finding confirmed that the rabies virus
could tolerate the addition of Cas9 endonuclease and hairpin gRNA sequences into its viral
genome without impairing viral replication or in vitro infectivity. Positive FLAG staining
also confirmed that the SaCas9-3xFLAG protein was being transcribed effectively by the
rabies virus.
4.2.4 WT DG Rabies gRNA NeuN SaCas9-3xFLAG can target endoge-
nous loci in vitro
Through FLAG Ab staining we had confirmed that a rabies virus encoding both a Cas9
endonuclease and gRNA sequence could be produced, used to infect cells in vitro and express
the SaCas9-3xFLAG protein. However, we needed also to assess whether the gRNA was
being transcribed effectively by the rabies virus L-P RNA polymerase complex to enable
efficient genome targeting. In order to do this, we conducted a mismatch cleavage assay
in the NeuN locus in mouse neuro2A cells infected with WT DG gRNA NeuN CAS9 viral
118 Genome-editing of Neural Circuits with Rabies Virus
WT B19 gRNA NeuN Cas9 N P M SaCas9-3xFLAG LgRNA
(Design A)







added to 6 well plate 
Fig. 4.3 Successful production of WT DG Rabies gRNA NeuN SaCas9-3xFLAG, design A (A)
Genome map of our preliminary first design of a WT DG Rabies virus encoding gRNA and SaCas9-
3xFLAG. (B) Staining of mouse neuro2A cells infected with 250µl of viral supernatant in 6 well
plates with a Cy3 conjugated anti-FLAG antibody (magenta). Cell nuclei were stained with DAPI
(blue). Quantification of FLAG+/DAPI+ cells revealed 70% infected cells showing successful viral
production, in vitro infectivity and SaCas9-3xFLAG protein expression.
supernatant. We first titered the viral supernatant to assess the number of infected neuro2A
cells following viral infection. We found the supernatant had an infectivity of 1.3x108
i.u./mL, with 50% of cells being infected following addition of 25µl to 80% confluent
neuro2A cells in 6 well plates (Fig. 4.4A,B). We then assessed the degree of indel mutation
accumulation in the targeted NeuN locus over time using a mismatch cleavage assay in these
cells infected with increasing viral titers at 3d and 6d p.i. (Fig. 4.4C,D).
First, we found that the WT B19 gRNA NeuN Cas9 rabies virus could indeed target the
endogenous NeuN locus in vitro. This was evident by the observation of cleaved NeuN exon
1 PCR fragments in infected cells both 3d and 6d p.i (Fig. 4.4C,D). This indicated that the
gRNA sequence that is usually expressed by RNA pol III systems in the nucleus for small
RNA transcription could also be transcribed and processed functionally by the viral L-P RNA
polymerase complex. It also indicated that even with this preliminary design, the rabies virus
could produce enough Cas9 and gRNA to induce clear genome editing in vitro as visualised
by the T7 endonuclease I assay.
Second, we found that there was increased mutation detection in the NeuN locus at 6d
p.i. compared to 3d p.i. in cells infected with the same volumes of viral supernatant (Fig.
4.4C). This showed us that although genome targeting is visible from as early as 3d p.i.,
the coverage of gene modifications in infected cells can increase with increasing time of
up to 6 days p.i.. Extrapolating from this result in vitro, we expected that as the period of
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transcriptional activity in SiR viruses is 2 weeks, the length of Cas9 and gRNA expression
from SiR vectors would not be a limiting factor for efficient genome editing in vivo.
Third we found that with increased % of infected cells, we observed more mismatch
cleavage. For example, with 25µl viral supernatant and hence 50% infected cells, we saw
fragmentation of 5% of PCR amplicons 6 days p.i. whereas with infection of 60% of cells
with 100µ l viral supernatant we observed fragmentation of 16% of PCR amplicons. This was
partly expected as with higher % of infected cells, more of the cells collected for mutation
analysis were expressing the viral gRNA-Cas9 cassette. However, between these two dilutions
the percentage of cells infected had only gone up by 25%, whilst the fragmentation efficiency
had almost tripled. The degree of mutation detection also increased when comparing cells
infected with 100 vs 200µl of viral supernatant even though visualisation of infected cells
using the FLAG antibody did not reveal significant differences in the number of infected
cells (both resulting in the infection of 61% of cells on average). Despite the similar numbers
of infected cells, cells infected with higher viral supernatant volumes showed more efficient
genome targeting. We hypothesised that this may be due to the higher multiplicity of
infection (m.o.i.) associated with infections with more viral supernatant, resulting in more
viral particles infecting each FLAG+ cell. For example, if we assume the poisson distribution
of viral particles infecting cells in culture and a derive a m.o.i. of 11 vs. 22 in cells infected
with 100 vs. 200µ l of viral supernatant from our titration analysis, we find that the percentage
of cells with multiple infection (i.e. infection with more then 1 viral particle) was 1.5x10 2%
vs. 3.3x10 7. It could be that cells infected with more viral particles express higher levels of
Cas9 and gRNA resulting in more efficient genome targeting.
Given our results, and our assumptions based on previous literature regarding the require-
ment for stringent and high gRNA expression for efficient CRISPR-cas9 mediated genome
editing, we aimed to investigate directly whether the efficiency of our system could be further
improved by improving gRNA expression.
4.2.5 Endogenous gene cleavage efficiency can be boosted with increased
gRNA expression
In order to investigate whether the efficiency of genome editing using the rabies virus vector
could be increased further by increasing gRNA expression, we compared the % cleavage of
NeuN PCR amplicons following the infection of mouse neuro2A cells with WT rabies alone
or WT rabies + plasmid driven U6-gRNA expression at 2 different viral titers. Unedited
neuro2A cells were used as a negative control, whilst cells transfected with both CMV-Cas9
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Fig. 4.4 WT B19 Rabies CAS9 gRNA, Design A can target endogenous genes in vitro (A) % of
FLAG+/DAPI+ cells following infection with increasing volumes of viral supernatant (B) Visualisation
of FLAG expression (green) by virally infected cells following infection with increasing volumes of
viral supernatant. (C) % of NeuN locus PCR amplicon fragmentation from the T7 endonuclease I
assay at 3d and 6d p.i. of cells infected with increasing volumes of viral supernatant. (D) Visualisation
of 3 experimental repeats of T7 endonuclease assay gel visualisation at 6d p.i..
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Fig. 4.5 Genome-targeting efficiency of WT DG B19 Rabies gRNA Cas9 can be enhanced by
higher gRNA expression Graph showing the % of NeuN exon 1 PCR amplicon cleavage from the
T7 endonuclease I assay following infection of cells with rabies virus with or without additional
U6-gRNA DNA plasmid transfection. PBS was used as the negative control for lack of genome
targeting, and co-transfection of CMV-Cas9 and U6-gRNA was used as a positive control for efficient
genome targeting. n=3, One-way ANOVA with Tukey correction for multiple comparisons.
We found that at both titers investigated, co-transfection of rabies infected cells with
plasmid U6-gRNA DNA resulted in increased cleavage efficiency to levels similar to the
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positive control (Fig. 4.5). This suggested that the limiting factor for cleavage efficiency
in rabies only infected cells was due to gRNA expression rather then SaCas9 expression
efficiency.
In addition, following co-transfection with U6-gRNA, we did not observe differences
in cleavage efficiency in cells infected with 100 vs 200 µl viral supernatant suggesting that
the differences in genome targeting efficiency observed previously between cell populations
with similar numbers of infected cells were due to increased gRNA expression at higher moi.
With this result we decided that in order to increase the efficiency of rabies mediated
genome editing, we needed to boost gRNA expression levels. Thus, we subsequently de-
signed, using our limited knowledge about transcriptional regulation of Rhabdoviruses
(mostly coming from vesicular stomatitis virus), multiple cassettes for the increased func-
tional expression of the CAS9-gRNA elements.
4.2.6 Designs to increase gRNA production from the rabies virus vec-
tor
In order to increase gRNA expression levels from the rabies virus genome, we designed
4 variants of WT B19 Cas9 gRNA NeuN, taking into consideration three known factors
regarding rabies viral transcription mechanisms. First that transcript levels are known to
decrease with increasing distance from the 3’ leader sequence of the viral genome (Fig. 4.6).
Second that intergenic region lengths and sequence can also heavily influence transgene
expression levels296. And third, that the addition of exogenous sequences to the rabies virus
at different loci can result in unpredictable alterations of transcription levels of subsequent
genes in the viral genome297.
4.2.6.1 Decreasing transcript levels with increasing distance from 3’ end in genome
Our knowledge of rabies virus transcription regulation is derived from investigations into the
transcriptional regulation of other non-segmented negative strand RNA viruses of the same
Mononegavirales order or Rhabdoviridae family. Study into the vesicular stomatitis virus
(a member of the Rhabdoviridae family) revealed that a major determinant of transcription
regulation in negative ssRNA viruses is the gene order. It is assumed that the viral RNA
polymerase initiates transcription from the 3’ leader sequence and subsequently transcribes
genes towards the 5’ direction298. At the border of each gene, there is a transcription
stop signal for polyadenylation of mRNA transcripts. The viral polymerase dissociates at
each gene border and as only a proportion of dissociated polymerase complexes re-initaite
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transcription at the subsequent gene there is a progressive loss of mRNA trnscript levels that
follows the order of genes from 3’ to 5’ end299. As such, the 5’ terminal gene (L) produces
the least mRNA transcripts in infected cells300,301.
We observed the same finding in rabies virus infected neurons in vivo following injection
of rabies virus into the hippocampus (Fig. 4.6). 1 week p.i., total RNA from infected
hippocampi were prepared for RNA-sequencing. Reads were aligned to the viral genome
and the density of reads to each gene was compared. We assumed that these reads obtained
from the total RNA preparation were derived from both from viral genome RNA as well
as virally transcribed gene mRNA molecules. Comparison of read density revealed that
there was significantly lower levels of L encoding RNA at the most 5’ end of the viral
genome in infected hippocampi compared to N encoding RNA at the most 3’ end. As such
we directly validated from rabies virus infected cells in vivo, the known transcriptional
regulation determinants of other members of the Rhabdoviridae family. Given these results,
we decided in our subsequent WT DG gRNA NeuN Cas9 designs to alter the locus of
exogenous sequence entry to increase gRNA transcription levels.
ΔG Rabies Virus N P M CRE-GFP L3’ 5’
1w p.i.

















Fig. 4.6 Viral mRNA transcription levels decrease with increasing distance from 3’ leader pro-
moter Adult mice were injected with WT B19 CRE-nuGFP virus in CA1 of the hippocampus. 1 week
p.i. total RNA was extracted from dissected hippocampi and prepared for Illumina RNA-sequencing.
Reads were then aligned to the viral genome and analysed for read density (log2RPKM) for each of
the 5 viral genes.
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4.2.6.2 Design of 4 Rabies-CAS9-gRNA variants
In order to try to increase gRNA expression from the rabies genome, we designed 4 variants
of a WT B19 D G virus to produce and screen for genome editing efficiency (Fig. 4.7).
Design A (Fig. 4.7) was our first preliminary design which was used in the previous
studies as a proof of principle that the rabies virus could structurally and functionally
incorporate gRNA and Cas9 sequences into its genome without impairment of replication,
production or infectivity. It also revealed that this rabies vector could successfully target
endogenous loci in vitro, but that the efficiency of this could be increased by increasing gRNA
expression. In this preliminary design, we inserted the gRNA NeuN and SaCas9-3xFLAG
sequence into the G locus with unedited M/G intergenic sequences and viral transcription
start and stop sites.
In design B, we attempted to boost gRNA expression by altering the intergenic regions
(IGRs) between genes. This was due to a previous study showing that the 2nt N/P intergenic
sequence yielded the highest amounts of subsequent transgene mRNA transcription compared
to all other intergenic sequences. If N/P IGR was considered to result in subsequent luciferase
transgene mRNA levels of 100%, the IGRs of the P/M, M/G and G/L locus resulted in 78,
81 and 11% mRNA transcription respectively296. As such, we designed a second variant
(design B) of the original WT B19 gRNA NeuN Cas9 design with the 5 nt M/G IGR sequence
replaced with a 2 nt N/P IGR sequence.
In design C, given our knowledge of increasing transcript levels in the 3’ end of the viral
genome, we moved our gRNA encoding sequence to the N/P locus (Fig. 4.6). In design D,
we incorporated 2 gRNA sequences into two loci of the viral genome (N/P and M/L locus).
In theory, if these two loci were used to express the same gRNA we thought this may further
increase gRNA expression levels and help increase genome targeting effiency. In addition,
we considered that in the future, the expression of 2 gRNAs with a mutant nickase Cas9
gRNA could result in DSB induction with less off-target effects. Or alternatively, the use of
2 different gRNAs with different target genes and a WT Cas9 could result in the targeting of
more than 1 gene with one rabies virus vector.
4.2.6.3 Production of the 4 variants
Having designed and cloned these 4 WT DG B19 gRNA NeuN Cas9 viruses into pSAD-
B19 DG genome vectors, we attempted to produce these viruses to see if they could all
be produced to high titers using standard WT DG B19 rabies virus production protocols
(Methods). Similar to the viral production of version A described previously, all these
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Fig. 4.7 4 designs of WT gRNA NeuN Cas9 for increased gRNA expression Preliminary design A
with insertion of Cas9 and gRNA sequences into the G locus with unedited intergenic regions (IGR)
and known viral trancsription start and stop sequences. Design B with replacement of the M/G IGR
with the N/P IGR to increase gRNA expression. Design C with gRNA sequence in the N/P locus,
closer to the 3’ end of the viral genome with known higher levels of transcription. Design D with
2 gRNA sequences in the N/P and M/G locus. This design could enable the expression of the same
gRNA from two different loci for increased overall expression. The two loci could also be used to
express different gRNAs for reduced off-target effects using mutant Cas9 nickase enzymes, or to
target two different genes using WT Cas9 endonucleases with one rabies virus vector
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productions were conducted "blind" due to restricted viral genome capacity. We did not
incorporate fluorescent proteins into the viral genome for visualisation of viral replication
and spreading during production in vitro. Thus, a WT DG B19 mCHERRY-CRE rabies
virus was produced in parallel with these "blind" viruses as a positive control for successful
plasmid transfection. In addition, the anatomical "rounding" of production cells during viral
supernatant collection was another live indicative marker of successful viral production and
spreading in vitro. Following the collection of viral supernatant from these productions, we
infected mouse neuro2A cells in 6 well plates with increasing volumes of viral supernatant
for confirmation of viral production and titration. 3 days p.i., cells were fixed and stained for
expression of the FLAG epitope on the C terminus of the SaCas9 protein to visualise virally
infected cells. We found that version A and B, with modifications only to the G locus could
be produced to high titers easily with standard production protocols (Fig. 4.8A,B).
However, versions C and D, with additional gRNA sequences in the N/P locus were not
produced with high efficiency and we could only visualise very few virally infected neuro2A
cells following infection compared to versions A and B, as well as the WT mCHERRY-CRE
rabies positive control (Fig. 4.8C,D). This suggested to us that addition of the gRNA sequence
to the N/P locus probably resulted in the disruption of viral transcription or replication
mechanisms, which delayed or impaired viral packaging, replication or spreading kinetics in
vitro. This was in contrast to previous studies showing that the insertion of the GFP coding
sequence into the N/P locus of a different rabies virus strain (HEP-Flury) was well tolerated
and resulted in higher GFP mRNA transcript levels297. However, our different results may
be a result of the different strain of rabies virus used, as well as the differences in the size,
structure and base composition of the GFP coding sequence vs. gRNA sequence.
Given the difficulty of production of versions C and D, we decided not to go forward
with these designs for SiR productions. This was because SiR productions show delayed
kinetics compared to WT DG productions due to attenuation of the viral N. Therefore, a blind
production of an inefficiently produced WT design in a SiR vector would have posed many
technical difficulties. Given that designs A and B were produced equally efficiently in vitro,
and that previous studies show higher transcription levels of viral genes preceded by 2nt N/P
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Fig. 4.8 Production of 4 WT gRNA NeuN Cas9 designs for increased gRNA expression The 4
designs of WT gRNA NeuN Cas9 viruses depicted in Fig. 4.8 were cloned into pSAD-B19 DG
genome vectors and produced following standard B19 DG production protocols. Viral supernatant
collected from these productions were used to infect mouse neuro2A cells and subsequent FLAG
epitope staining (green) to assess successful viral production and viral titration. Due to lack of virally
expressed fluorescent proteins in these viruses, a parallel production of a WT B19 mCHERRY-CRE
rabies was used as a positive control for successful plasmid transfection and viral spreading during
the production process. (TL = transmitted light imaging)
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4.2.7 SiR gRNA Cas9 mediated genome editing in vivo
4.2.7.1 SiR B19 gRNA NeuN Cas9 virus can be produced to high titers following a
standard SiR B19 production protocol
Following confirmation of WT DG rabies mediated CRISPR-Cas9 genome editing in vitro,
we then wanted to produce a SiR virus expressing the same CRISPR-Cas9 expression cassette
(design B) that would eventually be necessary for long-term rabies virus mediated genome
editing in circuits in vivo (Fig. 4.9A). Although derived from the WT B19, the attenuation
of the N in the SiR results in delayed viral replication and production kinetics and so we
needed to directly validate that a SiR B19 gRNA NeuN Cas9 virus (version B) could also be
produced to the high titers necessary for successful in vivo injections. Following the standard
production protocol of SiR B19 viruses (methods), we successfully recovered infective viral
supernatant following initial plasmid transfection in HEK-TGG production cells over a period
of 3 weeks. Subsequently, the viral supernatant was amplified further in new HEK-TGG
production cells for a week before purification of high-titer viral productions.
Following viral purification, the production was titered by infecting neuro2A cells in
culture with serially diluted purified virus. 3 days following infection, the infected cells
were fixed and stained with a Cy3 conjugated anti-FLAG primary antibody for visualisation
of virally infected cells (Fig. 4.9B). Titers of approximately 2x109 i.u./mL were obtained
following the standard protocol.
4.2.7.2 SiR B19 gRNA NeuN Cas9 shows effective genome editing in vivo
The purified SiR B19 gRNA NeuN Cas9 virus was subsequently injected into the CA1 of
mouse hippocampi to test whether this novel virus with 2kb payload over the WT genome and
a hairpin gRNA sequence retained the ability to infect neurons in vivo following intracerebral
injection. In addition, we wanted to assess in this preliminary experiment, whether the SiR
virus could target genomic loci efficiently in infected neurons in vivo. Again, although the
SiR is derived from the WT B19 virus, due to the attenuation of the N protein we observe the
SiR has lower transcriptional levels and kinetics. Therefore, there was a possibility that the
lower gRNA and SaCas9 expression in SiR would decrease the efficiency of genome editing.
However, compared to our tests of genome targeting efficiency of the WT virus over a period
of 3-6 days in vitro, the SiR vector could be used to express CRISPR-Cas9 components for a
much longer period of 1-2 weeks (the period of viral transcriptional activity following initial
infection but before viral self-inactivation). This longer expression would in theory also
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Fig. 4.9 SiR B19-gRNA-NeuN-SaCas9 can be produced to high titers and mediate genome-
editing of endogenous genes in vivo (A) Gene map of SiR B19-gRNA-NeuN-SaCas9-3xFLAG. (B)
Functional titration of purified SiR B19-gRNA-NeuN-SaCas9-3xFLAG virus in neuro2A cells using
FLAG antibody staining (red) to visualise virally infected cells. (C) SiR B19-gRNA-NeuN-SaCas9-
3xFLAG was injected into the CA1 region of adult mouse hippocampi. 2 weeks later, hippocampal
sections were stained for CTIP2 (CA1 neuronal marker, green), NeuN (gRNA targetted locus and
pan-neuronal marker, red) and FLAG (virally infected cells, magenta). Neurons in CA1 should be
both CTIP2+ and NeuN+. Images show the presence of CTIP2+NeuN- cells (C’, C”) which are all
FLAG+. This indicates the knockdown of an otherwise expressed NeuN protein in virally infected
cells.
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increase the on-target genome targeting efficiency of the SiR compared to the WT virus in
vitro.
2 weeks following injection, adult mice were perfused and hippocampal sections stained
for FLAG (magenta) to visualise virally infected cells with still transcriptionally active
rabies virus, NeuN (red) to visualise whether the virus had successfully targetted the NeuN
locus resulting in a decreased or absent staining of the NeuN protein in infected cells, and
CTIP2 (green) which is an alternative neuronal marker for CA1 neurons302. In theory, all
neurons in CA1 should be both CTIP2 and NeuN positive. However, we observed in our
SiR-B19-gRNA-NeuN-Cas9 infected sections neurons which were CTIP2 positive but NeuN
negative (Fig. 4.9C’, C”) which were all FLAG+ (Fig. 4.9C”’). This indicated SiR mediated
knockdown of an otherwise expressed endogenous NeuN gene in vivo.
For further robust quantification of this observation, we are planning further experiments
that would allow us to permanently label SiR gRNA NeuN Cas9 infected cells. In this
preliminary experiment, we can only visualise transcriptionally active SiR virus from its
expression of FLAG, and so cannot ensure labeling of the majority of virally infected cells
unless working within short time frames of 1 week p.i.. In addition, we are in the process of
producing a SiR gRNA scramble Cas9 control virus to confirm that indeed the decreased
NeuN staining observed in these preliminary experiments are a result of targeted Cas9
modification as opposed to being an off-target effect of Cas9 expression in neurons from the
SiR vector or a general consequence of viral infection.
4.2.7.3 CRISPR-Cas9 mediated genome-editing using the SiR 2.0 vector
As well as producing SiR-B19-gRNA-Cas9 viruses, we also wanted to produce SiR 2.0
CRISPR-Cas9 vectors. This was because the SiR 2.0 vector is less immunogenic then the
SiR 1.0 vector, and reduced immunogenicity is a very important advantageous trait for any
potential gene therapy vector. In addition, the SiR 2.0 vector allows more efficient targeting
of spinal motor neuron networks following peripheral injection (a commonly affected disease
network in motor disorders) that could potentially be a target for SiR mediated gene therapy.
Therefore, we initiated the viral production of two SiR 2.0s: a SiR-N2C-gRNA(scramble)-
SaCas9-FLAGx3 and a SiR-N2C-gRNA(tdTOMATO4)-Cas9-FLAGx3 virus. We selected
the tdTOMATO4 gRNA sequence for targeting the tdTOMATO locus of transgenic mice
following experimental validation in vitro (Fig. 4.13C, D).
Again, despite the addition of a very similar gRNA-SaCas9-FLAGx3 expression cassette,
we needed to directly verify that the SiR 2.0 virus could also be produced to high titers
for in vivo use whilst incorporating long SaCas9 and hairpin gRNA sequences. This was
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because SiR 2.0 displays much reduced transcriptional kinetics compared to the SiR 1.0
and may therefore respond to the same exogenous sequences in different ways. 3 weeks
following viral recovery from plasmids, production cells were stained with a Cy3 conjugated
anti-FLAG primary antibody for confirmation of successful viral production. Following
further viral amplification and high-titer viral purification, functional titration of the SiR-N2C-
gRNA(scramble)-SaCas9-FLAGx3 virus using FLAG antibody staining of virally expressed
proteins revealed that SiR 2.0 viruses encoding SaCas9 and gRNA sequences can be produced
to titers of 5X108 i.u./mL (Fig. 4.10). These functional titers were similar to those obtained
for the production of standard WT DG N2C viruses (Fig. 3.6). Such titers are more then
sufficient for efficient infection of neurons following intracerebral or peripheral intramuscular
injection.
These 2 viruses can be used to assess the efficiency of SiR 2.0 mediated CRISPR-Cas9
targeting of the tdTOMATO locus in transgenic mice in future experiments. Our motivation
for targeting the tdTOMATO gene using the tdTOMATO4 gRNA sequence was due to its
extremely high on-target efficiency as observed experimentally in vitro (Fig. 4.13C and
D). In addition to being approximately 3 times more efficient at on-target DSB induction
compared to the NeuN3 gRNA sequence, it can target the tdTOMATO coding sequence
in two different locations within the target gene. This is because the tdTOMATO coding
sequence is a tandem repeat of the dTomato fluorescent protein. Therefore, we expect that
CRISPR-Cas9 mediated knock-out of the tdTOMATO genomic locus can be visualised more
sensitively in vivo compared to that of the NeuN marker using gRNA NeuN3.
4.2.8 Tool developments to enable more efficient SiR gRNA Cas9 virus
production and screening in vitro and in vivo
4.2.8.1 Development of a split FLP system to enable live and permanent visualisation
of SiR-gRNA-Cas9 infected cells
One major technical difficulty faced during this project was the inability to observe viral
productions live. Although possible, "blind" productions are more labour intensive then the
production of viruses which express proteins that can be visualised directly in live cells. In
addition, when moving in vivo, our viral designs did not enable permanent labeling of SiR
infected cells. This was a limitation due to the fact that the SiR viruses self-inactivate over a
period of 1-3 weeks, and so for more longitudinal experiments, there is no method of labeling
cells that have once been infected with the genome-editing SiR virus. Even for shorter time
points before complete viral self-inactivation, one cannot ensure that all virally infected cells
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Fig. 4.10 High-titer production and functional titration of SiR N2C-gRNA-SaCas9-3xFLAG
viruses Purified viral productions of two different SiR N2C-gRNA-SaCas9-3xFLAG viruses (one
with a scrambled gRNA sequence, and another with the tdTOMATO4 gRNA sequence) were produced
blind and used to infected mouse neuro2A cells in culture for functional titration. Virally infected
cells were visualised 3d p.i. using a Cy3 conjugated anti-FLAG primary antibody. Titers of 5X108
i.u./mL were obtained.
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are being visualised due to variability of viral infections between neurons surrounding the
injection site in the same animal.
In order to overcome both these problems, we designed a split-FLP system whereby a
short C terminal fragment of FLP (flippase, a site directed recombinase) was added into
the viral cassette and could be complemented in infected cells by expression of the longer
N terminal FLP fragment(Fig. 4.11). This split FLP design was modified from a known
functional split site of the FLP enzyme (between AA 396-397) previously used in conjunction
with chemically inducible heterodimerization domains in order to reconstitute split-FLP
activity using phytohormone abscisic acid (ABA)303. In our case, we were looking to
reconstitute FLP activity when both fragments were co-expressed in a cell. Therefore we
added mutated Fos and Jun leucine zipper heterodimerization domains304 and SV40 nuclear
localisation signals to the C and N terminus of the AA1-396 and 397-423 FLP fragments
respectively via a flexible 23AA glycine/serine F6 linker for efficient spatial reconstitution.
This resulted in a short modified C terminal FLP sequence (297bp) that could be added
to the rabies virus genome to enable both live visualisation of viral transcription during viral
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Fig. 4.11 Design of a split FLP reporter system The design of a co-expression FLP reporter system
using known FLP split sites between AA 396-397. The FOS and JUNmut heterodimerisation domains
and SV40 nuclear localisation signals were added to the split FLP fragments to enable functional
reconstitution of FLP activity when co-expressed in the same cell. Dimerisation domains were added
via a flexible 23AA glycine/serine linker (F6) to the N terminus of the C terminal FLP fragment, and
the C terminus of the N terminal FLP fragment.
4.2.8.2 Development of a bidirectional fluorescent cellular assay for quick and sensi-
tive assessment of genome targeting efficiency in vitro
Another technical challenge we faced during the course of this project was the multi-step
time-consuming nature and low sensitivity of the T7 endonuclease assay for assessing
genome targeting efficiency of rabies virus variants in vitro. Use of the T7 endonuclease I
assay to assess genome targeting of Cas9-gRNA expressing rabies viruses would require 7
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intermediate experimental steps: the staining and fluorescence-activated cell sorting (FACS)
of virally infected cells, genomic DNA extraction from infected cells, PCR of the targeted
genomic locus, denaturation and reannealing of the PCR amplicon, incubation with the
T7 endonuclease I enzyme which can selectively cleave distorted duplex DNA formed via
cross-annealing of mutated and wild-type sequence, and finally cleavage analysis by gel
visualisation of PCR fragments (Fig. 4.12A).
In addition to this multi-step and time-consuming experimental workflow, we found from
our experience that the T7 endonuclease I assay resulted in quite high variability (e.g. three
experimental replicates depicted in Fig. 4.4D). In addition, it did not show high sensitivity to
WT B19 rabies virus induced CRISPR-Cas9 genomic mutations in vitro (Fig. 4.4C), thus
limiting its use for the comparison of genome editing efficiency of different viral cassettes.
The low sensitivity of this assay is partly a result of its methodology. Even with 100% gene
editing efficiency, opposing strands of PCR amplicons can re-anneal resulting in perfect
complementarity and thus lack of detection by resolvase enzymes, despite successful gene
targeting305. Studies in the literature have shown that compared to other biochemical methods,
the T7 endonuclease assay fails to measure weaker levels of Cas9 cleavage activity295.
Given the experimental difficulties and lack of sensitivity of the T7 endonuclease system,
we adopted a previously reported cellular double fluorescent reporter system where successful
gRNA directed DSBs in vitro result in a two way amplified fluorescent signal306. In this
design, reporter cells initially express GFP under the control of a CAG promoter (Fig. 4.12C).
As the GFP coding sequence is flanked by two gRNA target sites on either side, if there is
efficient gRNA targeting it results in excision of the GFP coding sequence and the subsequent
expression of a TagBFP2 fluorescent protein under the control of the same CAG promoter.
As a consequence, efficient genomic editing results in both a decrease in the GFP signal,
and an increase in the TagBFP2 signal. This system would in theory require just 2 steps
for measurement of genome editing efficiency by different rabies virus designs: antibody
staining of virally infected cells followed by FACS analysis of the two reporter fluorescent
proteins GFP and BFP in virally infected cells.
4.2.8.3 Screening of gRNA NeuN variants 1-3 and tdTomato variant 1-3 using double
reporter cell system
In order to test the double reporter cell system, we used it to screen the 3 NeuN targeting
gRNA variants that we had previously assessed using the T7 endonuclease assay (Fig.
4.13A). Using this method we had not detected significant NeuN locus PCR amplicon






































Fig. 4.12 Alternative assays for the detection of rabies virus mediated genome editing (A) Labour
intensive experimental workflow for the measurement of virus mediated genome editing efficiency
using the T7 endonuclease I assay. (B) Shorter 2-step experimental workflow for the measurement
of virus mediated genome editing efficiency using a double reporter cell system. (C) Mechanism of
the double reporter cell system. Unedited reporter cells contain expression cassettes that drive the
expression of GFP under a CAG promoter. The GFP coding sequence is flanked by gRNA target
sequences such that efficient DSB induction results in excision of the GFP sequence, and subsequent
expression of TagBFP2 under the same CAG promoter. This gives a faster and more sensitive read
out of genome targeting efficiency compared to the T7 endonuclease I assay.
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HEK293T cells were transfected in culture with plasmids encoding the double reporter
system construct containing target sequences for gRNA NeuN 1, 2 or 3. Cells were also
co-transfected with CMV-Cas9 and U6-gRNA NeuN 1, 2 or 3 encoding plasmids. In order
to test CRISPR-Cas9 induced reporter activation, the reporter construct needed to contain
target sequences complementary to the gRNA sequence being tested. Using this double
reporter cell system we found that all 3 NeuN gRNA designs did show significant genome
targeting activity compared to controls (Fig. 4.13B,D). This was unlike the lack of detection
of targeted genome editing by gRNA NeuN 1 and 2 using the T7 endonuclease assay.
We also used this system to screen 4 new gRNA sequences designed to target the
tdTOMATO coding sequence. This revealed that gRNA tdTOMATO4 showed extremely
high on-target DSB cleavage efficiency that was approximately triple that detected for gRNA
NeuN3 (Fig. 4.13C,D). We thus incorporated this gRNA tdTOMATO4 in the production of a
























































































Fig. 4.13 Testing of gRNAs with double reporter cell system (A) Screening of gene targeting
efficiency gRNA NeuN 1-3 using T7 endonuclease I mismatch cleavage assay. (B) Screening of the
same 3 NeuN gRNAs using double reporter cell system by FACS. (C) Screening of 4 tdTOMATO
targeting gRNAs using double reporter cell system by FACS. (D) Quantification of reporter cell
activation by % of BFP+ reporter cells for gRNA NeuN 1-3 and gRNA tdTOMATO 1-4. n=3, T-test
between -/+ Cas9gRNA conditions for each gRNA target sequence with correction for multiple
comparisons using the Holm-Sidak method.
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4.3 Summary
In this experimental chapter I have worked to express the two CRISPR-Cas9 components (a
Cas9 endonuclease and a gRNA) from the rabies virus in order to initiate the creation of a
circuit-specific genome editing vector that can be used both for long-term experiments into
the roles of genes within specific circuits for brain function, as well as for potential gene
therapy.
I have shown that despite various molecular caveats, the WT B19 DG rabies virus can
be modified successfully to express both Cas9 endonuclease and gRNA without impairing
normal viral replication, production or infectivity. This rabies virus can successfully target
endogenous gene loci such as the NeuN locus in mouse neuro2A cells in vitro. We also found
that increasing gRNA expression could significantly increase the efficiency of WT DG rabies
virus mediated CRISPR-Cas9 genome editing, and so we designed 4 different Cas9-gRNA
viral expression cassettes to increase gRNA expression levels using different known methods
of viral transcription regulation. We then screened these 4 designs for efficient production in
vitro.
Ultimately, we want to be able to genomically edit circuits in vivo to investigate the roles
of genes in behaviour of experimental animals, as well as for potential gene therapy. The
WT DG rabies virus would not be suitable for this purpose as it would result in the death
of genomically edited circuits within 1-4 weeks p.i.. Therefore, having selected a suitable
gRNA-Cas9 cassette design from the screening of WT viruses in vitro, we aimed to produce
high titers of both SiR 1.0 and 2.0 gRNA-Cas9 viruses for in vivo use. We found that both
such viruses could be produced to high-titers that would be necessary for successful infection
of neurons in vivo. In addition, a preliminary proof of principle experiment demonstrated
SiR B19 vector mediated NeuN locus targeting in the CA1 region of mice hippocampus 2
weeks p.i.. This indicates that SiR-gRNA-Cas9 vectors can be used to target endogenous
genes in circuits in vivo.
Chapter 5
Interneuronal Protein Transfer
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5.1 Introduction
In this project we aim to test the trans-synaptic circuit hypothesis of transneuronal protein
transfer. This model implies that proteins may move from one neuron to another much like the
electrical signal that flows through neural networks. Despite the accumulating evidence for
transneuronal protein transfer in both physiological and disease processes (covered in chapter
1.3), very little is understood of its mechanism, control or function. In addition, although
there is an observed correlation between protein movement and synaptically connected
neuronal pathways, it is still unclear whether this protein transfer is truly trans-synaptic.
5.1.1 The screening of experimental systems to study interneuronal
protein transfer
In order to investigate interneuronal movement, we needed to establish experimental paradigms
that would enable us to visualize and mechanistically probe this biological process. For
example, in the case of commonly observed pathological protein aggregate propagation
through circuits, this is a very slow process that accumulates over decades in patients and
over time-scales of months to years in experimental animals119,172. As such, use of such
systems to iteratively screen novel protein-tags and identify transcellularly moving proteins
would not be practically feasible in reasonable time-scales. Other faster examples of interneu-
ronal protein movement have been published. However, the observation of trans-synaptic
transfer varies hugely depending on the experimental conditions such as: the method of
establishment of donor cells (e.g. transgenic, viral injection, protein injection), the method
of detection of protein movement in receiver cells (e.g. radioactive labelling, immunofluores-
cence, immunocytochemistry), the age or period of development of the experimental animal
and the neural circuitry being investigated. As such, studies using protein tracers such as
WGA-HRP or CtxB have shown highly varied results as to whether they exhibit or do not
exhibit trans-synaptic transfer ability167,168.
Therefore, we decided to consider many different experimental systems to test if they
could be used, for our purposes, to observe and thus investigate interneuronal protein transfer
at relatively quick time-scales. Potential experimental systems are suggested in Fig. 5.1,
and those that were directly experimentally investigated are highlighted in red. Some of
the experimental paradigms that we investigated had not previously been used to study
interneuronal protein transfer but we thought in theory they could be good candidates (e.g.
in utero electroporation). Others were experimental systems that had repeatedly been used
to reveal interneuronal protein transfer in many different contexts (e.g. the primary visual
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sensory pathway through which trans-synaptic protein transfer has been detected following
intraocular injection of tritiated amino acids174, WGA-HRP307 and biotinylated Otx2169).
Ideally, we needed to develop an experimental system that would enable us to observe robust
interneuronal protein movement in the time-scale of days. In this way, we could use this
system to iteratively screen for the efficacy of novel protein movement visualisation tools.
We could also use this system to dissect in more details the mechanistic details of the process
being visualised within a shorter time-frame.















Experimental Systems for 
Investigation of inter-neuronal 
protein transfer
Fig. 5.1 Flow chart of possible experimental systems to investigate interneuronal protein trans-
fer Experimental systems highlighted in red are those that have been directly investigated.
5.1.2 Aims and experimental strategy
In such a context, the main aims of this project are:
1. To develop experimental paradigms that will allow us to efficiently probe the mecha-
nisms behind interneuronal protein transfer in vitro and trans-synaptic protein transfer
in vivo through neural circuits (Fig. 5.1).
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2. To determine the universality of this process by using top-down proteomic approaches
to label all proteins produced from a donor cell population. The two methods of whole
proteome labelling that I investigate are: a) the use of a promiscuous biotin ligase to
biotinylate all cytoplasmic proteins in donor cells (BioID2) and b) the use of a mutant
methionyl tRNA synthetase (mutRS) which enables the incorporation of an azide
labelled methionine analogue called azidonorleucine (AnI) into all newly synthesised
proteins.
3. To develop a small split CRE tag that we can append onto candidate proteins (e.g.
Tau, Otx2, WGA) that amplifies the signal of interneuronal protein movement and
genetically modifies receiver cells of trans-synaptic protein movement.
For aims 2-3, we adopt a general strategy where we express labelled proteins in a donor
neuron population and observe their movement into acceptor neurons which are cellularly
distinct to the donor neuron population (Fig. 5.2).
Fig. 5.2 Project strategy to investigate mechanistic details of interneuronal protein transfer
We propose two parallel approaches. First, a bottom-up approach involving the addition of small
recombinase inducing tags to proteins known to demonstrate interneuronal movement. Second, a top
down approach involving the unbiased labelling of the entire proteome of donor neurons, enabling the
identification of novel interneuronally transferred proteins.
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5.2 Results
5.2.1 The mouse visual circuitry as an in vivo model of interneuronal
protein transfer
The visual pathway has repeatedly been shown to be an exemplary in vivo circuit to investigate
trans-synaptic protein transfer. For example, the intraocular injection of tritiated amino
acids, WGA-HRP or biotinylated homeoprotein Otx2 into monkeys, mice or rats have all
demonstrated the presence of tritiated, HRP positive or biotinylated proteins respectively in
the contralateral visual cortex within time scales of hours to days169,174,307. For example, the
intraocular injection of 1% WGA-HRP resulted in the labelling of all known primary visual
pathways and ocular dominance columns in the visual cortex as well as neuronal soma in the
superior colliculus of monkeys and rats as revealed by tetramethyl benzidine histochemistry
3 days post-injection307. The visual cortex is anatomically almost on the opposite side of
the central nervous system to the eyes and is not known to receive direct input from retinal
ganglion cells. As such, the fact that one can observe specific contralateral positive staining
of the visual cortex in WGA-HRP injected animals but not HRP injected controls strongly
suggests that WGA-HRP is transferred trans-neuronally through the visual circuit (from
retinal ganglion cells to cells in the lateral geniculate nucleus which project to the visual
cortex). For our purposes, this data also reveals that visual pathways in vivo can demonstrate
clear interneuronal trans-synaptic transfer within a time scale of 3 days after intraocular
administration of proteins to donor retinal ganglion cells.
As such, we decided to investigate the use of the mouse visual pathway for further exper-
iments. We first tested whether we could indeed observe interneuronal protein movement
through the visual circuitry by injecting labelled proteins directly into the eye. This resulted
in the endocytic uptake of labelled proteins into retinal ganglion cells (RGCs) and subsequent
transfer of these proteins from RGCs into the visual circuit. Having verified intraocular
protein injections as an efficient method of visualising interneuronal protein transfer, we then
proceeded to design recombinant AAVs to transduce retinal ganglion cells. This was because
we wanted to investigate the movement of all or any RGC protein through the visual circuitry.
The preparation of highly concentrated purified protein preps for intraocular injections was
not an ideal system in which to screen proteomic level protein movement in an unbiased
manner. In contrast, AAV transductions are a more flexible system which allows us to label
entire proteomes by the integration of transgenes into RGC genome. Another advantage
of AAVs is that after successful infection and integration of transgenes into the donor cell
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genome, the donor RGC can permanently express labelled donor proteins at high levels
for the entire duration of the experiment. As such, AAV transduction enables more robust
and long-term investigations of trans-synaptic protein transfer. In addition, we could add
fluorescent or recombinase markers into the AAV genome in order to permanently label and
thus quantify or experimentally modify starting retinal ganglion cell donor populations.
5.2.1.1 Human A53T alpha synuclein-Dylight594 shows interneuronal movement from
RGCs into the visual cortex within 4 days
The direct injection of proteins into the eye to visualise protein movement through visual
networks has been conducted successfully in many different contexts. For example the
injection of WGA-HRP or biotinylated Otx2 directly into the eye results in transneuronal
movement of the labelled protein through the visual network169,307. In addition, intraocular
injection of tritiated amino acids into the vitreous humor results in the uptake and assimi-
lation of these amino acids into proteins within RGCs that then demonstrate transneuronal
movement174. To test the efficiency of this process of endocytic protein uptake directly from
the vitreous humor into the visual circuit, we injected fluorophore-tagged proteins cholera
toxin subunit B (CtB)-AF488 or aggregated human mutant (A53T) alpha synuclein-Dylight
594 into the eye (Fig. 5.3A). In this experiment, CtB-AF488 was used as a negative control
for transneuronal protein movement. CtB has not been shown to move transneuronally
in visual pathways following intraocular injection and is routinely used for non-synaptic
retrograde labelling of neurons in anatomical studies. CtB attaches to cells by binding to
ganglioside GM1 and is taken up into neurons by receptor mediated endocytosis. Aggregated
human mutant A53T alpha synuclein was used as a test protein as alpha synuclein aggregates
demonstrate interneuronal movement in disease108. We wanted to observe whether it could
also demonstrate interneuronal movement through mouse visual pathways.
4-7 days p.i., mice were perfused and retinal flat mounts prepared to assess successful
intraocular injection whilst serial coronal sections were taken throughout the entire brain
to visualise the transport of the protein into the visual pathway (Fig. 5.3A). We were able
to see uptake of injected protein into RGCs in the retina for both CtB and alpha synuclein,
demonstrating efficient endocytic uptake of intraocular proteins into RGCs (Fig. 5.3B, C).
In the case of CtB, we could also strongly visualise CtB in RGC axons and their direct
projection sites within the brain such as the suprachiasmatic nucleus, lateral geniculate
nucleus and superior colliculus (Fig. 5.3D, F, H). The superior colliculus (SC) and lateral
geniculate nucleus (LGN) which are known to be the main outputs of RGCs showed especially
strong fluorescence signals as expected. As previously reported, we did not observe any
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Fig. 5.3 Human mutant A53T alpha synuclein shows trans-neuronal movement through visual
circuitry (A) Fluorophore conjugated protein was injected into the right eye of adult mice. Retinal
flat mounts (B,C) and serial coronal sections throughout the whole brain (D-I) were prepared 3-7
days p.i. (Figure continued on next page...)
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Fig. 5.3 Human mutant A53T alpha synuclein shows trans-neuronal movement through visual
circuitry (J) Zoomed-in images of alpha synuclein-Dylight594 positive visual cortices, red nucleus
and superior colliculus in the posterior brain section. (K) Posterior coronal brain sections from 4
different animal replicates showing repeatable patterns of alpha synuclein-Dylight594 positive areas.
(L) Snapshot of Allen’s mouse connectivity map showing anterograde projections of AAV GFP
infected deep superior colliculus neurons to the red nucleus.
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transneuronal transfer of CtB into second order neurons. For example, there was no AF488
fluorescence visible in the visual cortex (Fig. 5.3H). In the case of alpha synuclein, we were
able to detect some faint protein fluorescence in the SC but not in the LGN. More strikingly
we were able to detect significant alpha synuclein within the visual cortex (Fig. 5.3I-K).
As there is no known direct output of RGCs into the visual cortex, the presence of alpha
synuclein-Dylight 594 signal in the visual cortex following intraocular injection is most
probably a result of the transneuronal transfer of this protein from RGCs into second order
neurons projecting to the visual cortex from the lateral geniculate nucleus. This was a very
promising result as it demonstrated experimentally detectable interneuronal protein transfer
through a neural network in vivo within a short time scale of 4 days. Hence, this system
would allow us to investigate the mechanisms behind the process fairly efficiently within
experimentally tractable timescales.
One interesting point to note however was that, quite oddly, the LGN (one of the main
projection sites of RGCs) did not show positive fluorescence signals following intraocular
injections of alpha synuclein-Dylight 594. This was especially odd given that the alpha
synuclein-Dylight 594 was visible in the visual cortex that receives input from lateral
geniculate nucleus neurons. In addition, the RGC cell bodies in the retina at the same time
points p.i also showed strong presence of alpha synuclein-Dylight594. Thus, the staining
pattern which we observed through the RGC to LGN to visual cortex pathway was the
presence of alpha synuclein in the retinal ganglion cell bodies and visual cortex, but not in
the LGN which receives direct input from RGCs. This pattern was shown independently in 4
out of 4 mice injected intraocularly with alpha synuclein-Dylight594 and analysed at 4 and 7
days p.i.(Fig. 5.3K). This pattern of fluorescence is probably at least partly due to the fact
that although there is a high load of alpha synculein in RGCs, the amounts of protein that
are transported axonally into projection sites in the brain are much lower and thus harder to
visualise. The more puzzling question was however, why there was more alpha synuclein
present in the visual cortex than in the lateral geniculate nucleus. One hypothesis could
be that the movement of alpha synuclein down the optic tract into the LGN is a limiting
step in transneuronal protein transfer through the visual circuit. As such, alpha synuclein is
inefficiently transported from RGCs into the LGN (resulting in high levels of protein in RGC
cell bodies) but any alpha synuclein that does reach the LGN is quickly transported to the
visual cortex thus not allowing a large build up of alpha synuclein in the LGN. In contrast,
CtB could be visualised in these first order projection sites such as the LGN and SC as it
cannot transfer interneuronally, so can accumulate in RGC axon terminals (Fig. 5.3F and H
respectively).
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5.2.1.2 Human A53T alpha synuclein-Dylight594 shows interneuronal movement from
RGCs into the red nucleus within 4 days
Although we had initially planned this experiment to visualise potential protein movement
through the RGC-LGN-visual cortex pathway, we found that repeatedly in our 4 mice
replicates alpha synuclein was visible also in the deep motor layers of the superior colliculus
and in the red nucleus (Fig. 5.3J,K). The deep superior colliculus has previously been shown
to be a major projection site of RGCs in the mouse brain308. Subsequently, deep superior
colliculus neurons are known to project directly to the red nucleus (Fig. 5.3L, Allen Brain
Atlas). Exp.175158132 from the Allen Brain Atlas shows the the strong presence of GFP+
axon terminals in the red nucleus following injection of an AAV-EGFP into the deep layer of
superior colliculus.
Given the repeatedly observed pattern of alpha synuclein detection in these sites, and our
current knowledge of mouse visual circuit connectivity, we thus concluded that the injection
of alpha synuclein into the eye resulted in the uptake of the protein into RGCs projecting
to the deep superior colliculus. Subsequently, the protein was trans-synaptically transferred
into the deep superior colliculus cell bodies which then project to the red nucleus. Further
anterograde transport of alpha synuclein to the axon terminals of these neurons resulted in
high alpha synuclein detection in the red nucleus.
To conclude, the strong fluorescence of RGCs post-injection of fluorescently labelled
proteins into the eye verified to us that direct intraocular protein injection was an efficient
method of incorporating labelled proteins into the RGCs as "donor neurons". In addition,
the visualisation of fluorescence in second order projection sites such as the visual cortex
and red nucleus within a few days after injection demonstrated that this system could be
used within very short experimental time scales to probe the mechanistic details of observed
interneuronal transfer.
5.2.1.3 AAV transduction of retinal ganglion cells for unbiased protein screening
Having confirmed that the introduction of labelled proteins into RGCs was an effective
method for visualising interneuronal protein transfer through the mouse visual circuitry in
vivo, we then wanted to develop a more scalable, quantifiable and long-term method of
establishing RGCs as protein donor cells. Essentially, we wanted to increase the numbers
of proteins that could be investigated for interneuronal protein transfer without relying on
the production of highly concentrated purified protein preps. In addition, due to the eventual
degradation of injected proteins by cells, the suitability of intraocular protein injection for
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longer-term manipulation studies of donor cell properties was limited. Therefore, we consid-
ered transducing RGC genomes with recombinant AAV vectors in order to produce "donor
RGCs" which would permanently express labelled donor proteins for further investigation.
Fig. 5.4 AAV2 infects RGCs at higher efficiency then rAAV2 viruses 2µL of either AAV2-GFP
or rAAV2-GFP virus were injected into the vitreous humor of adult mice at a titer of 8 x 1012. 2
weeks p.i., retinal flat mounts were prepared and stained for GFP (green, virally transduced cells),
NeuN (red, retinal ganglion cells) and DAPI (blue, nuclei). (A,B) Confocal imaging of the retinal
ganglion cell layer. (C,D) Confocal imaging of deeper inner plexiform/nuclear layers. Left inset,
cross-sectional image of WT BL6 mouse retina taken from Ruggeri et al. 2009309. RGC: retinal
ganglion cell layer; IP: inner plexiform layer; IN: inner nuclear layer; OP: outer plexiform layer; ON:
outer nuclear layer; ELM: external limiting membrane; RPE: retinal pigment epithelium.
Within the mouse retina, there are over 30 different types of RGCs. 90% of them project
to the superior colliculus (SC), 30-40% project to the lateral geniculate nucleus (LGN) and a
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smaller percentage project to other subcortical areas. For example, melanopsin expressing
RGCs project to the suprachiasmatic nucleus (Fig. 5.3D) and are involved in circadian
rhythms308,310. AAVs have been used extensively for the efficient infection of RGCs. Of
the many different AAV serotypes that have been used and modified, AAV serotype 2
(AAV2) has become a standard vector for transducing retinal ganglion cells with recombinant
genes. AAV2 can efficiently transduce over 85% of RGC populations in adult rodents after
intraocular injection311–313. Therefore we decided to test a AAV2-GFP construct to observe
the efficiency of virally mediated RGC targeting. We found that the AAV2-GFP was indeed
efficient at infecting RGCs within our experimental conditions (Fig. 5.4A). We also decided to
test the efficiency of a retro-AAV2-GFP virus (rAAV2). This was because, to our knowledge,
this serotype had not yet been tested for RGC transduction efficiency. This relatively new
serotype published in 2016 was developed through in vivo directed evolution for increased
retrograde targeting efficiency and shows enhanced retrograde targeting efficiency compared
to AAV2 in other intracerebral neural circuits314. In our case, we found that the rAAV2 was
less efficient then AAV2 at infecting RGCs (Fig. 5.4B) but more efficient at infecting cells
in the deeper layers of the retina (Fig. 5.4D). As such, we decided to use AAV2 for future
experiments requiring viral targeting of RGCs.
5.2.2 Identifying novel proteins exhibiting protein transfer movement
Having identified a suitable in vivo experimental system to visualise interneuronal protein
movement, we now wanted to implement into this system the ability to screen for novel
interneuronally transferred proteins. In order to do this we needed a method of labelling all
the proteins of a donor cell in an unbiased manner, so that if any protein were to be transported
intercellularly into an acceptor neuron we would be able to identify it as originating from a
donor cell. We investigated two methods of cell specific proteomic labelling.
1. By expression of a promiscuous biotin ligase enzyme that indiscriminately biotinylates
proximate proteins within a 10nm radius (BioID2)315. This is most commonly used
to detect protein–protein associations in subcellular locations by fusing BioID2 to
other proteins for subcellular targeting. However, in our case as we would like to
biotinylate indiscriminately all proteins within the cell, we will express BioID2 freely
in the cytoplasm of donor cells. The BioID2 system has been used successfully both in
vitro and in mice in vivo316.
2. By expression of a mutant murine methionyl-tRNA synthetase317 (MutRS) which
incorporates the noncanonical methionine analogue azidonorleucine (Anl) to elongator
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tRNAMet (Fig. 5.7A). In this way, proteins synthesised in donor cells that express
the MutRS will incorporate azide tags which can be labelled using click chemistry
for fluorescence imaging or enriched on an affinity resin to facilitate identification by
mass spectrometry (Fig. 5.7B). The method does not require expression of orthogonal
tRNAs or depletion of canonical amino acids. In addition, this method has been used
previously in vivo to enable cell-specific proteomic mass spectrometry analysis318.
5.2.2.1 In vivo BioID2 enables visualisation of interneuronal transfer of endogenous
mouse RGC proteins through visual circuitry
For the top-down unbiased approach, we wanted to identify all the proteins being exchanged
intercellularly between neurons in an unbiased manner. To this aim, we introduced the
system of promiscuous biotin ligation315,316 into mouse RGCs to observe the transfer of the
biotin-tagged donor proteome through the mouse visual circuit. As a preliminary test of
this system, we designed a donor construct which expressed both cytoplasmic GFP and a
promiscuous biotin ligase (BioID2). We first transfected this construct into neuro2A cells in
culture to test if the free cytoplasmic expression of BioID2 would enable efficient unbiased
biotinylation of all cellular proteins. We found that the addition of 50-100 µM biotin resulted
in a clear increase of biotinylated protein content in GFP+ transduced cells within 24 hours
(Fig. 5.5). In addition, we verified that there was no particular subcellular localisation of
biotin labelled proteins following the expression of BioID2 from our donor construct. This
was important as we wanted to use this method to label all cellular proteins in donor cells the
most unbiased manner possible.
Following this in vitro test, we then produced a recombinant AAV vector encoding the
same donor construct which expresses both cytoplasmic GFP and BioID2 for experiments of
intercellular donor protein transfer in vivo. As the mouse visual system has repeatedly been
shown to be an efficient system for the visualisation of interneuronal protein transfer from
RGCs to LGN neurons projecting to the visual cortex, we injected this AAV intraocularly into
the right eye of adult mice (Fig. 5.6A). 3 weeks following injections when transduced RGCs
were likely to be expressing high levels of rAAV inserted BioID2, we administered biotin
into the mouse to initiate biotinylation of donor cell proteins. We administered biotin both
intraocularly (enabling efficient access into donor cells) and intraperitoneally (which enabled
longer-term repeated daily biotin administration). Following 8 days of biotin administration
to allow for donor protein labelling and intercellular protein transfer, mice were sacrificed
and coronal sections taken in the posterior half of the brain to visualise the LGN and visual
cortex.
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Fig. 5.5 BioID2 enables fast biotinylation of cellular proteins in vitro Mouse neuro2A cells were
transfected at 80% confluency with a DNA expression plasmid encoding GFP and biotin ligase
(BioID2). The following day, the culture medium was exchanged with fresh medium with 0, 50 or
100 µM biotin. 24 hours later, cells were fixed and stained with Streptavidin-AF555 to visualise
biotinylated proteins.
By design of the donor construct, successfully transduced RGC donors express both a
cytoplasmic GFP marker and BioID2. As RGCs send major projections into the LGN, we
were able to observe GFP+ axon terminals within the LGN demonstrating successful RGC
transduction following intraocular injection (Fig. 5.6B). More strikingly, the visualisation of
biotinylated proteins using a streptavidin-HRP induced TSA Plus Cyanine 3 system (red)
revealed a distinct pattern of staining within the LGN that was different to that of GFP
staining. Whilst the GFP staining localised to show strong staining of LGN projecting RGC
axons, the staining of biotinylated proteins was present not in the axonic projections of RGCs
but within the more medial cell bodies of LGN neurons. More strikingly, we were then able
to observe the specific staining of biotinylated proteins in the contralateral visual cortex (Fig.
5.6C). This strongly supported the interpretation that these donor-RGC derived biotinylated
proteins had transferred intercellularly into LGN neurons which then projected to the visual
cortex.
Much like the finding with the intercellular transfer of alpha-synuclein through the visual
pathway, we noted that biotinylated proteins were visible only in the second order neurons
of the pathway but not in axons of LGN projecting RGCs themselves. This suggested
that intercellular protein transfer from RGC axon terminals into LGN cell bodies was an
efficient process which did not result in the build up of biotinylated donor proteins in the axon
terminals. However, if we looked at the axonic projections of RGCs in the superior colliculus,
5.2 Results 153
Fig. 5.6 In vivo BioID2 enables visualisation of interneuronal transfer of endogenous mouse
RGC proteins through visual circuitry (A) A flowchart of the in vivo BioID2 protocol. Whole
coronal section imaging of the LGN (B) and visual cortex (C) in AAV infected mice. (D) Whole
coronal section imaging of PBS injected control mice subject to the same biotin administration
protocol.
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we were able to see biotinylated proteins within the first order axonic terminals (Fig. 5.6C).
This difference may be due to the fact that whilst only 30-40% of RGCs project to the LGN,
90% of RGCs project to the SC. Therefore, our method of detection of biotinylated proteins
may not be sensitive enough to visualise biotinylated proteins in LGN projecting axonic
tracts, but enable visualisation of higher volume SC projecting axonic tracts.
In summary, this result strongly supported the case for the use of this BioID2 system in
vivo to enable further top-down investigation into the volume and identities of endogenous
RGC proteins moving interneuronally into LGN neurons.
5.2.2.2 Investigation of intercellular protein transfer in vitro using the MutRS system
The second method of unbiased total donor cell protein labelling that we investigated was
by expression of a mutant murine methionyl-tRNA synthetase317 (MutRS). This enables the
incorporation of the azide-tagged methionine analogue azidonorleucine (Anl) into all newly
synthesised proteins of cells expressing the MutRS enzyme. Therefore, MutRS expressing
cells could be established as donor neurons and mixed with wild type acceptor neurons
which could be investigated for the presence of azide-labelled donor-originating proteins.
Azide-tagged proteins can be labelled using click chemistry for fluorescence imaging or
enriched on an affinity resin to facilitate identification by mass spectrometry (Fig. 5.7B). To
this aim, we decided to create an in vitro model of donor and acceptor neurons using the
neuro2A mouse neuroblastoma cell line. Therefore we produced a stable donor cell line
expressing both a mCHERRY marker and the mutRS for azide incorporation into all newly
synthesised donor proteins
5.2.2.2.1 Maximising AnI incorporation into newly synthesised donor proteins In
order to maximise the detection of moving labelled proteins from donor to acceptor, we first
wanted to find the optimal conditions for the fast incorporation of AnI into newly synthesised
proteins in donor cells expressing MutRS. Undifferentiated donor neuro2a cells were grown
in 1 or 2mM AnI medium and collected over a period of 24 hours for analysis. AnI
incorporation was measured by AF488 signal intensity following the chemical labelling of
azide proteins with AF488-alkyne. We covalently attached the AF488 fluorophore specifically
to azide-labelled proteins via click chemistry for assessment of the speed and degree of AnI
incorporation. AnI incorporation was significantly faster at 2mM and was seen to increase
up till the last 24 hour time point (Fig. 5.7C,D). Following this result, we decided to quantify
AnI incorporation into donor cells beyond the 24 hour time point for a period of 6 days. We
found that continued exposure of donor cells to 2mM AnI beyond 2 days resulted in cell
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Fig. 5.7 Time course of AnI incorporation into newly synthesised donor proteins Legend on
following page...
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Fig. 5.7 Time course of AnI incorporation into newly synthesised donor proteins (A) Chemical
structures of canonical amino acid methionine (Met) and the non-canonical methionine analogue
azidonorleucine (AnI). (B) Use of click chemistry to covalently modify azide tagged donor proteins.
(C,D) 24 hour time course of AnI incorporation into newly synthesised donor proteins. Azide
incorporation was quantified by assessing AF488 signal intensity following click chemistry of azide
tagged proteins with AF488-alkyne. (E) AnI incorporation (Azide specific HRP signal/total protein)
over 6 days. Images show evidence of AnI-induced cytotoxicity beyond the 2 day time point.
death and a decrease in apparent AnI incorporation as defined by AnI+ proteins/total cellular
protein(Fig5.7E). Given the high incorporation of AnI into cellular proteins by the 48 hour
time point, we planned that for future experiments we would label donor proteins using a
short 24 hour pulse of 2mM AnI.
5.2.2.2.2 Investigation of intercellular transfer of azide labelled donor proteins in
vitro Having selected a relatively efficient AnI incorporation protocol, we wanted to verify
that only the donor cell line expressing mutRS, but not wild type acceptor cells, could
incorporate AnI into newly synthesised proteins. We therefore incubated the donor neuro2a
cell line and the WT acceptor neuro2a cell line separately in 2mM AnI culture for 24 hours
and assessed AnI incorporation. Only mCHERRY positive donor cells were found to have
incorporated AnI into their cell proteins when imaged by confocal microscopy following click
reaction with AF488-alkyne (Fig. 5.8A). In addition, donor cells grown in culture medium
without any AnI were found to have no AF488 signal thus supporting the azide-specificity of
the click reaction. The specificity of AnI incorporation only into donor cells was also verified
by mass spectrometry (Fig. 5.9).
In order to investigate intercellular protein movement, we then carried out a preliminary
experiment where donor and acceptor neuro2a cells were mixed at a 1:1 ratio and co-cultured
for 24 hours in medium containing 2mM AnI. Post-fixation, azide-containing proteins were
chemically reacted to AF488-alkyne by click chemistry and donor cells were stained with
anti-mCHERRY antibody (red). This rendered all donor cells expressing the mutRS red
and azide-labelled proteins green (Fig. 5.8B). By confocal imaging, we were able to see
acceptor cells that did not express mutRS (red) but contained azide-labelled protein (green).
From a total of 4500 non-red acceptor cells, 27 were found to be AF488 positive. Without
cell mixing, 0% of acceptor cells were found to be AF488 positive using the same imaging
and analysis settings. Given the specificity of azide incorporation and the click reaction, the
visibility of green signal in non-red WT acceptor cells following cell mixing suggested that
azide labelled proteins synthesised in donor cells had somehow moved into the acceptor cell.
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Fig. 5.8 (A) Neuro2Acells were grown with or without 2mM AnI added to the culture medium
for 24 hours pre-fixation. Donor cells stably express the CAG-mCHERRY-P2A-mutRS construct.
Post-fixation, azide positive proteins were chemically labelled with AF488-alkyne and donor cells
stained with anti-mCHERRY antibody (red). (B) Confocal imaging of donor and/or acceptor cells
following 24 hour incubation in 2mM AnI medium.
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5.2.2.2.3 Identification of azide-tagged donor proteins by mass spectrometry Using
this method of unbiased cell protein labeling, we eventually wanted to quantify and identify
the proteins being transferred intercellularly from donor cells into acceptor cells by mass
spectrometry. We predicted that the ratio of azide labelled donor proteins to unlabelled
acceptor proteins would be extremely low in acceptor cells. Therefore, we needed to develop
a very sensitive and stringent azide-enrichment protocol. We therefore considered the need
for optimal conditions for efficient click chemistry during the attachment of azide-tagged
proteins to alkyne resins, and stringent washes following the click chemistry to decrease
non-specific binding (Fig. 5.9A). We found that by using commercial kits with stringent
washing conditions (as described in the methods section), we could enrich and identify a total
of 1527 azide-tagged proteins in donor cells incubated for 24 hours in 2mM AnI medium
as opposed to only 196 proteins in WT acceptor cells incubated for 24 hours in 2mM AnI
medium. This was a reasonably low level of background using a preliminary commercial
protocol which we presume could be optimised further by altering some of the experimental
conditions. More interestingly, we found that of the many azide-tagged proteins identified in
donor cells, many were neurodegeneration related proteins such as Tau, EWSR1 and Fus.
This was a notable result as we were previously unaware that these proteins were expressed
by neuro2A cells in culture and indicated that such proteins, which have been shown to
demonstrate intercellular transfer in human disease, could be labelled to test for intercellular




related proteins (e.g. Tau, EWSR1, FUS) 
 
Fig. 5.9 Identification of azide-tagged donor proteins by mass spectrometry (A) Flowchart of
steps required for selective identification of azide-tagged proteins from total cell protein preparations
by mass spectrometry (B) Table and venn diagram showing the numbers of proteins identified in
+Synthetase donor cells or WT cells incubated for 24 hours in 2mM culture medium.
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5.2.2.2.4 In vitro differentiation of secondary neuronal cell lines As the ultimate aim
of this project is to study the transfer of proteins between neurons rather then neural pre-
cursor cells, we also worked to establish an efficient protocol to differentiate the mouse
neuroblastoma neuro2A cell line into into neurons in vitro. There are various methods
of producing in vitro cultures of neuronal cells, some of which are more laborious then
others and recapitulate the properties of neuronal cells in vivo to different degrees. As a
general rule, cells defined as "neurons" in culture should have neuronal morphology, express
neuron specific markers and also be electrically excitable319. Primary neuronal cell lines
are thought to best represent neurons in vivo as they are produced directly from dissected
nervous tissue from live animals. However, the preparation and culture of primary neurons
can be challenging and only yields a limited number of cells as cultured neurons are not
immortal320. In contrast, the differentiation of neuronal cultures from induced pluripotent
stem cells (iPSCs), which is especially useful in the modeling of human disease, can take up
to 3-5 weeks321.
One particular difficulty of culturing neuronal cells is that mature neuronal cells do not
undergo cell division and so are not amenable to amplification in cell culture. Secondary
neuronal cell lines derived from neuronal tumours are much easier to use for in vitro studies
as they can be grown easily in cell culture, amplified to give more homogenous and abundant
cell populations for experiments and can relatively easily and quickly be differentiated
into neurons by manipulation of culture conditions. They can be differentiated by serum
deprivation and/or treatment with environmental factors such as cAMP analogs, retinoids
and neurotrophic factors (e.g. nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF) or glial cell-derived neurotrophic factor (GDNF)). The disadvantage of secondary
cell lines is that they are tumor derived and have most likely accumulated many physiological
differences compared to true neurons in vivo during passaging after initial collection322.
However, to our intents and purposes, we decided that the differentiation of secondary cell
lines would be a sufficient strategy to investigate interneuronal protein transfer through cell
mixing experiments. The mouse neuro2A cell line is a fast-growing mouse neuroblastoma
cell line that has been used extensively as an in vitro model of neurons to study neuron differ-
entiation, neurite growth and synaptogenesis. The neuronal differentiation of neuro2A cells
can be induced by serum deprivation and/or addition of factors such as transforming growth
factor1 (TGF1), bone morphogenic protein 4 (BMP4), glial cell-derived neurotrophic factor
(GDNF), dibutyryl cyclic adenosine monophosphate (dbcAMP) or retionic acid (RA)322,323.
Neuro2A cells respond very quickly to serum deprivation and differentiating factors by
activation of ERK signalling pathways324–326 resulting in neurite growth and expression of
160 Interneuronal Protein Transfer
Fig. 5.10 Differentiation of mouse neuro2A cells Mouse neuro2A cells were seeded at 40% conflu-
ency and differentiated by serum deprivation (FBS 0.5%) and/or addition of retinoic acid at specifiied
concentrations. (A) Neuro2A cells differentiated with serum deprivation (left), serum deprivation
and 48h or constant addition of RA (middle two insets) or just with RA added to usual 10% medium
(right). (B) Investigation into different concentrations and lengths of RA addition to serum deprived
media and its effects on neuro2A neuronal differentiation. We find that constant 15 µM RA addition
gives optimal parameters for quick and effective neuronal differentiation without observable toxicity.
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neuron specific markers such as NeuN and choline acetyltransferase (ChAT)323. Differenti-
ated neuro2A cells can form randomly connected neuronal populations in cell culture327,328
or form pre-designed neural networks on micropatterned neurochips that display functional
excitability and interneuronal communication329.
We attempted to test two published methods of neuro2A cell differentiation to assess
which would be most suited to our purposes: serum deprivation and/or retinoic acid (RA)
induction (Fig. 5.10). We found that either serum deprivation or addition of 20M RA resulted
in neurite growth within 2 days (Fig. 5.10A). A combination of both a pulse of 20µM RA
addition and serum deprivation resulted in a higher density of neurite growth in cell culture
compared to either of the methods in isolation. However, the constant addition of RA with
serum deprived media resulted in cell toxicity. Subsequently, we attempted to find a suitable
RA concentration and delivery length within serum deprived medium for efficient neuro2A
differentiation. We found that constant addition of a lower concentration of 15M RA resulted
in long neurite processes in the majority of cultured cells with minimal cell toxicity. Thus,
we decided to use these conditions for our future cell mixing experiments with the MutRS
expressing neuro2A donor cell line (Fig. 5.10B).
5.2.3 Candidate based study of the mechanisms behind interneuronal
protein movement
In addition to conducting an unbiased screen for the identification of novel interneuronally
moving proteins, we also aimed to investigate the details of the mechanism of interneuronal
protein transfer using a candidate based approach. In this instance, we aimed to design a
molecular tag which could be appended to known interneuronally moving proteins and would
enable the selective manipulation of donor or acceptor proteins.
5.2.3.1 In vivo protein transfer of V5 Tau through mouse hippocampal circuits
To test the possibility of a candidate protein based approach, we decided to investigate
the interneuronal movement of the candidate protein tau through canonical hippocampal
circuits. This was for a variety of different reasons. First, tau has already been shown
to move interneuronally through the mouse hippocampal circuit both in WT and mutant
aggregate form119,172,173. Second, the synaptic connectivity and circuitry of the hippocampus
is very well established, as such increasing the confidence with which we can deduce specific
trans-synaptic protein transfer. Third, the hippocampal memory and learning neural circuits
have extensively been shown to demonstrate synaptic plasticity with the expression of the
162 Interneuronal Protein Transfer
known trans-synaptic retroviral gag like protein Arc. For example, after exposure to a novel
environment, there is a brief burst of Arc transcription in hippocamapal memory networks
which quickly returns to baseline levels within minutes to an hour184. Given Arc’s crucial
role in synaptic plasticity and learning, and given the ability of Arc to travel inter-cellularly
by forming capsid like structures170,187, we considered that the hippocampus may potentially
be a promising circuit within which to study other candidate proteins such as Arc in the
future.
The CA1 region of the mouse hippocampus is relatively easy to target through stereotaxic
intracerebral injections due to its relatively large coverage of all anterior-posterior, medio-
lateral and dorso-ventral axes. In addition, its connectivity within the hippocampal circuitry
and its major projection to the subiculum is very well established. As a preliminary test, we
designed a lentiviral vector that expressed a iCRE-GFP marker and V5 tagged human wild
type 0N4R Tau. In this design, the donor neuron could be identified by expression of the
nuclear GFP marker whilst the expression of V5-Tau expressed from the donor neuron and
any subsequent interneuronal transport of V5-Tau could be visualised by staining for the V5
tag. We also designed the donor neuron to express a CRE recombinase so that successfully
transduced donor neurons could be selectively re-targeted for future experiments if this
protocol was successful. For example, if interneuronal protein movement could be visualized
from the donor neuron, we could investigate whether this movement was activity dependent
by retargeting the donor neurons with a AAV vector encoding flexed DREADDs (Designer
Receptors Exclusively Activated by Designer Drugs). In another instance, we could re-target
donor neurons with a flexed TVA and oG encoding AAV vector for subsequent retrograde
trans-synaptic rabies virus tracing, allowing us to unambiguously correlate any retrograde
interneuronal protein movement with synaptic connectivity in vivo at the cellular level.
As a preliminary test of this approach, we injected the lentiviral vector into the CA1 of
adult WT mice. CA1 neurons are known to project to the subiculum within the canonical
hippocampal circuitry330. Subsequently, subicular neurons project to the entorhinal cortex
(Fig. 5.11A). 1 month p.i. we were clearly able to see the expression of GFP and V5-Tau
from transduced donor CA1 neurons (Fig. 5.11B). When looking into the first and second
order projection sites of CA1 neurons to test for interneuronal protein movement, we were
also able to see weaker V5-Tau staining both in the subiculum and entorhinal cortex (Fig.
5.11C). This specific pattern of V5-Tau staining strongly suggested that there had been
inter-neuronal transfer of V5-Tau from CA1 donor cells into the second order subicular
neurons which then projected to the entorhinal cortex. Although further experimental repeats
are required, this result strongly suggests that the hippocampal circuitry can also be targeted
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Fig. 5.11 Movement of V5-Tau through the hippocampal circuitry in vivo (A) Schematic of the
canonical hippocampal circuitry and hypothesised movement of V5-Tau through the circuit following
lentiviral transduction of CA1 donor cells. Lentivirus encoding iCREGFP and V5Tau was injected
into CA1 of adult mice. One month post injection, brain sections were stained for GFP (green, donor
neuron), V5-Tau (red) and DAPI (blue, nuclei). (B) An anterior section shows the expression of
nuclear GFP and V5 Tau in donor CA1 neurons transduced by the lentivirus. (C) A posterior section
shows the movement of V5 Tau from CA1 neurons into the subiculum and entorhinal cortex.
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for the investigation of interneuronal protein transfer, albeit at longer time-frames (1 month)
than for the visual pathway (4 days).
5.2.3.2 Design of a preliminary split-CRE design to investigate circuit logic of inter-
cellular protein spreading
Having observed that the mouse hippocampal circuit could be used to study the interneuronal
movement of tau, we wanted to develop a small split CRE tag that we could add onto tau
to enable further investigation of the mechanisms enabling this process. This was stated
as Aim 3 in the introduction of this chapter and the purpose of this aim was to A) enable
amplification of the signal of interneuronal protein movement by reconstitution of CRE
recombinase in the acceptor neuron and B) genetically manipulate acceptor neurons for
further mechanistic characterisation of the underlying biology behind protein transfer. For
example, in this case we could conduct retrograde trans-synaptic tracing from the labeled
acceptor neurons to unambiguously determine the trans-synaptic specificity of any protein
movement in the anterograde direction from donor neurons.
To begin, we designed a preliminary split-CRE system as depicted in Fig. 5.12A. This
design was derived from the known functional CRE split site between amino acids 59 and 60.
It was previously shown that functional CRE activity could be reconstituted on co-expression
of a short N terminal fragment of CRE (AA19-59) and longer C terminal fragment (AA60-
343) in the same cell. This reconstitution persisted following the addition of rapamycin-
dependent dimerisation domains onto the N terminus of both split-CRE fragments by short
flexible linkers (F2)331. In our case, as we did not require ligand-induced heterodimerisation,
we replaced the FKBP and FRB heterodimerisation domains used in this study with known
heterodimerising coiled coil domains of the GABA B receptor subtypes 1a and 2 (GBR1acc
and GBR2cc)332. We also added a 3XFLAG molecular tag onto the CCRE system for
visualisation of acceptor cells. In order to add the NCRE fragment onto candidate proteins,
we decided to use a long 43AA flexible glycine-serine (GS) linker with a TEV cleavage
site. The rationale behind this was to then express TEV protease in the acceptor cell,
enabling cleavage of the NCRE tag from the candidate protein and enabling effective CRE
reconstitution on heterodimerisation with CCRE.
We first tested whether these new additions to the N termini of NCRE and CCRE
fragments had impaired the ability of these fragments to functionally reconstitute CRE
activity following co-expression in the same cell (Fig. 5.12B). As a negative control, we
transfected cells with only the CCRE <mCH> plasmid. This plasmid expresses the CCRE
fragment as well as encoding a flexed mCHERRY marker and TEV protease. As the
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positive control, we co-transfected the CCRE <mCH> plasmid with CRE-expressing plasmid
constructs. As expected, we observed CRE activity in these cells as measured by positive
mCHERRY fluorescence. In order to test NCRE and CCRE reconstitution, we co-transfected
the CCRE <mCH> plasmid with donor construct plasmids expressing NCRE appended
to one of four different candidate proteins. We found that all 4 NCRE constructs enabled
functional CRE activity when co-expressed with CCRE. This clearly demonstrated that the
new modifications to the split CRE fragments had not impaired their ability to conduct DNA
recombination.
The rationale for adding the NCRE tag to the 4 proteins Tau, Otx2, Gsad and GFP are
as follows. Gsad-NCRE was designed as a positive control for protein movement as the G
protein of the SAD-B19 rabies virus is known to transfer intercellularly in vitro. In contrast
NCRE-GFP was the negative control as we did not expect GFP to move intercellularly in vitro.
NCRE-Tau and NCRE-Otx2 were test constructs which we wanted to test for intercellular
protein movement.
Following confirmation of effective CRE reconstitution following co-expression of NCRE
and CCRE within the same cell, we then conducted cell mixing experiments in order to test
the efficiency of this system for the visualisation of intercellular protein transfer (Fig5.12C).
In these cell mixing experiments, we transfected donor cells with plasmids expressing a
TVAeGFP marker and a NCRE tagged candidate protein. In contrast, acceptor cells were
transfected with plasmids encoding CCRE, TEV protease and flexed mCHERRY on a
separate cell culture plate. After transfection, donor and acceptor cells were mixed in culture
following DNAseI treatment as described in the methods section. 3 days post-transfection we
assessed the degree of mCHERRY activation of acceptor cells as a measure of intercellular
protein transfer. This was because the CCRE fragment on its own cannot activate the flexed
mCHERRY marker in acceptor cells. Therefore, increased mCHERRY activation could
only be enabled following the reconstitution of CRE activity due to the movement of NCRE
from donor cells into CCRE-expressing acceptor cells. In these experiments, donor neurons
expressing Gsad-CRE were used as a positive control for intercellular protein transfer (Gsad)
and activation of flexed mCHERRY (CRE) in acceptor cells. The results are depicted in
Fig. 5.12D. One can observe that if CCRE <mCH> acceptor cells are mixed with GFP and
Gsad-CRE expressing donor cells, there is a notable activation of mCHERRY in acceptor
cells. However, none of the NCRE-candidate protein expressing donor cells caused activation
of mCHERRY in acceptor cells. In particular, the observation that Gsad-CRE but not
Gsad-NCRE donor cells activated acceptor cells indicated to us that the NCRE design was
somehow reducing intercellular protein movement, or more likely, the split CRE system
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Fig. 5.12 In vitro test of preliminary split NCRE/CCRE design (A) Gene map of preliminary
NCRE and CCRE designs (B) Transfection of CCRE <mCH> acceptor plasmid into neuro2A cells
in isolation (left) or with CRE expressing plasmids (middle) or with NCRE-candidate protein (X)
expressing plasmids. (C) Scheme of cell mixing experiments. mCHERRY activation of acceptor cells
is taken as a measure of intercellular NCRE-candidate protein movement. (D) Confocal imaging of
mixed cell culture 3 days post-mixing. Only acceptor cells mixed with Gsad-CRE expressing donor
cells demonstrate clear mCHERRY activation. (E) Quantification of mCHERRY+ acceptor cells 3
days post-mixing. Two-tailed unpaired student’s T test.
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Fig. 5.13 In vivo test of preliminary split NCRE/CCRE design (A) Schematic representation
of dual viral injections for the establishment of NCRE-Tau expressing donor neurons and CCRE
expressing acceptor neurons in vivo. (B) Allen Brain Atlas, Experiment 177606858 showing the
projections of R CA3 neurons infected with AAV-EGFP into the L CA3. (C) Quantification of
mCHERRY+ acceptor cells in the left CA3 following injection of PBS, Lenti NCRE-Tau or Lenti
NCRE-GFP into the right CA3. Results demonstrate no significant differences in mCHERRY+ cell
numbers between all three experimental conditions.
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was not efficient enough to reconstitute functional CRE activity following the low levels of
intercellular transfer of Gsad-NCRE into CCRE expressing cells.
We also tested this preliminary split CRE system in vivo (Fig. 5.13A). First to trial the
experimental feasibility of this approach using double viral injections in vivo and second
to investigate whether longer term expression of NCRE-Tau from donor cells within neural
circuits in vivo would result in higher levels of intercellular protein transfer and thus activation
of CCRE <mCHERRY> acceptor neurons. To do this, we injected a lentivirus expressing the
donor construct as described in the in vitro experiments into the right CA3 of adult mice. As
there are known to be contralateral synaptic projections between CA3 regions (Allen Brain
Atlas, Experiment 177606858) we then injected an AAV encoding the acceptor construct into
the left CA3 (Fig. 5.13B). Quantification of mCHERRY+ acceptor neurons in the L CA3
showed that our preliminary split CRE design did not result in activated acceptor neurons in
vivo (Fig. 5.13B).
Given these negative results, we decided to further modify and optimise the efficacy of
our split-CRE system.
5.2.3.3 Design of multiple split-CRE variants to enhance the CRE reconstitution effi-
ciency of the preliminary split-CRE system
Given the finding that Gsad-CRE but not Gsad-NCRE could activate mCHERRY in CCRE
expressing acceptor cells in vitro, we concluded that the efficacy of NCRE/CCRE reconstitu-
tion needed to be improved such that functional CRE activity would be present with even
very low levels of NCRE/CCRE dimers. With this aim, we rationally altered 4 aspects of the
preliminary split-CRE design (Fig. 5.14A).
First, we decided to alter the nuclear localisation signal (NLS) on the CCRE fragment. In
the preliminary design, it was thought in theory to increase CRE reconstitution efficiency by
increasing the transport of NCRE/CCRE dimerised complexes to the nucleus. However, we
also considered the possibility that nuclear translocation of non-heterodimerised CCRE to
the nucleus may reduce the chances of CCRE dimerising with incoming NCRE molecules to
enable efficient reconstitution in the first place. Therefore, we designed a CCRE construct
which did not encode a NLS. On the other hand, as CCRE is translated in the cytoplasm one
may argue that heterodimerisation with incoming NCRE should not be impaired significantly
by the addition of a NLS given the continuous expression of CCRE in the cytoplasm
acceptor cells. As such we also considered the opposite possibility that the NLS needed
to be stronger in order to enable more efficient nuclear transport of any heterodimers that
may form in the cytoplasm. Therefore, we also designed a CCRE construct where the
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Fig. 5.14 Modifications to the preliminary SPLIT-CRE design (A) Gene maps of preliminary
SPLIT-CRE design with superimposed red circles indicating the 4 points at which we decided to
introduce adjustments. (B) Gene map of the alternative split-CRE designs that were cloned for in
vitro tests.
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SV40 NLS sequence was replaced with a stronger bipartite SV40 NLS (BPNLS - sequence
KRTADGSEFESPKKKRKVE) which had previously been shown to cause greater nuclear
localisation of proteins compared to the SV40 NLS sequence333.
Second, we altered the heterodimerisation domain used in the preliminary split-CRE
design. Our two main criteria in the search of new heterodimerisation domains was that A)
the dimerisation domains had high affinity interactions and B) they did not have any obvious
endogenous ligands which could interfere with the dimerisation of our split-CRE system. We
especially noted that the heterodimers used in the preliminary design (the coiled coil domains
of GABA B receptor subtypes 1a and 2332) could also bind endogenous GABA B receptors
in neurons which could interfere not only with effective NCRE/CCRE dimerisation but also
with intercellular protein movement mechanisms. As such we considered two alternatives.
One was a mutated leucine zipper Fosmut and Junmut heterodimersiation system which
had been developed by the complementary mutation of charged residues responsible for
wild type Fos-Jun binding. This resulted in a mutated Fos and Jun which were still able to
bind one another at high affinity but could not bind endogenous Fos and Jun proteins334. In
addition, we considered the use of the GFP:GFP nanobody system which, by nature of being
an antibody-derived system has both high affinity and specificity188. One caveat however was
that the GFP nanobody (or GBP for GFP Binding Protein) is 117AAs, which is significantly
bigger than the Fosmut: Junmut leucine zipper system which was only 37AAs in size.
Third, we considered altering the split site of the CRE protein. Although the AA59-60
split site used in the preliminary design has been shown to be functional, rational design
of an alternative split site between AA104-106 has also been shown to have functional
reconstitution ability335. In fact, the level of CRE recombination was actually found to be
higher with the AA104-106 split site compared to the AA59-60 split site. One disadvantage
of this alternative split site was that this would increase the size of the NCRE-tag which we
wanted to keep as small as possible.
Fourth, we also considered increasing the length of the F2 linker on the N terminus of the
N and CCRE fragments. It had been shown previously that especially for the new AA104-106
CRE split site that we had now incorporated, longer linker arms increased recombination
activity335. We thought the need for longer linkers was also greater due to the increased size
of some of our new heterodimerisation domains (e.g. the GBP). Thus we also attempted
replacing the F2 linker with F6 or F9 linkers. These are flexible linkers similar in design to
the F2 linker but 23 and 35AAs long respectively.
As such, we designed and cloned many combinatorial variants of these 4 different factors
into the original split-CRE design as shown in Fig. 5.14B for further testing in vitro.
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5.2.3.4 In vitro screening of different split-CRE designs
Following the design and cloning of multiple combinatorial variants of the original split-CRE
design, we then wanted to assess whether any of the modifications made had actually impaired
the ability of NCRE and CCRE fragments to reconstitute CRE activity when co-expressed
in the same cell. Given the increasing size of the dimerisation domains, linker lengths
and split CRE sites, we deduced that some of our modifications could potentially impair
DNA recombination by steric hindrance. On co-transfection of various NCRE and CCRE
pairs (Fig. 5.15A), we observed that the use of the GFP:GBP dimerisation system impaired
DNA recombination resulting in an absence or vast reduction of mCHERRY activation in
co-transfected cells. In contrast the Fosmut:Junmut dimerisation system seemed to enable
efficient DNA recombination for either of the two CRE split sites. Interestingly, we also
observed functional reconstitution of CRE activity on the co-expression of overlapping
NCRE104 (AA19-104) and CCRE60 (AA60-343) fragments.
Given these results, we conducted a cell mixing experiment in differentiating neuro2A
cells with donor cells expressing Gsad-Fosmut F6 NCRE 104 and acceptor cells expressing
NLS Junmut F6 CCRE 106 <mCH> (Fig. 5.15B). We observed a possible increase of
DNA recombination activity in mixed cells (right) compared to the non-mixed acceptor cells
control (left). However, the system still appeared inefficient, especially when compared
to the Gsad-CRE mixed positive control which resulted in a much larger number of more
strongly mCHERRY positive acceptor cells.
5.3 Summary
In this final experimental chapter, we aimed to initiate investigations into the understudied
phenomenon of interneuronal protein transfer. In order to do this we first tested different in
vitro and in vivo systems that could be manipulated to establish protein donating "donor"
neurons into a neural network. We found that both the mouse visual circuitry and hippocampal
circuitry could be targeted relatively easily for this purpose. In both cases, we were able to
obtain promising preliminary data showing intercellular protein movement into the axonic
projection sites of second order neurons within the circuit.
Secondly, we investigated two independent methods of total proteome labelling to enable
top-down identification of proteins demonstrating intercellular transfer in an unbiased manner.
Most notably, we show that the expression of the promiscuous biotin ligase BioID2 in RGCs
enables the biotinylation of RGC proteins which then appear to move intercellularly into
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Fig. 5.15 In vitro screening of multiple split-CRE designs (A) Cotransfection of different
NCRE:CCRE design pairs to assess efficiency of DNA recombination on co-expression in the same
cell. The efficiency of DNA recombination is assessed by the number and intensity of mCHERRY+
cells. (B) Representative cell mixing experiment with the Fosmut F6 NCRE105 and NLS Junmut F6
CCRE106 split-CRE pair.
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LGN neuron cell bodies and transport anterogradely into the visual cortex. This is an exciting
result which can be investigated further to identify novel RGC endogenous proteins that
demonstrate interneuronal protein transfer.
Thirdly, we aimed to develop a small split-CRE tag which would enable more sensitive
visualisation of intercellular protein transfer and also enable genetic manipulation of protein-
receiving "acceptor" neurons in the circuit. Although we were able to slightly improve the
efficiency of the split-CRE tag through the screening of multiple designs, we were yet unable
to obtain an efficiency of functional split-CRE reconstitution high enough to visualise the
small amounts of NCRE-tagged proteins moving intercellularly.

Chapter 6
General Discussion and Conclusions
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6.1 The design and in vivo characterisation of a second gen-
eration Self-Inactivating Rabies vector (SiR 2.0)
In the first experimental chapter I describe the design, production and in vivo characterisation
of a second generation Self-inactivating Rabies virus (SiR 2.0 or SiR N2C). This new SiR
2.0 virus incorporates a C-terminal TEVs-PEST addition design to the N protein of the WT
DG CVS-N2C rabies virus. SiR 2.0 therefore incorporates the already existing rabies self
inactivation technology into a less immunogenic and more neuroinvasive rabies virus strain.
By design, the improved SiR 2.0 vector abolishes WT rabies virus toxicity like the SiR
1.0 but enables more efficient circuit targeting and reduced immunological impairment of
targeted circuits which is advantageous both for research and for potential therapuetic use.
I show that the SiR 2.0 viruses can be functionally produced from plasmids in HEK 293T
cells within an experimentally tractable time frame (5-6 weeks). These viral preparations are
produced to high functional titers that can successfully infect neurons following injection in
vivo. Thus, we confirm that the TEVs-PEST modification does not inadvertantly impair the
production, infectivity or trans-synaptic transfer ability of the CVS-N2C strain, and that the
SiR 2.0 can be used functionally in vivo.
6.1.1 The SiR virus does not accumulate revertant mutations to any
appreciable level in vitro or in vivo
Given the common knowledge that ssRNA viruses are subject to a high rate of mutations
and a recent report concerning the two viral batches of SiR virus that had accumulated WT
reverting mutations192, we conducted a thorough analysis of the genomic stability of multiple
SiR virus preparations. We show through sequencing analyses of the viral genomes collected
from both non-injected SiR virus preparations and from SiR infected neurons in vivo, that
the TEVs-PEST modification that is crucial for the self-inactivation and thus reduced toxicity
of the SiR virus is not selectively mutated either during production in cell culture in vitro or
following infection of neurons in vivo.
Next generation sequencing of viral RNA from infected hippocampi 1 week p.i. does
not identify any mutations within the TEVs-PEST modification, despite identifying multiple
mutations elsewhere in the genome. In addition, trans-synaptically labelled premotor neurons
also demonstrate positive staining for the TEVs epitope that can only be expressed by
non-revertant bona fide SiR viral particles. As such, this data suggests that SiR viruses,
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if produced as previously described191, show a very low risk of accumulating revertant
mutations during production in vitro and following in vivo injection.
6.1.2 The SiR 2.0 virus as a potential first step towards a therapeutic
rabies vector
In this chapter I demonstrate that the SiR 2.0 has many characteristics different to the SiR 1.0
virus that increase its suitability as a potential therapeutic vector for circuit-based therapy.
6.1.2.1 Increased genomic stability of the CVS-N2C strain
First I show data regarding the increased genomic stability of the CVS-N2C strain compared
to the SAD-B19 strain. Although no stringently controlled comparison of mutation rates
have been conducted, I show, through the comparison of multiple parallel productions of WT
or SiR SAD-B19 vs. WT or SiR CVS-N2C, that the SAD-B19 productions unanimously
demonstrate a higher accumulation of mutation events. This is despite the fact that viral
production conditions are in fact biased for the increased mutation accumulation of the
CVS-N2C strain as these viruses take longer to produce in vitro enabling a longer time for
mutation accumulation. Nonetheless, our results show that even under these favourable
conditions, the SAD-B19 demonstrates higher mutation accumulation.
These comparisons are informative as they analyse the genomic stability of SAD-B19 or
CVS-N2C viral preparations that have been produced as described in the methods section for
quick high-titer productions. Therefore, they accurately reflect the genomic heterogeneity
of viral populations that would be used for in vivo injections of either of the two strains.
Undoubtedly, the ability to produce more homogenous viral productions is an advantageous
quality for the large-scale production of therapuetic viral vectors for therapy as they must be
quality controlled to a very high level.
6.1.2.2 Simple SiR design modifications that could be implemented to abolish rever-
tant mutation risk for safe therapuetic use
Another important point regarding SiR genomic stability and potential therapeutic use is
that, for patient safety-considerations, the risk of revertant SiR viruses in therapy should
effectively be zero. Although our sequencing data shows that the risk of revertant mutations
accumulating in SiR viruses is extremely low if produced in the correct conditions, it may
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also be worth to consider other simple measures that could be taken to reduce this potential
risk even further.
For example, one could consider adding the TEVs-PEST addition to the N terminus of
the N protein. In this way, the introduction of frameshift or nonsense mutations resulting in
premature truncation of the protein would result in a lack of N expression altogether. Such
mutations would therefore inactivate the virus without posing a risk for patients. In contrast,
frameshift or nonsense mutations of C terminal protein modifications result in potential toxic
revertant mutations as is the case for our current C terminal TEVs-PEST additions.
In addition, further study into the mechanism of the viral RNA polymerase complex could
reveal particular genomic signatures that result in higher or lower mutation accumulation.
Therefore, with such an understanding, the sequence of the TEVs-PEST addition could be
modified to reduce this risk as much as possible.
6.1.2.3 SiR 2.0 enables more efficient targeting of the motor-premotor networks im-
plicated in ALS
A direct comparison into the neurotropism of the SiR 2.0 compared to the SiR 1.0 vector
shows that the SiR 2.0 demonstrates a significantly higher efficiency of motor neuron
terminal targeting following intramuscular injection compared to the SiR 1.0 vector. This
finding confirms previous studies describing the higher neurotropism of the CVS-N2C strain
compared to the SAD-B19 strain.
However, our experimental design enables, for the first time, the direct comparison of the
neurotropism of the recently optimised oG coated SAD-B19 virus with the neurotropism of
the CVS-N2C virus within the same circuit in the same experimental conditions. Previous
reports specify that the CVS-N2C strain has roughly 10-20 fold higher trans-synaptic tracing
efficiency compared to the SAD-B19 in corticostriatal and spinal motor circuits190. Compari-
son of the original WT DG SAD-B19 strain with a new optimized glycoprotein (oG) coated
SAD-B19 strain has also been shown to improve monosynaptic tracing efficiency by around
10- to 20- in thalamocortical circuits244. Therefore this would suggest that the CVS-N2C and
the oG coated SAD-B19 wuold show roughly similar tracing efficiency. However, we show
that in the case of motor neuron terminal targeting following intramuscular injection, the
CVS-N2C still demonstrates an almost 30 fold higher neurotropism despite oG modifications
to the SAD-B19 strain. We also show that the trans-synaptic transfer kinetics and efficiency
of the CVS-N2C strain is significantly greater then the oG coated SAD-B19 strain.
The significance of this finding is relevant for therapy due to the need for efficient circuit
targeting in vivo. As described in the introduction, efficient circuit-targeting is key for neuro-
6.1 The design and in vivo characterisation of a second generation Self-Inactivating Rabies
vector (SiR 2.0) 179
logical therapy as it reduces the risk of immunological responses to therapeutic vectors and
off-target effects. Equally importantly, efficient circuit targeting enables higher therapeutic
doses into the networks actually implicated in the neural pathology. We demonstrate this
targeting efficiency in a therapeutically relevant motor-premotor network that is affected in
the onset of ALS. ALS pathology is known to initiate in the spinal cord a motorneurons
and Betz cells of the motor cortex121. Therefore, the testing of the SiR 2.0 vector for high
tropism to motor neurons and efficient retrograde trans-synaptic transfer from spinal motor
neurons demonstrates the advantages of the SiR 2.0 vector directly within ALS-implicated
circuits.
6.1.2.4 SiR 2.0 is significantly less immunogenic compared to the SiR 1.0
In this chapter, I also demonstrate through immunohistochemistry and through RNA-Seq
experiments in two different circuits in vivo that the immune response to rabies virus infection
is markedly reduced in the new SiR 2.0 vector when compared to its WT or SAD-B19
counterpart. This is a relevant result with view to therapy as viral immunogenicity is a
key factor determining the success of viral therapeutic vectors. For example, the effective
use of systemic AAV delivery for CNS targeting is hindered significantly by the fact that
the high systemic doses of recombinant AAV required for efficient CNS targeting triggers
host immune responses. This is despite the fact that recombinant AAVs and lentiviruses
are already the preferred therapeutic vectors of choice due to their low immunogenicities
compared to other viruses.
6.1.2.5 Other potential future modifications that could dampen rabies virus immuno-
genicity
As our immunofluorescence and RNA-seq data implicated the activation of the PRR RIG-I
as a sensor for rabies infection, we considered that rabies virus immunogenicity could be
reduced even further by the expression of RIG-I inhibitors by the rabies genome. This
could be performed through multiple different mechanisms. For example, rabies mediated
expression of RIG-I targeting siRNA could reduce RIG-I induction in rabies infected cells.
In a similar vein, the ablation of RIG-I using antisense morpholino oligonucleotide in
mouse neuro2A cells is known to negatively regulate RIG-I activation following infection by
Japenese Encephalitis Virus (JEV)245. JEV is also a RNA virus which is recognised by the
PRR RIG-I.
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In addition, one could consider expressing RIG-I inhibiting proteins from the rabies
genome. For example, the viral nonstructural protein 1 (NS1) of the influenza virus negatively
regulates RIG-I activation at many levels336: it interacts directly with RIG-I, binds dsRNA
to reduce RIG-I activation and prevents the induction of downstream IFN responses by
inhibiting the activation of transcription factors such as IRF3.
6.1.3 Considerations for the use of SiR 2.0 in research
Here we show that the SiR 2.0 demonstrates higher neurotropism, higher trans-synaptic
transfer efficiency and decreased immunogenicity compared to the SiR 1.0. These changes
are undoubtedly unanimously advantageous for the development of rabies vector derived
therapies.
However, for the use of SiRs for research, choice of vector depends on a wider variety
of factors. For example, the production of SiR 2.0 is more difficult then the production of
SiR 1.0 mainly due to the inability to visually track viral production in vitro. Therefore,
in cases where reduced immune perturbation of targeted circuits is not critical, one may
prefer to use the SiR 1.0 vector. In addition, although we demonstrate that the SiR 2.0 is
more neurotropic when injected into peripheral organs (and this is clearly advantageous for
non-invasive therapeutic use), we do not find that the SiR 2.0 is significantly more neurotropic
when injected intracerebrally (e.g. into mouse CA1). Therefore, although the SiR 2.0 may be
preferred for more efficient and complete trans-synaptic targeting of peripherally infected
circuits, it would not have the same advantage when targeting circuits by intracerebral
injection. In addition, in cases where a shorter length or higher level of exogenous gene
expression is important, one may prefer the SAD-B19 derived SiR 1.0 which shows more
transient but higher levels of transgene expression following infection.
6.2 The use of SiR 2.0 for CRISPR/Cas9 mediated genome-
editing
In the second experimental chapter I present data showing the functional incorporation of
both a Cas9 endonuclease and a gRNA sequence into the WT DG rabies virus genome.
Through screening of multiple designs, we show that such a virus can be produced and
used to target endogenous loci in vitro. We also produce SiR rabies viruses incorporating
the same design cassette, and show through a preliminary experiment, that this virus can
perform SiR mediated CRISPR/Cas9 genome editing in vivo. Given the repeated observation
6.2 The use of SiR 2.0 for CRISPR/Cas9 mediated genome-editing 181
that neurodegenerative disorders are characterized by the network-level progression of
pathological protein aggregates, and given that familial forms of these diseases are caused by
specific gene mutations, circuit-level genome editing vectors in theory would be a promising
therapeutic strategy for these diseases.
6.2.1 SiR-Cas9-gRNA could potentially target many different disease
circuits by non-invasive peripheral injection
As the rabies virus can infect a multitude of different peripheral sensory and motor neurons,
trans-synaptic transfer of rabies virus from these different primary neurons opens up the
possibility of using the rabies virus to target many different disease circuits. The key example
I focus on throughout this thesis is the targeting of lower and upper motor neurons by single
intramuscular injection of rabies virus, and the clear advantages this has in targeting all of
the two areas initially involved in the pathology of ALS121.
However, this principle could in theory be applied to many other diseases. For example,
Parkinson’s disease is known to present in patients initially by involvement of the olfactory
circuitry. In fact, loss of a sense of smell is very commonly the very first symptom that
Parkinson’s patients experience121. Therefore, it is tempting to consider the intranasal
administration of a trans-synaptic rabies virus to the olfactory epithelium to enable the
targeting of olfactory circuits for therapy.
In addition, the lateral hypothalamus and arcuate nucleus are highly involved in the
neural control of appetite337,338. As hypothalamic pathways are known to project polysy-
naptically into peripheral adipose tissue, one could consider targeting these hypothalamic
neural networks by peripheral rabies injection into peripheral adipose tissue339,340. Here,
the injection of rabies virus into the adipose tissue or the stellate ganglion would enable
retrograde targeting of crucial feeding centers of the brain and thus be used to modulate
feeding behaviour for the treatment of eating disorders.
Given our preliminary finding that the SiR can conduct genome editing in vivo, we
propose that the continued improvement of this vector could one day enable the execution of
these proposed examples of network-targeted therapy.
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6.2.2 Improving the production and quantification methods of SiR-Cas9-
gRNA viruses that do not express fluorescent markers
Although we show preliminary in vivo data showing SiR mediated targeting of endogenous
genomic loci, we need to design an experimental protocol that would enable robust quantifi-
cation of genome-editing efficiency to successfully develop a genome-editing SiR. However,
the current design presents some time-limiting challenges for such developments. First we
find that the production of unlabelled viruses is much more difficult and labour intensive then
for rabies viruses expressing fluorescent markers, as live visualisation of viral replication
and amplification is not possible. Second, following injection in vivo, there is no method of
permanently labeling once SiR infected cells. Therefore, it is hard to quantify exactly what
percentage of SiR infected cells show successful SiR-mediated genome editing. As such,
we have already described a preliminary design of a split-FLP tag in order to permanently
label SiR infected cells. We know from our studies of split-CRE reconstitution that the
design of efficient split-recombinase enzymes can be difficult. However, given the fact that
virally driven split-FLP expression will be very high and that co-transfection of split-CRE
fragments to high levels does result in clearly visible recombinase activity, we suspect that
high efficiency of reconstitution will not be a key limiting factor in this development.
6.2.3 Other potential modifications to boost gRNA expression from the
rabies genome
Further study into the structural elements of single gRNA has revealed that some parts of
the gRNA are not necessary for efficient Cas9 targeting295. In addition, there is also the
potential for rational modifications to the gRNA structure to improve gRNA stability or Cas9
targeting. Such changes may help to increase the efficiency of SiR mediated CRISPR/Cas9
genome editing. For example, the sequence flexibility of the lower stem, upper stem and
hairpin 1 suggest that gRNAs can be designed that are more compact and more functionally
and structurally stable295.
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6.3 Identification and mechanistic elucidation of neuronal
proteins demonstrating interneuronal transfer through
neural circuits
In the final experimental chapter I present exploratory work aiming to identify efficient
interneuronal protein transfer systems within well-established neural circuits in vivo. I also
aim to implement existing cell-specific proteomic labeling techniques into such circuits. Here
our most notable findings are the observation that intraocularly injected proteins (human
A53T mutant alpha synuclein) as well as BioID2-tagged RGC donor proteins demonstrate
interneuronal protein transfer from RGCs into the visual cortex in a time scale of days. Given
the relative ease of RGC targeting by intraocular injection, and the fast time-scale of protein
movement observed in this system, it should be pursued for future mechanistic elucidation of
intercellular protein movement mechanisms. We also note that although considerably slower,
the movement of V5 Tau through the hippocampal circuitry also lends itself nicely to further
mechanistic elucidation. Lastly, although not demonstrated directly in this thesis, the use of
candidate based or proteomic labeling techniques can also be implemented in neural circuitry
in vitro following the differentiation of neuro2A cells.
6.3.1 Mechanistic investigation into the observed transfer of V5-Tau
through hippocampal circuitry
So far, we have successfully designed and produced a lentivirus which, following injection
into the mouse hippocampus, establishes a V5-Tau expressing donor neuron population.
Analyses of brains injected with lentivirus-CAMKII-CREGFP-P2A-V5Tau in mouse CA1
showed that our viral design was suitable for generating donor neuron populations within
prescribed restricted regions in the mouse brain. We have also observed what appears to be
specific V5 staining both in the subiculum (the first order projection site of CA1 neurons)
and the entorhinal cortex (the projection site of second order neurons from the subiculum).
This strongly suggests that V5-Tau was transferred interneuronally through the canonical
hippocampal circuitry. However, the addition of a cytoplasmic or membrane marker to donor
neurons may aid further assertion that the V5 staining is present in bona fide acceptor neurons
which are cellularly distinct to lentivirally infected donor neurons. This could be done by
injecting the same construct into a transgenic lox-stop-lox membrane GFP mouse, such that
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CRE-GFP expression in donor neurons will not only label donor neurons with a nuclear GFP
signal, but also by GFP staining of its plasma membrane.
In addition, to expand this approach, we could replace tau in this design to test other
candidate proteins in order to compare their relative mobilities within the same mouse
hippocampal network. These other candidate proteins may be proteins which are unrelated
to neurodegeneration but have been shown to move transneuronally in other systems (eg.
neuronal transcription factors such as Otx2, or retroviral gag like proteins such as Arc). This
would offer insight into the specificity or generalisability of protein transfer within particular
circuitry. For example, it may be the case that although Otx2 demonstrates interneuronal
movement through the visual circuitry, it may not do so within the hippocampal circuitry.
The expression of CRE in donor cells also enables the versatile subsequent manipulation
of donor cells to elucidate various aspects behind the mechanism of protein transfer. For
example, CRE dependent optogenetic manipulation of neuronal activity or knockout of genes
in specific molecular pathways would offer new insight into the mechanisms underlying
interneuronal protein transfer. Alternatively, through the CRE dependent expression of
DREADDs in donor cells, one could investigate whether protein transfer increases with
increased synaptic activity.
Lastly, by inducing candidate protein expression in different distinct classes of neurons
by modifying the promoter of our donor construct, we can also assess the contribution of
different molecularly defined neuronal classes to protein propagation, which remains, so far,
unclear.
6.3.2 The use of neuro2A cell mixing experiments to study interneu-
ronal protein transfer in vitro
Differentiated neuro2A cells are known to form randomly connected neuronal populations
in culture327,328. Following the establishment of such in vitro neural circuitry we could
subsequently use sparse lentiviral labelling to create a donor population. Additional rabies
tracing or optogenetic methods as described for the in vivo experiments above would be
equally feasible in such an in vitro system. In addition, the cell mixing experiments between
WT and mutRS expressing neuro2A cells in Fig. 5.8 suggest that there may be some
intercellular transfer of azide labelled proteins from donor cells into acceptor cells in vitro.
However, a key consideration that should be taken when studying protein transfer in
vitro is the possibility that there may be non-specific uptake of donor proteins released
from dead donor cells into acceptor cells. To address such issues, one could consider
6.3 Identification and mechanistic elucidation of neuronal proteins demonstrating
interneuronal transfer through neural circuits 185
the use of microfluidic chambers to separate the culture medium of donor and acceptor
cells. Alternatively, one could use culture medium from donor neurons and add them onto
separately cultured acceptor neurons for control experiments. The establishment of a reliable
and representative in vitro neural network model could potentially be a very powerful platform
for future studies. For example, the system could be used to perform large scale screening
tests to investigate whether the systematic knock out of various genes inhibits or enhances
the intercellular transfer of proteins. This could reveal various pathways or genes that are
implicated in the intercellular protein transfer mechanism. In a medical context, this sort
of system may be useful to screen drug targets that could help prevent the propagation of
pathological proteins through neural networks in neurodegenerative disease.
6.3.3 Identification of trans-synaptically transported endogenous RGC
proteins in the visual cortex by mass spectrometry
Lastly, we demonstrate that AAV driven expression of BioID2 in RGCs followed by biotin
administration (intraocularly and intraperitoneally) results in efficient biotinylation of the
RGC proteome. We also observe that this protocol results in specific biotin-staining in
the cell bodies of the LGN and the contralateral visual cortex. This strongly suggests
that biotinylated RGC proteins are being transferred transsynaptically into LGN neurons
projecting to the visual cortex. Therefore protein purification from visual cortex samples
followed by enrichment of biotinylated proteins and mass spectrometry identification would
enable us, in an unbiased manner, to identify interneuronally transported endogenous RGC
proteins.
Very recently, biotinylation of the RGC proteome was in fact used to subsequently
identify RGC proteins transported to various first order projection sites of RGCs including
the SC and LGN337. In this report, RGC proteome biotinylation was achieved by intraocular
injection of N-hydroxysuccinimidobiotin (NHS-biotin) which binds covalently to lysines and
N-terminal amino acids of proteins. Interestingly, they identified some proteins within the
RGC transportome that overlap with post-synaptic density enriched protein datasets such as
SYN1, STX1B, STX1BP, NSF, and SNAP25. These proteins support vesicle fusion in pre-
and post-synaptic compartments, potentially suggesting a role for these axonally transported
RGC proteins in interneuronal protein transfer.
One potential advantage of using AAV-transduced RGC systems over direct intraocular
injection of proteins or protein tags is the ability for long-term biotinylation enabling larger
biotinylated protein volumes transported from the RGC over longer time scales. In our case,
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where we want to identify biotinylated proteins from a second order projection site, this may
be largely helpful. In addition, establishment of RGCs by AAV transduction enables both the
quantification and selective modification of RGC donor neuron properties. This also enables
further mechanistic investigation into the molecular processes involved in intercellular protein
transfer.
6.4 Final Summary
Neural circuits underlie human brain function. In this thesis I have aimed to develop novel
tools to target and manipulate neural circuits in vivo.
First, I have developed and characterised a second generation self-inactivating rabies
virus vector (SiR 2.0) which expands the trans-synaptic tracing vector toolbox for circuit
neuroscience research and implements key improvements over the SiR 1.0 vector for its
further development as a therapeutic vector. SiR 2.0 enables more efficient targeting of
peripheral neural circuits, enhanced trans-synaptic labelling efficiency and markedly reduced
immunogenicity when compared to its previous WT and SiR 1.0 counterparts.
Second, I have incorporated into the SiR 2.0 genome the two components of the
CAS9/gRNA system and shown a proof of principle that the rabies virus genome can
functionally encode these two components without compromising viral production or in-
fectivity in vivo. I also discuss the potential experimental and therapeutic applications of a
circuit-specific genome-editing vector for both research and therapy. In addition, I discuss
the technical challenges that need to be overcome for the future development, improvement
and in vivo characterisation of these SiR-Cas9-gRNA viruses. In theory, we propose that the
rabies virus could be modified and optimised further to express multiple gRNAs to target
multiple genomic loci.
Third, in my final experimental chapter, I identify different possible experimental systems
that would enable further investigation into the mechanisms behind interneuronal protein
transfer. We work to design and implement tools into these different experimental systems
that would enable either a candidate based bottom up mechanistic approach or an unbiased
top-bottom proteomic approach. In this work I have identified the mouse visual circuitry
as a particularly accessible and efficient in vivo system for further investigation. I have
demonstrated its uses both for candidate-protein based approaches as well as for further study
into the generalisability of interneuronal protein transfer by RGC proteome biotinylation
using the BioID2 system. It may be possible that the identification of novel proteins that
are transferred interneuronally as well as a greater understanding of the underlying biology
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of this process will enable the development of better tools for anterograde trans-synaptic
labelling and targeting of neural circuits in the future.
I envisage that the further development and optimisation of such tools will help to unravel
some of the important unanswered questions in circuit neuroscience and pave the way for
efficient therapeutic targeting of neural networks in disease.

References
1. Hughes, J. T. The Edwin Smith Surgical Papyrus: An analysis of the first case reports
of spinal cord injuries. Paraplegia 26, 71–82 (1988).
2. Celesia, G. G. Alcmaeon of Croton’s Observations on Health, Brain, Mind, and Soul.
Journal of the History of the Neurosciences 21, 409–426. ISSN: 0964-704X (2012).
3. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of
structural and functional systems. Nature Reviews Neuroscience 10, 186–198. ISSN:
1471-003X (2009).
4. Warren, J. D., Rohrer, J. D., Schott, J. M., Fox, N. C., Hardy, J. & Rossor, M. N.
Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends in
Neurosciences 36, 561–569. ISSN: 01662236 (2013).
5. Sepehri Rad, M., Choi, Y., Cohen, L. B., Baker, B. J., Zhong, S., Storace, D. A. &
Braubach, O. R. Voltage and Calcium Imaging of Brain Activity. Biophysical Journal
113, 2160–2167. ISSN: 0006-3495 (2017).
6. Vlasov, K., Van Dort, C. J. & Solt, K. Methods in enzymology 181–196 (2018).
doi:10.1016/bs.mie.2018.01.022.
7. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E. &
Church, G. M. RNA-guided human genome engineering via Cas9. Science (New York,
N.Y.) 339, 823–6. ISSN: 1095-9203 (2013).
8. Cajal, S. y. Estructura de los centros nerviosos de las aves (1888).
9. Sherrington, C. S. Observations on the scratch-reflex in the spinal dog. The Journal of
Physiology 34, 1–50. ISSN: 00223751 (1906).
10. Golgi, C. Sulla sostanza grigia del cervello. Gazetta Medica Italiana 33, 244–246
(1873).
11. Adrian, E. D. The impulses produced by sensory nerve endings: Part I. The Journal of
physiology 61, 49–72. ISSN: 0022-3751 (1926).
12. Adrian, E. D. A. The basis of sensation, the action of the sense organs (Christophers,
1928).
190 References
13. HUBEL, D. H. Tungsten Microelectrode for Recording from Single Units. Science
125, 549–550. ISSN: 0036-8075 (1957).
14. Hubel, D. H. & Wiesel, T. N. Receptive fields of single neurones in the cat’s striate
cortex. The Journal of physiology 148, 574–91. ISSN: 0022-3751 (1959).
15. Gross, C. G. Genealogy of the “Grandmother Cell”. The Neuroscientist 8, 512–518.
ISSN: 1073-8584 (2002).
16. Weibell, C. J. Principles of learning: 7 principles to guide personalized, student-
centered learning in the technology-enhanced, blended learning environment. PhD
thesis (2011), Chapter 3.
17. Bain, A. Mind and body : the theories of their relation ISBN: 1402199740 (Henry S.
King & Co., 1873).
18. McCulloch, W. S. & Pitts, W. A logical calculus of the ideas immanent in nervous
activity. The Bulletin of Mathematical Biophysics 5, 115–133. ISSN: 00074985 (1943).
19. Rosenblatt, F. THE PERCEPTRON: A PROBABILISTIC MODEL FOR INFORMA-
TION STORAGE AND ORGANIZATION IN THE BRAIN 1. 65, 19–27 (1958).
20. Hebb, D. O.D. O. The organization of behavior; a neuropsychological theory 335.
ISBN: 0471367273 (John Wiley and Sons, 1949).
21. Minsky, M. & Papert, S. Perceptrons; an introduction to computational geometry 258.
ISBN: 9780262130431 (MIT Press, 1969).
22. Rumelhart, D. E., Hinton, G. E. & Williams, R. J. Learning representations by back-
propagating errors. Nature 323, 533–536. ISSN: 0028-0836 (1986).
23. Johnson, G. Artificial Brain Again Seen As a Guide To the Mind. New York Times
(1988).
24. Hopfield, J. J. Neural networks and physical systems with emergent collective com-
putational abilities. Proceedings of the National Academy of Sciences of the United
States of America 79, 2554–8. ISSN: 0027-8424 (1982).
25. Ichinose, T., Aso, Y., Yamagata, N., Abe, A., Rubin, G. M. & Tanimoto, H. Reward
signal in a recurrent circuit drives appetitive long-term memory formation. eLife 4,
e10719. ISSN: 2050-084X (2015).
26. Eichler, K. et al. The complete connectome of a learning and memory centre in an
insect brain. Nature 548, 175–182. ISSN: 1476-4687 (2017).
27. Bedia, M. G., Corchado, J. M. & Castillo, L. F. Bio-inspired Memory Generation by
Recurrent Neural Networks tech. rep. (2007), 55–62. doi:10.1007/978-3-540-73007-
1_8.
28. LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436–444. ISSN:
0028-0836 (2015).
References 191
29. Cho, K., van Merrienboer, B., Gulcehre, C., Bahdanau, D., Bougares, F., Schwenk,
H. & Bengio, Y. Learning Phrase Representations using RNN Encoder-Decoder for
Statistical Machine Translation. arXiv: 1406.1078 (2014).
30. Bahdanau, D., Cho, K. & Bengio, Y. Neural Machine Translation by Jointly Learning
to Align and Translate tech. rep. (2014). arXiv: 1409.0473.
31. Sutskever, I., Vinyals, O. & Le, Q. V. Sequence to Sequence Learning with Neural
Networks 2014.
32. Krizhevsky, A., Sutskever, I. & E. Hinton, G. ImageNet Classification with Deep
Convolutional Neural Networks. Neural Information Processing Systems 25. doi:10.
1145/3065386 (2012).
33. He, K., Zhang, X., Ren, S. & Sun, J. Delving Deep into Rectifiers: Surpassing Human-
Level Performance on ImageNet Classification. arXiv: 1502.01852 (2015).
34. Erhan, D., Bengio, Y., Courville, A. & Vincent, P. Visualizing Higher-Layer Features of
a Deep Network tech. rep. (Département d’Informatique et Recherche Opérationnelle,
2009).
35. Zeiler, M. D. & Fergus, R. LNCS 8689 - Visualizing and Understanding Convolutional
Networks tech. rep. (2014).
36. Zhou, B., Khosla, A., Lapedriza, A., Oliva, A. & Torralba, A. Object Detectors Emerge
in Deep Scene CNNs tech. rep. (2014). arXiv: 1412.6856.
37. Yamins, D. L., Hong, H., Cadieu, C. & DiCarlo, J. J. Hierarchical Modular Optimiza-
tion of Convolutional Networks Achieves Representations Similar to Macaque IT and
Human Ventral Stream 2013.
38. Cichy, R. M., Khosla, A., Pantazis, D., Torralba, A. & Oliva, A. Comparison of
deep neural networks to spatio-temporal cortical dynamics of human visual object
recognition reveals hierarchical correspondence. Scientific Reports 6, 27755. ISSN:
2045-2322 (2016).
39. Cadieu, C. F., Hong, H., Yamins, D. L. K., Pinto, N., Ardila, D., Solomon, E. A.,
Majaj, N. J. & DiCarlo, J. J. Deep Neural Networks Rival the Representation of
Primate IT Cortex for Core Visual Object Recognition. PLoS Computational Biology
10 (ed Bethge, M.) e1003963. ISSN: 1553-7358 (2014).
40. Sejnowski, T. J. & Rosenberg, C. R. Parallel Networks that Learn to Pronounce
English Text tech. rep. (1987), 145–168.
41. Schüz, A. & Palm, G. Density of neurons and synapses in the cerebral cortex of the
mouse. Journal of Comparative Neurology 286, 442–455. ISSN: 00219967 (1989).
42. Braitenberg, V. & Schüz, A. Anatomy of the Cortex ISBN: 978-3-540-53233-0. doi:10.
1007/978-3-662-02728-8 (Springer Berlin Heidelberg, Berlin, Heidelberg, 1991).
192 References
43. Cerebral Cortex (eds Jones, E. G. & Peters, A.) ISBN: 978-1-4613-6706-2. doi:10.
1007/978-1-4615-3824-0 (Springer US, Boston, MA, 1990).
44. Llinás, R. R. & Sugimori, M. The Cerebellum Revisited 167–181 (Springer US, New
York, NY, 1992). doi:10.1007/978-1-4612-2840-0_8.
45. Holmgren, C., Harkany, T., Svennenfors, B. & Zilberter, Y. Pyramidal cell communi-
cation within local networks in layer 2/3 of rat neocortex. The Journal of Physiology
551, 139–153. ISSN: 0022-3751 (2003).
46. Feldmeyer, D., Lübke, J. & Sakmann, B. Efficacy and connectivity of intracolumnar
pairs of layer 2/3 pyramidal cells in the barrel cortex of juvenile rats. The Journal of
Physiology 575, 583–602. ISSN: 00223751 (2006).
47. Avermann, M., Tomm, C., Mateo, C., Gerstner, W. & Petersen, C. C. H. Microcircuits
of excitatory and inhibitory neurons in layer 2/3 of mouse barrel cortex. Journal of
Neurophysiology 107, 3116–3134. ISSN: 0022-3077 (2012).
48. Fino, E., Packer, A. M. & Yuste, R. The Logic of Inhibitory Connectivity in the
Neocortex. The Neuroscientist 19, 228–237. ISSN: 1073-8584 (2013).
49. Karnani, M. M., Agetsuma, M. & Yuste, R. A blanket of inhibition: functional in-
ferences from dense inhibitory connectivity. Current Opinion in Neurobiology 26,
96–102. ISSN: 0959-4388 (2014).
50. Yuste, R. From the neuron doctrine to neural networks. Nature Reviews Neuroscience
16, 487 (2015).
51. Watts, D. J. & Strogatz, S. H. Collective dynamics of ‘small-world’ networks. Nature
393, 440–442. ISSN: 0028-0836 (1998).
52. Milgram, S. The small world problem. Psychology today 2, 60–67 (1967).
53. Bullmore, E. & Sporns, O. The economy of brain network organization. Nature
Reviews Neuroscience 13, 336–349. ISSN: 1471-003X (2012).
54. Wernicke, C. The aphasic symptom complex: a psychological study on a neurological
basis. Breslau: Cohn and Weigert. Reprinted. Boston studies in the philosophy of
science 4 (1874).
55. Pribram, K. H. & Mishkin, M. Simultaneous and successive visual discrimination
by monkeys with inferotemporal lesions. Journal of comparative and physiological
psychology 48, 198–202. ISSN: 0021-9940 (1955).
56. Desimone, R., Albrightj, T. D., Gross, C. G. & Bruce, C. STIMULUS-SELECTIVE
PROPERTIES OF INFERIOR TEMPORAL NEURONS IN THE MACAQUE1 tech. rep.
8 (1984), 2051–2062.
References 193
57. Gross, C. G., Rocha-Miranda, C. E. & Bender, D. B. Visual properties of neurons in
inferotemporal cortex of the Macaque. tech. rep. 1 (1972), 96–111. doi:10.1152/jn.
1972.35.1.96.
58. Perrett, D., Rolls, E. & Caan, W. Visual neurones responsive to faces in the monkey
temporal cortex tech. rep. 3 (1982), 329–342. doi:10.1007/BF00239352.
59. Quiroga, R. Q., Reddy, L., Kreiman, G., Koch, C. & Fried, I. Invariant visual repre-
sentation by single neurons in the human brain tech. rep. 7045 (2005), 1102–1107.
doi:10.1038/nature03687.
60. James, W. The Principles of Psychology (Dover Publications, 1890).
61. Konorski, J. Integrative activity of the brain; an interdisciplinary approach (1967).
62. Barlow, H. B. Single units and sensation: A neuron doctrine for perceptual psychol-
ogy? tech. rep. (1972), 371–394.
63. Chang, L. & Tsao, D. Y. The Code for Facial Identity in the Primate Brain. Cell 169,
1013–1028.e14. ISSN: 1097-4172 (2017).
64. Quiroga, R. Q., Kreiman, G., Koch, C. & Fried, I. Sparse but not ‘Grandmother-cell’
coding in the medial temporal lobe. Trends in Cognitive Sciences 12, 87–91. ISSN:
1364-6613 (2008).
65. Munevar, G. Proceedings of the XXII World Congress of Philosophy 25–31 (Philoso-
phy Documentation Center, 2008). doi:10.5840/wcp22200834552.
66. Sherrington, C. S. Man on his Nature ISBN: 9780511694196. doi:10.1017/CBO9780511694196
(Cambridge University Press, Cambridge, 1940).
67. Saxena, S. & Cunningham, J. P. Towards the neural population doctrine. Current
Opinion in Neurobiology 55, 103–111. ISSN: 0959-4388 (2019).
68. Briggman, K. L., Abarbanel, H. D. I. & Kristan, W. B. Optical imaging of neuronal
populations during decision-making. Science (New York, N.Y.) 307, 896–901. ISSN:
1095-9203 (2005).
69. Harvey, C. D., Coen, P. & Tank, D. W. Choice-specific sequences in parietal cortex
during a virtual-navigation decision task. Nature 484, 62–68. ISSN: 0028-0836 (2012).
70. Yu, B. M., Cunningham, J. P., Santhanam, G., Ryu, S. I., Shenoy, K. V. & Sahani,
M. Gaussian-Process Factor Analysis for Low-Dimensional Single-Trial Analysis of
Neural Population Activity. Journal of Neurophysiology 102, 614–635. ISSN: 0022-
3077 (2009).
71. Pandarinath, C. et al. Inferring single-trial neural population dynamics using sequential
auto-encoders. Nature Methods 15, 805–815. ISSN: 1548-7091 (2018).
194 References
72. Morcos, A. S. & Harvey, C. D. History-dependent variability in population dynamics
during evidence accumulation in cortex. Nature Neuroscience 19, 1672–1681. ISSN:
1097-6256 (2016).
73. Afshar, A., Santhanam, G., Yu, B., Ryu, S., Sahani, M. & Shenoy, K. Single-Trial
Neural Correlates of Arm Movement Preparation. Neuron 71, 555–564. ISSN: 0896-
6273 (2011).
74. Krasne, F. B. & Lee, S. C. Response-dedicated trigger neurons as control points
for behavioral actions: selective inhibition of lateral giant command neurons during
feeding in crayfish. The Journal of neuroscience : the official journal of the Society
for Neuroscience 8, 3703–12. ISSN: 0270-6474 (1988).
75. Esch, T. & Kristan, W. B. Decision-Making in the Leech Nervous System. Integrative
and Comparative Biology 42, 716–724. ISSN: 1540-7063 (2002).
76. Getting, P. A. & Dekin, M. S. Model Neural Networks and Behavior 3–20 (Springer
US, Boston, MA, 1984). doi:10.1007/978-1-4757-5858-0_1.
77. Getting, P. A. Emerging Principles Governing the Operation of Neural Networks.
Annual Review of Neuroscience 12, 185–204. ISSN: 0147-006X (1989).
78. Popescu, I. R. & Frost, W. N. Highly dissimilar behaviors mediated by a multifunc-
tional network in the marine mollusk Tritonia diomedea. The Journal of neuroscience
: the official journal of the Society for Neuroscience 22, 1985–93. ISSN: 1529-2401
(2002).
79. Lieske, S. P., Thoby-Brisson, M., Telgkamp, P. & Ramirez, J. M. Reconfiguration of
the neural network controlling multiple breathing patterns: eupnea, sighs and gasps.
Nature Neuroscience 3, 600–607. ISSN: 1097-6256 (2000).
80. Travers, J. B., DiNardo, L. A. & Karimnamazi, H. Medullary reticular formation
activity during ingestion and rejection in the awake rat. Experimental brain research
130, 78–92. ISSN: 0014-4819 (2000).
81. Stringer, C., Pachitariu, M., Steinmetz, N., Reddy, C. B., Carandini, M. & Harris, K. D.
Spontaneous behaviors drive multidimensional, brainwide activity. Science (New York,
N.Y.) 364, 255. ISSN: 1095-9203 (2019).
82. Golde, T. E., Borchelt, D. R., Giasson, B. I. & Lewis, J. Thinking laterally about
neurodegenerative proteinopathies. The Journal of Clinical Investigation 123, 1847–
1855. ISSN: 0021-9738 (2013).
83. Rubinov, M. & Bullmore, E. Fledgling pathoconnectomics of psychiatric disorders.
Trends in Cognitive Sciences 17, 641–647. ISSN: 1364-6613 (2013).
84. John Martyn Harlow. Recovery from the passage of an iron bar through the head.
Publications of the Massachusetts Medical Society 2, 327–347 (1868).
85. Anonymous. Report of Prof. Bigelow. Stethoscope Va Med Gaz 1 1, 162–163 (1851).
References 195
86. Catani, M. & Ffytche, D. H. The rises and falls of disconnection syndromes. Brain
128, 2224–2239. ISSN: 1460-2156 (2005).
87. WHO. The world health report 2001 - Mental Health: New Understanding, New Hope
tech. rep. (2013).
88. Association, A. P. et al. Diagnostic and statistical manual of mental disorders (DSM-
5®) (American Psychiatric Pub, 2013).
89. Uhlhaas, P. & Singer, W. Neuronal Dynamics and Neuropsychiatric Disorders: Toward
a Translational Paradigm for Dysfunctional Large-Scale Networks. Neuron 75, 963–
980. ISSN: 08966273 (2012).
90. Bullmore, E. & Sporns, O. The economy of brain network organization. Nature
Reviews Neuroscience 13, 336–349. ISSN: 1471-003X (2012).
91. Kubicki, M. & Shenton, M. E. Diffusion Tensor Imaging findings and their implica-
tions in schizophrenia. Current Opinion in Psychiatry 27, 179–184. ISSN: 0951-7367
(2014).
92. Rotarska-Jagiela, A., Schönmeyer, R., Oertel, V., Haenschel, C., Vogeley, K. & Linden,
D. E. The corpus callosum in schizophrenia-volume and connectivity changes affect
specific regions. NeuroImage 39, 1522–1532. ISSN: 10538119 (2008).
93. Henze, R., Brunner, R., Thiemann, U., Parzer, P., Klein, J., Resch, F. & Stieltjes, B.
White matter alterations in the corpus callosum of adolescents with first-admission
schizophrenia. Neuroscience Letters 513, 178–182. ISSN: 03043940 (2012).
94. Alexander-Bloch, A. F., Vértes, P. E., Stidd, R., Lalonde, F., Clasen, L., Rapoport,
J., Giedd, J., Bullmore, E. T. & Gogtay, N. The Anatomical Distance of Functional
Connections Predicts Brain Network Topology in Health and Schizophrenia. Cerebral
Cortex 23, 127–138. ISSN: 1460-2199 (2013).
95. Van den Heuvel, M. P., Mandl, R. C. W., Stam, C. J., Kahn, R. S. & Hulshoff Pol,
H. E. Aberrant Frontal and Temporal Complex Network Structure in Schizophrenia:
A Graph Theoretical Analysis. Journal of Neuroscience 30, 15915–15926. ISSN:
0270-6474 (2010).
96. Liu, X., Lai, Y., Wang, X., Hao, C., Chen, L., Zhou, Z., Yu, X. & Hong, N. Reduced
white matter integrity and cognitive deficit in never-medicated chronic schizophrenia:
A diffusion tensor study using TBSS. Behavioural Brain Research 252, 157–163.
ISSN: 01664328 (2013).
97. Guo, W., Liu, F., Liu, Z., Gao, K., Xiao, C., Chen, H. & Zhao, J. Right lateralized white
matter abnormalities in first-episode, drug-naive paranoid schizophrenia. Neuroscience
Letters 531, 5–9. ISSN: 03043940 (2012).
196 References
98. Hadjikhani, N., Joseph, R. M., Snyder, J. & Tager-Flusberg, H. Anatomical Differences
in the Mirror Neuron System and Social Cognition Network in Autism. Cerebral
Cortex 16, 1276–1282. ISSN: 1460-2199 (2006).
99. Gotts, S. J., Simmons, W. K., Milbury, L. A., Wallace, G. L., Cox, R. W. & Martin, A.
Fractionation of social brain circuits in autism spectrum disorders. A JOURNAL OF
NEUROLOGY 135, 2711–2725 (2012).
100. Liao, Y. et al. Is depression a disconnection syndrome? Meta- analysis of diffusion
tensor imaging studies in patients with MDD. Journal of Psychiatry & Neuroscience
38, 49–56. ISSN: 11804882 (2013).
101. Sacchet, M. D., Prasad, G., Foland-Ross, L. C., Joshi, S. H., Hamilton, J, Thomp-
son, P. M. & Gotlib, I. H. Structural abnormality of the corticospinal tract in major
depressive disorder. Biology of Mood & Anxiety Disorders 4, 8. ISSN: 2045-5380
(2014).
102. Rutter, L., Carver, F. W., Holroyd, T., Nadar, S. R., Mitchell-Francis, J., Apud, J.,
Weinberger, D. R. & Coppola, R. Magnetoencephalographic gamma power reduction
in patients with schizophrenia during resting condition. Human brain mapping 30,
3254–64. ISSN: 1097-0193 (2009).
103. Uhlhaas, P. J. & Singer, W. Abnormal neural oscillations and synchrony in schizophre-
nia. Nature Reviews Neuroscience 11, 100–113. ISSN: 1471-003X (2010).
104. Boutros, N. N., Arfken, C., Galderisi, S., Warrick, J., Pratt, G. & Iacono, W. The status
of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophrenia
Research 99, 225–237. ISSN: 0920-9964 (2008).
105. Bernier, R, Dawson, G, Webb, S & Murias, M. EEG mu rhythm and imitation impair-
ments in individuals with autism spectrum disorder. Brain and cognition 64, 228–37.
ISSN: 0278-2626 (2007).
106. Oberman, L. M., Hubbard, E. M., McCleery, J. P., Altschuler, E. L., Ramachandran,
V. S. & Pineda, J. A. EEG evidence for mirror neuron dysfunction in autism spectrum
disorders. Cognitive Brain Research 24, 190–198. ISSN: 0926-6410 (2005).
107. Braak, H & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta
neuropathologica 82, 239–59. ISSN: 0001-6322 (1991).
108. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the
development of Parkinson’s disease-related pathology. Cell and Tissue Research 318,
121–134. ISSN: 0302-766X (2004).
109. Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis.
Annals of Neurology 74, 20–38. ISSN: 03645134 (2013).
110. Kassubek, J., Müller, H.-P., Del Tredici, K., Brettschneider, J., Pinkhardt, E. H., Lulé,
D., Böhm, S., Braak, H. & Ludolph, A. C. Diffusion tensor imaging analysis of
References 197
sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of
TDP-43 pathology. Brain 137 (2014).
111. Sapp, E, Penney, J, Young, A, Aronin, N, Vonsattel, J. P. & DiFiglia, M. Axonal trans-
port of N-terminal huntingtin suggests early pathology of corticostriatal projections
in Huntington disease. Journal of neuropathology and experimental neurology 58,
165–73. ISSN: 0022-3069 (1999).
112. Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye,
D., Ferrante, R. J., Hersch, S. M. & Li, X.-J. Nuclear and Neuropil Aggregates in
Huntington’s Disease: Relationship to Neuropathology. Journal of Neuroscience 19
(1999).
113. Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve,
D., Hevelone, N. & Hersch, S. M. Cerebral cortex and the clinical expression of
Huntington’s disease: complexity and heterogeneity. Brain : a journal of neurology
131, 1057–68. ISSN: 1460-2156 (2008).
114. G. Vonsattel, J. P. & DiFiglia, M. Huntington Disease. Journal of Neuropathology and
Experimental Neurology 57, 369–384. ISSN: 0022-3069 (1998).
115. Brettschneider, J. et al. Sequential distribution of pTDP-43 pathology in behavioral
variant frontotemporal dementia (bvFTD). Acta Neuropathologica 127, 423–439.
ISSN: 0001-6322 (2014).
116. Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee,
J.-M. & Holtzman, D. M. Neuronal activity regulates the regional vulnerability to
amyloid-b deposition. Nature Neuroscience 14, 750–756. ISSN: 1097-6256 (2011).
117. Pooler, A. M. et al. Physiological release of endogenous tau is stimulated by neuronal
activity. EMBO reports 14, 389–94. ISSN: 1469-3178 (2013).
118. Pecho-Vrieseling, E. et al. Transneuronal propagation of mutant huntingtin contributes
to non–cell autonomous pathology in neurons. Nature Neuroscience 17, 1064–1072.
ISSN: 1097-6256 (2014).
119. de Calignon, A. et al. Propagation of Tau Pathology in a Model of Early Alzheimer’s
Disease. Neuron 73, 685–697. ISSN: 08966273 (2012).
120. Palop, J. J., Chin, J. & Mucke, L. A network dysfunction perspective on neurodegen-
erative diseases. Nature 443, 768–773. ISSN: 0028-0836 (2006).
121. British Medical Journal. BMJ Best Practices (BMJ Publ. Group, 2019).
122. Lomen-Hoerth, C, Murphy, J, Langmore, S, Kramer, J. H., Olney, R. K. & Miller, B.
Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 60, 1094–7.
ISSN: 1526-632X (2003).
198 References
123. Ringholz, G. M., Appel, S. H., Bradshaw, M., Cooke, N. A., Mosnik, D. M. & Schulz,
P. E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65,
586–590. ISSN: 0028-3878 (2005).
124. Strong, M. J., Grace, G. M., Orange, J. B., Leeper, H. A., Menon, R. S. & Aere, C.
A prospective study of cognitive impairment in ALS. Neurology 53, 1665–70. ISSN:
0028-3878 (1999).
125. Bowen, B., Pattany, P., Bradley, W., Seres, P., Lynch, M., Sekhon, R., Johnston, W. &
Kalra, S. MR Imaging and Localized Proton Spectroscopy of the Precentral Gyrus
in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology 21, 647–658.
ISSN: 0195-6108 (2011).
126. Wilson, C. M., Grace, G. M., Munoz, D. G., He, B. P. & Strong, M. J. Cognitive
impairment in sporadic ALS: a pathologic continuum underlying a multisystem
disorder. Neurology 57, 651–7. ISSN: 0028-3878 (2001).
127. Walker, M. P., Ayre, G. A., Cummings, J. L., Wesnes, K., McKeith, I. G., O’Brien, J. T.
& Ballard, C. G. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s
disease, and vascular dementia. Neurology 54, 1616–1625. ISSN: 0028-3878 (2000).
128. Bradshaw, J. Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s
disease is qualitatively distinct. Journal of Neurology, Neurosurgery & Psychiatry 75,
382–387. ISSN: 0022-3050 (2004).
129. Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S. & Malinow, R.
Amyloid beta from axons and dendrites reduces local spine number and plasticity.
Nature Neuroscience 13, 190–196. ISSN: 1097-6256 (2010).
130. Imlach, W., Beck, E., Choi, B., Lotti, F., Pellizzoni, L. & McCabe, B. SMN Is
Required for Sensory-Motor Circuit Function in Drosophila. Cell 151, 427–439. ISSN:
00928674 (2012).
131. Roselli, F. & Caroni, P. A Circuit Mechanism for Neurodegeneration. Cell 151, 250–
252. ISSN: 0092-8674 (2012).
132. Katsuno, M., Sahashi, K., Iguchi, Y. & Hashizume, A. Preclinical progression of
neurodegenerative diseases. Nagoya journal of medical science 80, 289–298. ISSN:
2186-3326 (2018).
133. Smith, M. L., Glass, G. V. & Miller, T. I. The benefits of psychotherapy. 269 (Johns
Hopkins University Press, Baltimore, 1980).
134. Wampold, B. E. The Great Psychotherapy Debate: Models, Methods, and Findings
(2001).
135. Chorpita, B. F. et al. Evidence-Based Treatments for Children and Adolescents: An
Updated Review of Indicators of Efficacy and Effectiveness. Clinical Psychology:
Science and Practice 18, 154–172. ISSN: 09695893 (2011).
References 199
136. DeRubeis, R. J., Siegle, G. J. & Hollon, S. D. Cognitive therapy versus medication for
depression: treatment outcomes and neural mechanisms. Nature reviews. Neuroscience
9, 788–96. ISSN: 1471-0048 (2008).
137. Brooks, S. J. & Stein, D. J. A systematic review of the neural bases of psychotherapy
for anxiety and related disorders. Dialogues in clinical neuroscience 17, 261–79. ISSN:
1958-5969 (2015).
138. Shapiro, F. Eye movement desensitization: A new treatment for post-traumatic stress
disorder. Journal of Behavior Therapy and Experimental Psychiatry 20, 211–217.
ISSN: 0005-7916 (1989).
139. Shapiro, F. Eye movement desensitization and reprocessing (EMDR) therapy : basic
principles, protocols, and procedures 568. ISBN: 1462532764 (2001).
140. Foa, E. B., Keane, T. M., Friedman, M. J. & Cohen, J. A. Effective treatments for
PTSD: practice guidelines from the International Society for Traumatic Stress Studies
(Guilford Press, 2008).
141. WHO et al. Guidelines for the management of conditions that are specifically related
to stress (World Health Organization, 2013).
142. Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M. &
van Balkom, A. J.L. M. Risk of relapse after antidepressant discontinuation in anxiety
disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: system-
atic review and meta-analysis of relapse prevention trials. BMJ (Clinical research ed.)
358, j3927. ISSN: 1756-1833 (2017).
143. Wurtz, H., El-Khoury-Malhame, M., Wilhelm, F., Michael, T., Beetz, E., Roques, J.,
Reynaud, E., Courtin, J., Khalfa, S. & Herry, C. Preventing long-lasting fear recovery
using bilateral alternating sensory stimulation: A translational study. Neuroscience
321, 222–235. ISSN: 0306-4522 (2016).
144. Baek, J. et al. Neural circuits underlying a psychotherapeutic regimen for fear disor-
ders. Nature 566, 339. ISSN: 0028-0836 (2019).
145. Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers
to successful gene therapy. Blood 122, 23–36. ISSN: 1528-0020 (2013).
146. Verma, I. M. Gene Therapy That Works. Science 341, 853–855. ISSN: 0036-8075
(2013).
147. Costantini, L. C., Bakowska, J. C., Breakefield, X. O. & Isacson, O. Gene therapy in
the CNS. Gene Therapy 7, 93–109. ISSN: 0969-7128 (2000).
148. Hwu, W.-L., Muramatsu, S.-i., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H.,
Snyder, R. O., Byrne, B. J., Tai, C.-H. & Wu, R.-M. Gene Therapy for Aromatic
l-Amino Acid Decarboxylase Deficiency. Science Translational Medicine 4, 134ra61–
134ra61. ISSN: 1946-6234 (2012).
200 References
149. Yang, B. et al. Global CNS transduction of adult mice by intravenously delivered
rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Molecular therapy :
the journal of the American Society of Gene Therapy 22, 1299–1309. ISSN: 1525-0024
(2014).
150. Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the
central and peripheral nervous systems. Nature neuroscience 20, 1172–1179. ISSN:
1546-1726 (2017).
151. Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic
leukodystrophy. Science (New York, N.Y.) 341, 1233158. ISSN: 1095-9203 (2013).
152. Serlin, Y., Shelef, I., Knyazer, B. & Friedman, A. Anatomy and physiology of the
blood-brain barrier. Seminars in cell & developmental biology 38, 2–6. ISSN: 1096-
3634 (2015).
153. Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Moghrabi,
A. & Béliveau, R. Drug transport to the brain: key roles for the efflux pump P-
glycoprotein in the blood-brain barrier. Vascular pharmacology 38, 339–48. ISSN:
1537-1891 (2002).
154. Loscher, W. & Potschka, H. Role of Multidrug Transporters in Pharmacoresistance to
Antiepileptic Drugs. Journal of Pharmacology and Experimental Therapeutics 301,
7–14. ISSN: 00223565 (2002).
155. Salunkhe, S. S., Bhatia, N. M., Kawade, V. S. & Bhatia, M. S. Development of
Lipid Based Nanoparticulate Drug Delivery Systems and Drug Carrier Complexes
for Delivery to Brain. Journal of Applied Pharmaceutical Science 5, 110–129. ISSN:
2231-3354 (2015).
156. Kantor, B., McCown, T., Leone, P. & Gray, S. J. Clinical applications involving CNS
gene transfer. Advances in genetics 87, 71–124. ISSN: 0065-2660 (2014).
157. Dencker, D., Thomsen, M., Wörtwein, G., Weikop, P., Cui, Y., Jeon, J., Wess, J.
& Fink-Jensen, A. Muscarinic Acetylcholine Receptor Subtypes as Potential Drug
Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson’s Disease.
ACS chemical neuroscience 3, 80–89. ISSN: 1948-7193 (2012).
158. Ito, H. T. & Schuman, E. M. Frequency-dependent signal transmission and modulation
by neuromodulators. Frontiers in neuroscience 2, 138–44. ISSN: 1662-453X (2008).
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Table A.1 Sequences of individual SiR B19 particles
List of detected mutations divided by batch (50 individual clones per batch). The position of the
mutations is calculated referring to +1 as the first base of the nucleoprotein N coding sequence.
Table A.2 Sequences of individual SiR N2C particles
List of detected mutations divided by batch (47 individual clones per batch). The position of the
mutations is calculated referring to +1 as the first base of the nucleoprotein N coding sequence.
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Table B.1 SiR N2C mutations detected by NGS 1 week post injection in vivo Mice were injected
in CA1 with SiR N2C and hippocampal total RNA extracted 1 week p.i. Sequenced reads from NGS of
extracted RNA were aligned to the SiR N2C reference genome and a list of mutations identified using
freeBayes software. Table lists the genome position, genomic change, type of mutation (snp = single-
nucleotide polymorphism, indel = insertions and deletions, mnp = multi-nucleotide polymorphism,
complex = composite insertion and substitution events), frequency of mutation identification from
triplicate samples and total read depth.
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Table C.1 Table of upregulated transcripts following in vivo injection of SiR N2C List of upreg-
ulated transcripts following SiR N2C infection in CA1 region of the hippocampus in vivo as identified
by DESeq2 analysis. Genes listed in order of fold change differences in transcript levels compared to
PBS injected control mice.
